

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)


PCT

(10) International Publication Number
WO 2004/026888 A2

- (51) International Patent Classification⁷: C07H (72) Inventors; and
(21) International Application Number: PCT/US2003/029577 (75) Inventors/Applicants (*for US only*): LIPPFORD, Grayson, B. [US/US]; 38 Bates Road, Watertown, MA 02472 (US). MOOKHERJEE, Neeloffer [IN/CA]; Apt 408, 2233 Allison Road,, Vancouver, BC V6T 1T7 (CA). BABIUK, Lorne [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA). BROWNLIE, Robert [CA/CA]; 123 O'Brien Crescent, Saskatoon, Saskatchewan S7K 5K3 (CA). GRIEBEL, Philip [CA/CA]; Box 36, RR5, Saskatoon, Saskatchewan S7K 3J8 (CA). MUTWIRI, George [CA/CA]; 569 Nordstrum Road, Saskatoon, Saskatchewan S7K 7X6 (CA). HECKER, Rolf [DE/DE]; Benrodestr. 60, 40597 Düsseldorf (DE).
- (22) International Filing Date: 19 September 2003 (19.09.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data: 60/412,479 19 September 2002 (19.09.2002) US
(71) Applicants (*for all designated States except US*): COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE). UNIVERSITY OF SASKATCHEWAN [CA/CA]; Kirk Hall, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). QIAGEN GMBH [DE/DE]; Max-Volmer-Strasse 4, 40724 Hilden (DE).
- (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
(81) Designated States (*national*): AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

[Continued on next page]

(54) Title: TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES



WO 2004/026888 A2

(57) Abstract: Novel amino acid and nucleotide sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) Toll-like receptor 9 (TLR9) are provided. Also provided are amino acid and nucleotide sequences for dog (canine), cat (feline), mouse (murine), and human TLR9. Comparison of these sequences, especially in combination with functional assessment for species-specific CpG motif preferences, permits identification of specific regions and amino acid residues of interest in TLR9 ligand interaction. Novel chimeric TLR9 receptor molecules, cells expressing these molecules, and methods for their use in screening assays for TLR9 ligands are also provided.



MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES**Background of the Invention**

Synthetic oligodeoxynucleotides (ODN) and DNA containing immunostimulatory CpG motifs (CpG DNA) function as potent adjuvants and activators of the innate immune system. Heeg K et al. (2000) *Int Arch Allergy Immunol* 121:87-97; Krieg AM (2001) *Vaccine* 19:618-22. A wide variety of CpG-containing sequences have been screened for biological activity and it is reported that optimal CpG DNA sequences can vary among species. Rankin R et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:333-40.

Toll-like receptor 9 (TLR9) has recently been identified as a receptor for CpG ODN. Hemmi H et al. (2000) *Nature* 408:740-5. The molecular mechanism by which TLR9 recognizes CpG DNA is not understood.

Summary of the Invention

Toll-like receptor 9 (TLR9) is known to be involved in innate immunity and to signal in response to CpG DNA. To date, the amino acid sequences only of human and murine TLR9 have been reported, and, interestingly, these two species are known to prefer different CpG motifs. The structural basis for this species-specific CpG motif preference has not yet been fully elucidated. The instant invention provides, in part, novel amino acid and nucleotide sequences of rat, pig, cow, and horse TLR9. These novel TLR9 sequences are useful for elucidating certain key structural features of TLR9. Specifically, comparison of sequences of murine, human, and these novel TLR9 sequences permits identification of areas of highly conserved sequence, areas of group conservation, and areas of hypervariability. In addition, such comparisons permit an assessment of evolutionary relatedness among TLR9 molecules of the various species, as well as an assessment of inter-species homologies. Importantly, such comparisons permit a rational basis for identifying amino acids in TLR9 that may be involved in the CpG binding site, as well as amino acids involved in conferring species specificity for particular CpG motifs. Such information may be used to design and construct novel TLR9 molecules which incorporate specific point or regional mutations and which possess desired ligand binding characteristics. Such information may also be useful in designing and identifying novel ligands for TLR9 of a given species.

- 2 -

In one aspect, the invention provides isolated polypeptides having amino acid sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) TLR9 polypeptides. These amino acid sequences correspond to SEQ ID NOs 1, 5, 9, 13, and 17, respectively. Each of these sequences is believed to include at least a majority of an extracellular domain, as well as a transmembrane region and at least part of a TLR/IL-1 receptor (TIR) domain. To the extent any such sequence may lack an amino-terminal and/or carboxy-terminal sequence, such sequence is ascertainable, without undue experimentation, using conventional molecular biology techniques and the sequence information provided herein.

In another aspect the invention provides isolated polypeptides having amino acid sequences for essentially the whole extracellular domain, optionally including a signal peptide, of each of rat, porcine, bovine, equine, and ovine TLR9. These amino acid sequences correspond to SEQ ID NOs 2, 6, 10, 14, and 18, respectively. Such extracellular domains are believed to include sequence specifically involved in binding to TLR9 ligand, such as CpG DNA. In addition, such extracellular domains are believed to include sequence that confers species specificity for particular CpG motifs.

Isolated nucleic acid molecules encoding the polypeptides just described above are also provided according to further aspects of the invention. Such nucleic acid molecules include, but are not limited to, nucleic acid molecules having sequences provided by SEQ ID NOs 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively. Isolated nucleic acid molecules encoding the TLR9 polypeptides of SEQ ID NOs 1, 5, 9, 13, 17; and 2, 6, 10, 14, and 18 also include nucleic acid molecules that differ in sequence from SEQ ID NOs 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively, due to degeneracy of the genetic code. Such nucleic acid molecules will hybridize, under stringent conditions, with suitably selected nucleic acid molecules having sequences selected from SEQ ID NOs 3, 4, 7, 8, 11, 12, 15, 16, 19, and 20.

In another aspect the invention provides a vector which includes an isolated nucleic acid molecule of the invention. In one embodiment the vector is an expression vector and the isolated nucleic acid molecule of the invention is operably linked to a regulatory sequence in the vector. When present within a cell, an expression vector according to this aspect of the invention causes the cell to express a polypeptide of the invention.

The invention according to another aspect provides a cell in which a vector of the invention is present. In one embodiment the cell containing the vector expresses a

- 3 -

polypeptide of the invention. In certain embodiments the cell also contains a reporter construct that transduces a TLR9-mediated signal in response to contact of the polypeptide of the invention or a TLR9 with a suitable TLR9 ligand. The cell containing the vector, and optionally containing the reporter construct, can be used in screening methods also provided by the invention.

In yet another aspect the invention provides an antibody or antibody fragment that binds specifically to an isolated polypeptide of the invention. In certain embodiments the antibody or antibody fragment binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide. More specifically, the antibody or antibody fragment binds uniquely to one of the isolated polypeptides of the invention. In one embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide also binds to either mouse or human TLR9. In another embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide does not also bind to either mouse or human TLR9. In some embodiments the antibody or antibody fragment binds selectively to a chimeric TLR9 polypeptide of the invention. In certain embodiments the antibody or antibody fragment of the invention is a monoclonal antibody or fragment of a monoclonal antibody.

In one aspect the invention provides a method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species. The method involves aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species; generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

- 4 -

In another aspect the invention provides a method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9. The method according to this aspect of the invention involves aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9; generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids. In one embodiment the method according to this aspect of the invention is performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

In another aspect the invention also provides an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (extracellular domain (ECD) of murine TLR9) except for substitution of at least one key amino acid identified according to the method above. The polypeptide according to this aspect of the invention is a chimeric TLR9 polypeptide. Preferably the polypeptide according to this aspect of the invention binds to CpG DNA optimized for human TLR9 better than does the isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (ECD of murine TLR9). In one embodiment the polypeptide includes only one substituted amino acid. The isolated polypeptide according to this aspect of the invention may further include sequence involved in TLR/IL-1R signal transduction, e.g., intracellular domain of TLR9 as provided in SEQ ID NOS 29 and 33. For example, in one embodiment a polypeptide according to this aspect of the invention is an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:29 (full length murine TLR9) except for substitution of at least one key amino acid identified according to the method above.

- 5 -

In another aspect the invention provides an isolated nucleic acid molecule including a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described. In one embodiment the isolated nucleic acid molecule has a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described.

5 In yet another aspect, the invention provides a screening method to identify a TLR9 ligand. The method involves contacting a polypeptide (including a chimeric TLR9 polypeptide) of the invention with a candidate TLR9 ligand; measuring a signal in response to the contacting; and identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling. In one embodiment
10 the candidate TLR9 ligand is an immunostimulatory nucleic acid. In one embodiment the candidate TLR9 ligand is a CpG DNA.

The invention also provides, in yet a further aspect, a screening method to identify species-specific CpG-motif preference of an isolated polypeptide of the invention. The method according to this aspect of the invention involves contacting an isolated polypeptide of the invention with a CpG DNA including a hexamer sequence selected from the group consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGC GTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACTTT, GACGCT, GACGAT, GACGGT, GACGTC, GACGTA, and GACGTG; measuring a signal in response to the contacting; and identifying a species-specific CpG-motif preference when the signal in response to the contacting is consistent with TLR9 signaling. In one embodiment the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

TCCATGACGTTTTGATGTT	(SEQ ID NO:39),
TCCATAACGTTTTGATGTT	(SEQ ID NO:40),
TCCATCACGTTTTGATGTT	(SEQ ID NO:41),
25 TCCATTACGTTTTGATGTT	(SEQ ID NO:42),
TCCATGGCGTTTGATGTT	(SEQ ID NO:43),
TCCATGCCGTTTGATGTT	(SEQ ID NO:44),
TCCATGTCGTTTGATGTT	(SEQ ID NO:45),
TCCATGATGTTTGATGTT	(SEQ ID NO:46),
30 TCCATGAAGTTTGATGTT	(SEQ ID NO:47),
TCCATGAGGTTTGATGTT	(SEQ ID NO:48),
TCCATGACATTGATGTT	(SEQ ID NO:49),
TCCATGACCTTTGATGTT	(SEQ ID NO:50),
TCCATGACTTTTGATGTT	(SEQ ID NO:51),
35 TCCATGACGTTTGATGTT	(SEQ ID NO:52),
TCCATGACGATTTGATGTT	(SEQ ID NO:53),
TCCATGACGGTTTGATGTT	(SEQ ID NO:54),

- 6 -

TCCATGACGTCTTGATGTT (SEQ ID NO:55),
TCCATGACGTATTGATGTT (SEQ ID NO:56), and
TCCATGACGTGTTGATGTT (SEQ ID NO:57).

In certain embodiments of the screening methods of the invention, the signal includes expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway. In one embodiment the reporter gene is operatively linked to a promoter sensitive to NF- κ B. In one embodiment the signal in response to contacting is binding of the candidate TLR9 ligand or CpG DNA to the polypeptide of the invention.

In one embodiment the screening method is performed on a plurality of test compounds. In one embodiment the response mediated by the TLR9 signal transduction pathway is measured quantitatively and the response mediated by the TLR9 signal transduction pathway associated with each of the plurality of test compounds is compared with a response arising as a result of an interaction between the functional TLR9 and a reference immunostimulatory compound.

15

Brief Description of the Figures

Figure 1 depicts a Clustal W multiple sequence alignment of deduced amino acid sequences for cat (feline), dog (canine), cow (bovine), mouse (murine), sheep (ovine), pig (porcine), horse (equine), human, and rat TLR9 polypeptides. The deduced amino acid sequences for feline, canine, bovine, murine, ovine, porcine, equine, human, and rat TLR9 polypeptides shown in the figure correspond to SEQ ID NOS 25, 21, 9, 29, 17, 5, 13, 33, and 1, respectively. Lines labeled "multiple" refer to the multiple sequence alignment of all six sequences shown. Lines labeled "mo/hu" refer to a paired sequence alignment of mouse and human TLR9 sequences alone.

25 Figure 2 is a cladogram depicting an evolutionary relatedness tree for rat, murine, porcine, bovine, equine, and human TLR9 polypeptides in Figure 1.

Figure 3 is a graph depicting species specificity of TLR9 signaling with selected oligonucleotides having strong specificity for human (2006), mouse (5890), or neither (1982).

30

Detailed Description of the Invention

The present invention provides novel amino acid and nucleotide sequences for TLR9 derived from rat, pig, cow, horse, and sheep. These sequences can be used to identify key features of the primary sequences of these and related TLR molecules, including previously

- 7 -

known primary sequences of human and mouse (murine) TLR9. Such key features include binding site information and species specificity toward particular CpG motifs. Native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to identify and to design novel TLR9 ligands.

- 5 Additionally, the native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to compare various TLR9 ligands, including CpG DNA.

In one aspect the invention provides isolated TLR9 polypeptides, and isolated nucleic acid molecules encoding them, from rat, pig, cow, horse, and sheep. The term "isolated" as 10 used herein with reference to a nucleic acid molecule or polypeptide means substantially free of or separated from components with which it is normally associated in nature, e.g., other nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids or polypeptides are sufficiently pure and are sufficiently free from other biological constituents of host cells so as 15 to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid or polypeptide of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the nucleic acid or polypeptide may represent only a small percentage by weight of such a preparation. The nucleic acid or polypeptide is nonetheless substantially pure in that it has been substantially separated from 20 the substances with which it may be associated in living systems.

An amino acid sequence of rat TLR9 is provided as SEQ ID NO:1. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:1 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of rat TLR9 (See 25 Figure 1). Amino acids numbered 1-821 of SEQ ID NO:1 are presumptively extracellular domain and correspond to SEQ ID NO:2. SEQ ID NO:3 is a nucleotide sequence of rat TLR9 cDNA having an open reading frame corresponding to nucleotides 1-3096. SEQ ID NO:4 is a nucleotide sequence of rat cDNA encoding amino acids 1-821 of SEQ ID NO:1.

An amino acid sequence of porcine TLR9 is provided as SEQ ID NO:5. Based on 30 comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:5 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of porcine TLR9

- 8 -

(See Figure 1). Amino acids numbered 1-819 of SEQ ID NO:5 are presumptively extracellular domain and correspond to SEQ ID NO:6. SEQ ID NO:7 is a nucleotide sequence of porcine TLR9 cDNA having an open reading frame corresponding to nucleotides 77-3166. SEQ ID NO:8 is a nucleotide sequence of porcine cDNA encoding amino acids 1-819 of SEQ ID NO:5.

An amino acid sequence of bovine TLR9 is provided as SEQ ID NO:9. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:9 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of bovine TLR9

10 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:9 are presumptively extracellular domain and correspond to SEQ ID NO:10. SEQ ID NO:11 is a nucleotide sequence of bovine TLR9 cDNA having an open reading frame corresponding to nucleotides 84-3170. SEQ ID NO:12 is a nucleotide sequence of bovine cDNA encoding amino acids 1-818 of SEQ ID NO:9.

15 An amino acid sequence of equine TLR9 is provided as SEQ ID NO:13. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:13 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of equine TLR9

(See Figure 1). Amino acids numbered 1-820 of SEQ ID NO:13 are presumptively extracellular domain and correspond to SEQ ID NO:14. SEQ ID NO:15 is a nucleotide sequence of equine TLR9 cDNA having an open reading frame corresponding to nucleotides 115-3207. SEQ ID NO:16 is a nucleotide sequence of equine cDNA encoding amino acids 1-820 of SEQ ID NO:13.

25 An amino acid sequence of ovine TLR9 is provided as SEQ ID NO:17. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:17 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of ovine TLR9 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:17 are presumptively extracellular domain and correspond to SEQ ID NO:18. SEQ ID NO:19 is a nucleotide sequence of ovine 30 TLR9 cDNA having an open reading frame corresponding to nucleotides 92-3178. SEQ ID NO:20 is a nucleotide sequence of ovine cDNA encoding amino acids 1-818 of SEQ ID NO:17.

- 9 -

SEQ ID NO:1 (Rat TLR9)

MVLCCRRLHPLSLLVQAAVLAELALGTLPAFLPCELKPHGLVDCNWFLKSVPFSAEPRSNITSLSLIANRI
5 HHLHNLDVFVHLPNVRQLNLKWNCPPGGLSPHFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSL
SHTNLVLDASSLAGLHSRLVLFMDGNCYYKNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYL
LLSYNLIVKLGAEDLANLTSRMLDVGNCRRCDHAPDLCTECRQKSLLHPQTFFHLSHLEGIVLKDSLHSLN
SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLFSNYCKVFSFARLHLASSFKSLVSLQELNMIGF
FRLLNKNTLRWLAGLPKLHTLHLQMNFINQAQLSVFSTFRALRFVDLSNNRISGPPTLSRVAPEKADEAEKGVPW
10 PASLTPALPSTPVSKNFMRCKNLRTMDLSRNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK
VLDLSYNKLDLYHSKSFSelpQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS
VEYLDMSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNLYPKSLSTKLSFRDNHLSFFNWSSL
FLPNLRDLDLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVPAFFALAVELEKVNLSHNIKTVDRSWFGPIV
MNLTVLDVSSNPLHACGAPFVDLLEVQTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFGLSLL
AVAVGTVLPLQHLCGWDVVYCFHLCIAWLPLLTRGRRSAQALPYDAFWFDKAQSADWVYNELRVRLERRG
15 RRALRCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQRLLEDRKDVVVLVILRPDA
HRSRYVRLRORLCROSVLFWPHOPNGOGSFWAOLSTALTRDNHHFYNRNFCRGPTAE

SEQ ID NO:2 (Rat TLR9)

MVLCRRTLHPLSLLVQAAVLAELALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAEPRSNITSLSLIANRI
HHLHNLDVFHLPNVRQLNLKWNCPPGGLSPHFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSSL
SHTNILVLDASSLAGLHSRVLFDGNCYYKNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYL
LLSYNLIVKLGAEIDLNLTSLRMLDVGGNCRRCDHAPDLCTECRQKSLDLHPQTFHLSHLEGIVLKDSLHSLN
SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSFKSLVSLQELNMNGIF
FRLLNKNTLRLWLAGLPLKHLTLHQMFNINQAQLSVFSTFRALRFVDLSSNRISGPPTLSRVAPEKADEAEKGVPWL
PASLTPALPSTPVSKNFMRCKNLRTMDLSRNQNVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLKL
VLDLSYNKLDLYHSKSFSELPOQLALDLSYNSQPFSM0GIGHNFSPLANLSRLQNLSLAHNDIHSRPVSSRLYSTS
VEYLDFTSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYPKSLTCLSFRDNHLSFFNWSSLAL
FLPNLRLDLDLAGNLLKALTNGTLPNGTILLQKLDVSSNSIVFVVPAFFALABELKEVNLSLHNIKTVDRSWFGPIV
MNLTIVLDVSSNPLHCACGAPFV DLL LEVOTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFG

SEQ ID NO:3 (Rat TLR9)

35 atggttctctgtcgaggaccctgcaccccttgcacccctgtctccctggtagccgcagtgctggctgaggctctggcc
ctgggtacctcgctgccttcctaccctgtgaactgaagcctcatggcctggtagactgcacactggctttccctg
aagtctgtgcctacttctgtcccgagaacccgttccaacatcaccagccttcctgtatcgccaaaccgcac
caccacactgcacaacactcgactttgtccacctgcccacgtgcagactgaacctcaagtggaaactgtccggcc
cctggcctcagccccctgcacttctctggccatgaccattgagccccaaaaccttcctggctatgcgcatgctg
gaagagctgaacctgagctataacggtatcaccaactgtgccccgcctgcccagctccctgacgaatctgaggcta
agccacaccaaactcctggtaactcgatgccagcagcctcgatggcctgcacagcctgcagttcttcatggac
gggaactgtactacaagaacccctgcaacggggcggtaacgtgacccggacgccttcctgggcttgagacaac
40 ctcacccacttgtcccttaagtataacaacactcacagaggtgccccgccaactgccccccagcctggagtaccc
ctgctgtccctataacactcatcgtaagctggggccgaagacactgccaacactgaccccttcgaatgctgt
gtgggtggaaattgcctgtcgctgtgatcacgccccgacctctgtacagaatgcccggagaagtccttgatctg
caccctcagactttccatcacctgagccaccttgaaggcctggtaaggacagttctccactcgctgaac
tccaagtggttccagggtctggcaacctctcggtctggacctaagcgagaactttctacgagagcatcaac
45 aaaaccagcgccttcagaacactgaccctgtcgcaagctgacactgtcctcaattactgcaagaaggatcg
ttccggccgcctccacctggcaagtccctcaagagcctgggtcgctgcaggagctgaacatgaacggcatctt
ttccgcttactcaacaagaacacgctcagggtggctggctgcccacacgctgcacccatcaatg
aatttcatcaaccaggcgcagctcagcgttttagtaccttcgagcccttcgctttgtggacactgtccaataat
cgcatcagcgggcctccaaacgcgttccagactgcggccggaaaaggcagacgcggggagaaggggggttccatgg
50 cctgcaagtctcacccttcacccatctcccgagactccctgtccaaagaacttcatggtcaggtgttaagaacccatcg
ttcaccatggacactgtctcggaacaaccaggtaactatcaagccagagatgttcgtcaacacttccatctcc
tgtctgagccctgagccacaactgcattcgccgaggctgtcaatggctctcagttccctggctgaccaacctgaa
gtgctggacactgtccctataacaagctggacactgttaccattcgaaatcggtcaagtgcagttccacagttgcaggcc

- 10 -

ctggacctgagctacaacagccagccattcagcatgcaggggataggccacaacttcagtttctggcaatctg
 tccagggtacagaacccttagcctggcacacaatgacattcacagccgcgtgcctcacgcctctacagcacctca
 gtggagtatctggacttcagcccaacgggtgtggccgcattgtggacgaggaggacccatcttaccttctatctc
 caagacctgagaagccctgattcatctggacctgttcagaataagctgcacatccctccggccccagaacctcaac
 5 tacctccccaaagagccctgacgaagctgagttccgtgacaatcacctcttctttaactggagcagtctggcc
 ttcctgcccataactcgagacctggacctggcaggcaatctactaaaggccctgaccaacggcacccctgccta
 ggcacgcctccagaaactggatgtcagtagcaacagtatcgtcttgggtcccgcccttgccttgcgg
 10 gtagagctaaaagaggtaacctcagccataacatcctcaagactgtggatcgccttggttggccatttgt
 atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgcctgcggtgacccctttagacttaactg
 ctggaaagtgcagaccaagggtgcctggcatacgggtgtgaagtgtggcagttcccgccagctgcaggccgc
 agcatcttgcgcaagacctgcggctgtgcctggatgacgtccttctcgccactgccttggccttcactcc
 gctgtggccgtggcaeggtgttgccttactgcagcatctgcggctggacgtctggactctttccatctg
 15 tgccctggcatggctacccctgtgaccctggccggcgcagcggccaaagctcccttatgatgccttcgtgg
 ttcgataaggcgccagagcgcgggtgctgactgggtgtataacgagcttcgagtgccgctagaggagcggccgc
 cgcccgccctacgctgtgtggaggaccgagattggctgcctggccagacactttcgagaaacctctggcc
 tccatctatggcagcccaagactctgtttgtgcctggccacacggacaaggctcagtgcccttcgcaccagc
 20 ttccctgctggctcagcagccctgtggaggaccgcaaggacgtgtgggttggatcctgcggccatgtgcc
 caccgctcccgatcgtgcactgcgcagcgccttcgcggccagactgtgtcttcgtggccatcagccaa
 gggcaggccagcttctggggccagctgagtagacgcctgacttagggacaaccaccattctataaccggaa
 ctgcggggacctacagcagaatag

SEQ ID NO:4 (Rat TLR9)

atggttctctgtcgcaggaccctgcaccccttgcgttgcctctgttgcgtacaggccgcagtcgtggctgaggctctggcc
 ctgggtaccctgcctgccttcttaccctgtgaactgaagccctcatggccctggtagactgcaactggctttccctg
 25 aagtctgtgcctcaactctctgtccgcagaacccctgttccaacatcaccaggcccttcttgcgtatgcgcacccgcac
 caccacctgcacaacacctcgactttgtccacccctggcccaacgtgcgcagactgttccaacttcgatggaaactgtccgc
 cctgcctcagcccttgcacttctccctggccatgaccattggccaaaccccttcgtccatgcgcatgt
 gaagagctgaacctgagctataacggtacttcacccatgtgcctggccctggccagactccctgcacgaatctgaggc
 30 agccacaccaacatctggacttcgatggccagcgccttcgtccatgtgcacaggccctgcgcaggatgttcttcatggac
 gggactgctactacaagaacccctgcacccgggggggtgaactgtgaccccccggccgccttcgtggcttgc
 ctcacccacttgccttaagtataacacccatcagcggacttcggcccaactgcctggacttgc
 35 ctgcgtcctataacccatcgtaactgtggggggcgaagacttagccaaactgcaccccttcgtgaatgttgc
 gtgggtggaaatggccgtcgctgtgatcacggcccccacctctgtacagaatgcggcagaagtcccttgc
 caccctcagacttccatcacctgagccacccctgatggcctgtgaaggacagtctctccactcgctgac
 40 tccaagtggttccagggtctggcaaccttcggtgtggacttcacgcgagaactttcttctacgc
 aaaaccagcgcccttcaacccatgcggccatgtccgcaccccttcgatggacttgc
 ttcggccgcctccacctggcaagttccctcaagagccctgtcgctgcaggagactgac
 45 ttccgccttactcaacaagaacacgcgtcagggtggctggctggccaaactcc
 aatttcatcaaccaggcgccagctcagcgttttagtacccctcgagcccttcgcttgc
 tggacacttcgtccatggacccatgcgtccatggccacaacttcgatggcc
 50 cgcatcaggccgcctccaaacgcgttccagactgcaccccgaaaaggcc
 cctgcacacttcaccccgacttcggcggactcccgatctca
 ttcaccatggacacttcgtccatggacccatgcgtccatggcc
 tgcgtccatggacccatgcgtccatggacccatgcgtccatgg
 55 ctggacccatgcgtccatggacccatgcgtccatggacccatgcgtccatgg
 tccagggtacagaacccatgcgtccatggacccatgcgtccatgg
 gtggagtatctggacttcagcccaacgggtgtggccgcattgt
 caagacctgagaagccctgattcatgcgtccatggacccatgc
 tacctccccaaagagccctgacgaagctgagttccgtgacaat
 60 ttcctgcccataactcgagacccatggacccatgcgtccatgg
 ggcacgcctccatggacccatgcgtccatggacccatgcgtccat
 gtagagctaaaagaggtaacccatgcgtccatggacccatgc
 atgaacctgacggttctagacgtgagcagcaaccctctgc
 ctggaaagtgcagaccaagggtgcctggcatacgggtgt
 65 agcatcttgcgcaagacccatgcgtccatggacccatgcgtccat

- 11 -

SEQ ID NO:5 (Porcine TLR9)

5 MGPRTCLHPLSLLVQVTALAAAALAQGRPAFLPCELQPHGLVCNCWLFLKSVPHFSAAPRANVTSLSLLSNRIHL
HLHDSDFVHSSLRLTNLKWNCPPAGLSPMHFPCHMTIEPNFLAVPTLEELNLSYNSITTVPALPDLSVSLSLSR
RTNILVLDPTHLTGLHALRYLYMDGNCYYKNPCQGALEVPGALLGLGNLTHLSLKYNNTEVPRSLPPSLETLL
LSYNHIVTLPEDLANLTALRVLDVGNCRRCDHARNPCRECPKDHPKLSHSDTFSHSLRLEGVLKDSSLYNLDT
RWFRLDRLQVLDLSENFLYDCITKTTFQGLARLRSILNLSFNHYKKVSFAHLHLAPSFGHLRSLKELDMHGIFF
RSLSETTLQPLVQLPMLQTLRLQMNFINQAQLSIFGAFPGLLYVDLSDNRISGAARPVAITREVGDGRERVWLPSR
NLAPRPLDTRLSEDFFMPNCKAFSTLTLDSRNNLVTIQSEMFARLSRLECLRLSHNSISQAVNGSQFVPLTSRLV
DLSHNKLDLYHGRSFTELPRLAEALDLSYNSQPFTMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASLC
10 ALDFSGNDLSRMWAEGDLYLRRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKSALKHLHRDNNLAFFNWSSLTLL
PKLETLDLAGNQLKALSNGSLPSGTQLRRLDLSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWFSGSMVGN
LKVLDDSANPLHACGATFVGFLLEVQAAPGLPSRVKGSPGQLOQHSIFAQDRLRCLCDETLSWNCFGISLLAM
ALGLVVPMILHLCGWDLWYCFHLCIAWLPHRGQRRGADALFYDAFVVFDKAQSavadwvynelrvqleerrgrra
15 LRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLAQQRLLLEDRKDVVVLVILRPDAYRS
RYVRLRQRLCRQSVLLWPHQPRQGQGSFWAQLGTALTRDNHHFYNRNFCRGPTTAE

SEQ ID NO:6 (Porcine TLR9)

20 MGPRTCTLHPLSLLVQVTALAAAQAQGRLP AFLP CELQPHGLVNCNWLF LKSVPHF SAAAPRANVTSLSLLSNRIH
HLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNSITTVPALPDLSVLSSLSS
RTNILVLDPTHLTGLHALRYLYMDGNCYYKNPCQGALEVPGALLGLGNLTHLSLKYNLTLTEVPRSLPPSLETLL
LSYNHIVTLPEDLANLTALRVL DVGGNCRRCDHARNPCRECPKDHPKLHSDFSHSLRLEGVLKDSSLNLDTT
RWFRLDRLQVLDLSENFLYDCITKTAFQGLARLRSLNLSFNHYKKVSFAHLHLAPSFGHLRSLKELDMHGIFF
RSLSETTLQPLVQLPMLQTLRLQMNFINQAOQLSIFGAFPGLYVDLSDNRISGAARPVAITREVDRERVWLPSR
NLAPRPLDTLRS EDFMPNCKAFSFTLDSRNLLVTIQSEMFARLSRLECLRLSHNSISQAVNGSQFVPLTLSRVL
25 DL SHNKLDLYHGRSFTELPRLAEALDLSYNSQPFTM QVGVGHMLS FVAQLPALR YLSLAHNDIHSRVSQOLCSASLC
ALDFSGNDLSRMWAEGDLYLRRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKS LKHLHLRDNNLIAFFNWSSLTLL
PKLETLDLAGNQLKALSNGSLPSGTQLRRLDLSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWF GMSMVGN
LKVL DVSANPLHCACGATFVGFLLEVQAAVPGPLPSRVKGSPGOLOGHSIFAODLRLCLDETL SWNCFG

30 SEQ ID NO:7 (Porcine TLR9)

gagcacgaacatccctactgttagctgcccggctgcacagccagacccttggagaagaccccactccctgt
catggggcccccgctgcaccccttcctctcggcggcggctgcacccctttctctcggcggctgcggctctggcca
gggcaggctgcctgccttcctgcctgtgagctccagccccacggcctggtaactgcactggctttcttgc
gtccgtgcccacttctcggcggcagcggccggcaacgtcaccagccctccttactctccaaccgcaccca
35 ccacctgcacgactccgacttcgtccacctgtccagcctaactctaaccctaacttggaaactgcccgcggc
tggcctcagccccatgcacttccctgccacatgaccatcgagcccaacacccttccctggccgtgcccaccctgg
ggagctgaacctgagctacaacagcatcacgaccgtgcctgcccactccctcgttccctgtcgtgag
ccgcaccaacatcctgggtctagaccccacccacctcactggcctacatgcctgcgtacactgtacatggatgg
caactgtactacaagaacccctgcagggggcgtggagggtggccgggtgcctcctggccctggcaacct
40 cacacatcttcactcaagtacaacaatctcacggagggtgcggccgcagcctgcggcccaagccctgt
gttgcctacaaccacattgtcaccctgacgcctgaggaccctggccaatctgactgcctgcgtgttgc
gggggggaactgcgcgcgtgtgaccatgcggcaacccctgcagggagtgcggcaaggaccaccccaagctgca
ctctgacacccctagccacctgagccgcctcgaaggcctgggtgaaagacagtccctctacaacactggacac
45 caggtggttcccgaggcctggacaggctcaagtgtcggaccctgagtgagaacttccctacgactgcaccc
gaccacggcccccagggcctggccgactgcgcagcctcaacctgtcctcaattaccacaagaagggtgtcc
tgcccacctgcacctggcaccctcttgggcacccctccggccctgaaggagctggacatgcatggcatctt
ccgctcgctcaagtgagaccacgcctcaacctctggccactgcctatgctccagaccctgcgcctgcagatgaa
50 cttcattaaccaggcccagctcagcatcttgggcctccctggccctgtgtacgtggaccctatcgaccaacc
catcagcggagctgcaaggccagtgccattactagggagggtggtagggagagggtctggctgccttccag
gaacctcgctccacgtccactggacacttcggcgtcagaggacttcgtccaaactgcacccctcagcttc
cttggacactgtctcggaacaacactggtagacatccagtcggagatgttgcctgccttcacgcctcgagtgc
gcccgcgtgacccacaacagcatctcccaaggcggtaatggctcgttgcctgcgtgaccagccctgcgggtgt
ggacctgtcccaacaacaagctggactgtatcacggccgcgttgcgttgcgtccgcgcctggaaagactgg
cctcagctacaatagccaccccttaccatgcagggtgtggccacaacactcagctcgtqgcccacqtcqccc

- 12 -

5 cctgcgcctaccccgccggcgcacaatgacatccatagccgagtgtcccagcagctctgttaggcgcctcaactgtg
cgccctggactttagccgcaacgatctgagccgatgtggctgaggagaccttatctccgccttcttccaagg
cctaagaaggcttagtctggctggacctgtcccaagaaccacccatgcacacccttcgtccacgtgccctggacaacct
ccccaaaaggctgaagcatctgcattccgtgacaataacctggccttcaactggagcagcgtaccctctt
5 gcccaagctggaaaccctggacttggctggaaaccagctgaaggccctaagcaatggcagccatctggcac
ccagctgcccggaggctggacctcagtgcaacagcatccgccttgcataccctggcttgcctggccaagca
gttagaagagactcaacccatgcgcacaatggccctaagacagactggagccctctggctcgatggggcaa
cctgaaaggcttagacgtgagcccaaccctctgactgtgcctgtggggcaccctcgtdggcttcgtgg
10 ggtacaggctccgtgctggctggccagccgcgtcaagtgtggcagtcgcggggcagtcgcaggccatagcat
cttgcgcgaagacccctgcgcctctgcctggatgagaccctctgcgtggactgtttggcatctgcgtctggccat
ggccctgggctgggttgcccatgctgcaccacccctgcggctggacctctggtaactgctccacctgtgcct
ggcctggctgccccaccggagggcagccggggcgcagacgcctgttctatgatgccttcgtggcttgcacaa
agctcagagtgctgtggccactgggtgtacaacgcggactgtgcgggtcagctggaggagcgcgcgtggcgc
15 actgcgcctgtgcctggaggagcggagactggtaacctggcaagacgccttcgtggactgtggccctcagtct
cagcagccgcgaagaccctgttgcgtggccacacggaccgtgtcagccgccttgcgtggcagttctgt
ggcccgccgcgtggaggaccgcgaaggacgttgttagtgcgtggatctgcgcggccatgcctaccgc
ccgctacgtcgccgtgcgcgcgcgtggccagactgtccctctggcccccaccgcgcgtggcagg
cagcttctggcccaagctgggcacagccctgaccaggacaaaccaccacttctataaccggacttctgcgggg
20 cccacgcacagccgaatagactgtgacggccagttgcgtggccctggatttgcctctgcgtgg
tgcccaacactgtttgcgtggccacaccactgtctgtccctgtttcccaaaaaaaa
aacatgtgccaataatgttacccggaggccaaaaaaaaaaaaaaaaaaaaaa

SEQ ID NO:8 (Porcine TLR9)

- 13 -

SEQ ID NO:9 (Bovine TLR9)

5 MGPYCAPHPLSLLVQAAALAAAALAEGLPAFLPCELOPHQVDCNWLFLKSVPHFSAGAPRANVTSLSLISNRH
 HTLHDSDFVHLNSNLRVLNWKWCPPAGLSPMHPCRMTIEPNFLAVPTLEELNSYNGITTVPALPSSLVSLSLIS
 HTSILVLGPTHFTGLHALRFLYMDGNCCYMNCPRALEVAPGALLGLGNLTHLSKYNNLTENVPRRLPPSLDTLL
 LSYNHIVTLAPEDLANLTALRVLDVGNCRRCDHARNPCRECPKNFPKLHPDTSFHSRSLEGLVLKDSSLYKLEK
 DWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHASSFGSLVSLEKLDMHGIFF
 RSLTNITLQSLTRLPKLQSLHQLNFINQAQLSIFGAFPSLLFVDLSDNRISGAATPAAALGEVDSRVEVWRLP
 GLAPGPLDAVSSKDFMPSCNLFNTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLD
 10 LSHNKLDLYHGRSFTELPQLEALDLISYNSQPFSMQGVGHNLFSVAQLPSRLYLSLAHNGIHSRVSQKLSSASLRA
 LDFSGNSLSQMWAEGLDLYLCFFKGRLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLDNNLAFNWSSLTVLP
 RLEALDLAGNQLKALSNGSLPPGIRLKQLDVSSNSIGFVIPGFFVRATRLIELNLSANALKTVDPSWFGSLAGTL
 KILDVSANPLHCACGAAFVDFLLERQEAVPGLSRRTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGSLLMVA
 15 LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRQRGEDTLLYDAVVVFDKVQSAADVWVNELRVQLEERRGRRAL
 RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAOQLLEDRKDVVVLVILRPAAYRSR
 YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNRFYNRNFCRGPTTAE

SEQ ID NO:10 (Bovine TLR9)

20 MGPYCAPHPLSLLVQAAALAAAALAEGLPAFLPCELOPHQVDCNWLFLKSVPHFSAGAPRANVTSLSLISNRH
 HTLHDSDFVHLNSNLRVLNWKWCPPAGLSPMHPCRMTIEPNFLAVPTLEELNSYNGITTVPALPSSLVSLSLIS
 HTSILVLGPTHFTGLHALRFLYMDGNCCYMNCPRALEVAPGALLGLGNLTHLSKYNNLTENVPRRLPPSLDTLL
 LSYNHIVTLAPEDLANLTALRVLDVGNCRRCDHARNPCRECPKNFPKLHPDTSFHSRSLEGLVLKDSSLYKLEK
 DWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHASSFGSLVSLEKLDMHGIFF
 RSLTNITLQSLTRLPKLQSLHQLNFINQAQLSIFGAFPSLLFVDLSDNRISGAATPAAALGEVDSRVEVWRLP
 25 GLAPGPLDAVSSKDFMPSCNLFNTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLD
 LSHNKLDLYHGRSFTELPQLEALDLISYNSQPFSMQGVGHNLFSVAQLPSRLYLSLAHNGIHSRVSQKLSSASLRA
 LDFSGNSLSQMWAEGLDLYLCFFKGRLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLDNNLAFNWSSLTVLP
 RLEALDLAGNQLKALSNGSLPPGIRLKQLDVSSNSIGFVIPGFFVRATRLIELNLSANALKTVDPSWFGSLAGTL
 KILDVSANPLHCACGAAFVDFLLERQEAVPGLSRRTCGSPGQLQGRSIFTQDLRLCLDETSLDCFG
 30

SEQ ID NO:11 (Bovine TLR9)

gggaagtgggcgccaagcatacccttcgtcagctgcctccaaacctgcggcccgacaccctctggagaagcccat
 tccctgtcatggcccactgtgccccgcaccccttctctctgtcaggctccagccatggcagggtggactgcaactggctgt
 35 tggccgagggcacccctgcctgccttcgtcaggctgtcaggctccagccatggcagggtggactgcaactggctgt
 tcctgaagtctgtgccgcactttcggctggagccccccggccaatgtcaccagccttccttaatctcaacc
 gcatccaccacttgcactgactctgacttcgtccacctgtccacactgcgggtctcaacctcaagtggactgca
 cgccggccggcctcagcccattgcacttccctgcctgtcaggatcggacccaaacaccttcctggctgtgc
 ccctggaggagctgaaccttagtacaacggcatcacgaccgtgcctgcctgcggacttccctcggtccctgt
 cgctgagccacaccagcatctggcttaggccccaccacttcaccggcctgcacgcctgegcttcgttaca
 40 tggacggcaactgtactacatgaacccctgcccgcggccctggagggtggccccaggcgcccttcctggcctgg
 gcaacctcacgcacctgtcgtcaagtacaacaacctcacggagggtggccgcctgcggccctggac
 ccctgctgtgtccataaccacattgtcaccctgcacccggaggacactggccaaacctgactgcctgc
 ttgacgtgggtggaaactgcgcgcgtgcaccatggcacaaccttcgtcaggagtgccaaagaacttccca
 agctgcaccctgacaccattcagtcacccatggcgcctgcggacttgggtgaaggacagttctctaca
 45 tagagaaaatggttccggccctggcaggctccaagtgcgtcaccgtggactgtggatggacttcccttat
 tcaccaagaccaccatctcaacgcacccatggcaggactcaacactgtccttcattaccacaagg
 tgccttcgtccacccatgtcacttagcgtccctttggagtcgtgtccctggagaagactggacatgc
 50 tcttcctccgtccctcaccacatcacgcctccatgcgtcaccggcgtggccaaacctcagactgtcat
 agctgaacttcatcaaccaggcccagctcagcatcttggggccttccggactgcctgtggacactgt
 acaaccgcacgcggaggccgcacgcgcacggccctggggagggtggacagcagggtggaaactgt
 tgcccgaggggccctgcgtccaggcccgctggacgcggcgtcggactcatgc
 tcacccatggacccatgtcaccggacaacactggtgcataatccggcaaggagatgttacc
 ggctgcgcctgagccacaacagcatctcgcaggcgttaatggctccagg
 ctgcgtgcccgtaccaggcctgc

- 14 -

5 tgctcgaccctgtcccacaacaagctggacctgtaccatggcgctcattcacggagctgccgcagctggaggcac
tggacctcagtcacaaacagccagcccttcagcatgcagggcgctggccacaacactcagttcgtggcccaactcgt
cctccctgcgtcacctcagccttcgcacaatggcatccacagccgtgtcacagaagctcagcagcgcctcg
tgcgccctggacttcagcggcaactccctgagccagatgtggccgagggagactctatctgttttca
aaggcttgaggaacctgttccagctggacctgtccgagaaccatctgcacaccctctgcctcgacactggaca
acctgccaagagcctgcggcagctgcgtctccggacaataacactggcccttcactggagcagcctgacc
tcctgccccggcttggaaagccctggatctggcagggaaaccagctgaagggccctgagcaacggcagcctgccc
gcatccggctccagaagctggacgtgagcagcaacagcatcggttcgtgatccccggcttcgtccggcga
ctcggctgatagagcttaacctcagcggcaatggccctgaagacagtggatccctctgggttcggcccttagcag
ggaccctgaaaatcctagacgtgagcggcaaccgcgtccactgcgcctgcggggcgcccttggacttcctgc
tggagagacaggaggccgtgcccggctgtccaggcgcgtcacatgtggcagtccggccagctccaggccga
gcatcttcacacaggacacctgcgccttcgcctgatggagacccttcctggactgccttggcttcactgtaa
tggtggcgctggccctggcagtgccatgtgcaccacctgtggctggacactgtggactgttccacccgt
gtctggcccatggcccgacggcggcggcagcggggcgaggacaccctgtctatgtatgcgtcggttcc
15 acaagggtgcagagtgcagtggctgattgggttacaacgagctccgcgtgcagctggaggagcggccgggggg
ggcgcgtccgccttcgcctggaggagcggagactggctccctggtaagacgttcgcagaacctgtggccctcg
tctacagcagccgcaagaccatgttgcgtggaccacacggaccgggtcagcggcccttcgcgcgcagctcc
tgctggcccagcagcgcctgttggaggaccgcagggacgtcgtagtgcgtggatctgcgcggccgcctatc
ggtcccgtacgtgcggcgtgcgcacgcgccttcgcgcagagcgtccctctggcccccaccagcccagtgcc
20 aggttagttctggccaaacctggcatagccctgaccaggacaaccgtacttcataaccggaaacttcgc
ggggccccacagccgaatagcacagagtgactgcccag

SEQ ID NO:12 (Bovine TLR9)

25 atggggccccctactgtgccccgcacccccccttctcttcggcggcaggcgccggactggcagcggccctggccgg
ggcacccctgcctgccttcgtggactcagccccatggtcaggactcaactggcgtttccatggccatccac
tctgtggcgactttcgctggagccccccggccaatgtcaccagcctctcttaatctccaaaccgcacccac
cacttgcatgactctgacttcgtccacctgtccaaacctgccccggcttcacacctaagtggaaactggccgg
ggcctcagccccatgcacttccctgcgtatgaccatcgagcccaacaccccttcggctgtgccccccctgg
gagctgaacctgagctacaacggcatcagcaccgtgcctgcctgccccagttccctgtgtccctgtcgctgagc
30 cacaccagcatcctggcttaggccccacccacttcaccggcctgcacgcctgcgccttcgtatcatggacggc
aactgctactacatgaacccctgcccggggccctggaggtggccccaggcgcccttcggccttggcaaccc
acgcacccctgcgtcaagtacaacaacccctacggaggtgccccggcctgccccccagcctggacaccctgt
ctgtcttacaaccacattgtcaccctggcaccggaggacctggcaactgactgcctgcgtgtacatgg
35 ggtgggaaactggccgcgtgcgaccatgcccgaacccctgcagggagtgcccaaagaacttcccaagctgcac
cctgacacccctcagtcacccctgagccgcctcgaaggcctgggttgaaggacagttctcttacaaaactagagaaa
gattggttccggccctggcaggctccaagtgtcgacccctgagtgagaacttccttatgactacatcacc
accaccatcttcaacgacccctgacccctgacactcaacccctgtccttcaattaccacaagaagggtgt
40 gcccacccctgcacccatgcgtccttccttggagttctgggtgtccctggagaagctggacatgcacggcat
cgcccttaccaacatcacgcctcagtcgtgaccggcgtcccaagctccagatgtcgatctgcagctgaac
ttcatcaaccaggccccagctcagcatcttggggcctcccgagccctgtcttcgtggacccctgtcgac
atcageggaggccgcacgccagccggccctggggaggtggacagcagggtggaaacttgggatggccagg
ggcctcgctccaggccccctggacccctgacccctgacgtcaaaaggacttcatggcaacccctcaacttc
gacccctgtcaggaacaacctggtgcacaatccagcaagagatgttaccggccttcggccctccagg
45 ctgagccacaacagcatctcgccaggcggttaatggctccctgatccgtggccctgaccaggccctgc
gagtgccactggccacttcgtccatggccctgcgtccatggccctggggccactggccactggcc
ctgtcccacaacaagctggacccctgttaccatggccctgcgtccatggccctggggccactggcc
actacaacagccagcccttcagcatgcagggcggtggccacaacctcagtcgtggccctggggcc
cgctacccctgcgtccatggccactggccctggggccactggccactggcc
50 ctggacttcagccggcaactccctgagccagatgtggccggagggagacccctatctgttttcaagg
aggaaacctggccagctggacccctgtccgagaaccatctgcacaccctc
tgcgtccctgcgtccatggccactggcc
aagagccctggccagctgcgtccctgggacaataacccctggcccttc
aactggagccctggccactggcc
cgctggaaaggccctggatctggcaggaaaccagctgaaggccct
gagcaacccggcaggccctggccctggccatccgg
ctccagaagctggacccctgtccgtccatggccctggcc
actggccctggccactccgg
atagagcttacccctcagcccaatggccctgaagac
actggatcccttc
ctgggttccctttagcaggagg
aaaatccctagacgtgagcccaacc
ccgtccactgcgcctgcggggcc
cttggacttc
ctgtggagaga
caggaggccgtgcccgggctgtcc
caggccgt
cactatgtgg
cagtc
ccggcc
cagcc
actcc
caggggcc
cagcc
cagcat
ttcc

- 15 -

SEQ ID NO:13 (Equine TLR9)

5 MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRDNVTSLSLLSNRI
 HHLHSDFAQLSNLQKLNWKWCNCPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLNSYNGITTVPALPSSLVSLIL
 SRTNILQLDPTSLTGLHALRFLYMDGNCYYKNPCGRALEVAPGALLGLGNLTHLSLKYNMNTTVPRSLPPSLEYL
 LLSYNHIVTIAPEDLANLTALRVLDVGNCRRCDHARNPCVECPHKFPQLHSDFSHLSRLEGVLKDSSLYQLN
 PRWFRGLGNLTVIDLSENFLYDCITKTKAFOGLAQLRRRNLSFNYHKKVSFAHLLAPSFGSLLSLQELDMHGIF
 FRSLSQKTLQPLARLPMLQRLYLMQMFINQAOQLGIFKDFPGLRYIDLSNDNRISGAVEPVATTGEVDGGKKVWLTS
 RDLTPGPLDTPSSEDFMPSCKNLSFTLDSLRSNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV
 10 10 LDLSHNKLDLYHGRSFTELPRLAEALDLSYNSQPFMSMRGVGHNLFSVAQLPTLRLSLAHNGIHSRVSQQLCSTSL
 WALDFSGNSLSQWMWAEGDLYLRFQGLRSLIRLDLSQNRLHLLPCTLGNLPKSLQLLRLRNNSLAFFNWSSLTL
 LPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRSNIIIFVVPGFFALATRLRELNLSANALRTEEPSWFGFLAG
 SLEVLDSANPLHCACGAAFDLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFGSLLLV
 15 VALGLAMPMLHHLCGWDLWYCFHLGLAWLPRRGWQRGADALSYDAFVVFDAQSAVADWVYNELRVLEERRGR
 ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQLLEDRKDVVVLVILSPDARR
 SRYVRLRQRLCRQSVLFWPQPSGQRSFWAQLGMALTRDNRFYQNQFCRGPTMAE

SEQ ID NO:14 (Equine TLR9)

20 MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRDNVTSLSLLSNRI
 HHLHSDFAQLSNLQKLNWKWCNCPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLNSYNGITTVPALPSSLVSLIL
 SRTNILQLDPTSLTGLHALRFLYMDGNCYYKNPCGRALEVAPGALLGLGNLTHLSLKYNMNTTVPRSLPPSLEYL
 LLSYNHIVTIAPEDLANLTALRVLDVGNCRRCDHARNPCVECPHKFPQLHSDFSHLSRLEGVLKDSSLYQLN
 PRWFRGLGNLTVIDLSENFLYDCITKTKAFOGLAQLRRRNLSFNYHKKVSFAHLLAPSFGSLLSLQELDMHGIF
 FRSLSQKTLQPLARLPMLQRLYLMQMFINQAOQLGIFKDFPGLRYIDLSNDNRISGAVEPVATTGEVDGGKKVWLTS
 RDLTPGPLDTPSSEDFMPSCKNLSFTLDSLRSNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV
 25 25 LDLSHNKLDLYHGRSFTELPRLAEALDLSYNSQPFMSMRGVGHNLFSVAQLPTLRLSLAHNGIHSRVSQQLCSTSL
 WALDFSGNSLSQWMWAEGDLYLRFQGLRSLIRLDLSQNRLHLLPCTLGNLPKSLQLLRLRNNSLAFFNWSSLTL
 LPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRSNIIIFVVPGFFALATRLRELNLSANALRTEEPSWFGFLAG
 SLEVLDSANPLHCACGAAFDLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFG

30

SEQ ID NO:15 (Equine TLR9)

ctctgttctctgagctgtggccgcgtgaaggactgcgagcacaaagcatctcttcgtcagctgtgtccccagtg
 tgccagctggaccctctggatcatctccactccctgtcatggcccttgcacatgtggccctgtcagccccctgt
 35 ctcctggatcgaggccatgtggccgtggactgtggccatgtggccatggccatgtggccctgtcagccccctgt
 gacaatgtcaccaggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 aacatgtcaccaggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 accatgtcaccaggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 40 40 gtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 ctcacaggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 ctggagggtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 acgggtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 45 45 gaggacatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 aacccctgcgtggagtgcccacataattccccatgtggccatgtggccatgtggccatgtggccatgtggcc
 ggcctcggttgtgaggataggctcttaccagctgaaacccatgtggccatgtggccatgtggccatgtggcc
 ctgcacccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 agactcaacttgtcattaccataagaagggtgtggccatgtggccatgtggccatgtggccatgtggcc
 50 50 ctgcctccctgcaggaaactggacatgcacatggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 gcccgcctgcccattgtccacatgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 gactttccctggctcgctacatagacccatgtggccatgtggccatgtggccatgtggccatgtggcc
 ggggagggtggatggatggaaagggtgtggccatgtggccatgtggccatgtggccatgtggccatgtggcc
 tctgaggacttcatgccaactgtcaagaacccatgtggccatgtggccatgtggccatgtggccatgtggcc
 cagccagagatgttgcctccagctctcgccctccagtcgtgcctgcgcctgagccacaacagcatctcg
 caggcggt

- 16 -

5 aatggctcacagttcgccactgaccagcctgcagggtctggacctgtcccataacaaactggacctgtaccat
ggcgctcgtaacggagctggccgcactggaggccctggacactcagactacaacagccagccctcagcatgcgg
ggtgtggccacaacctcagttgtggccagctgcccacccctgcgcacacttcagcctggcacacaatggcatt
cacagccgtgtgtcccagcagctctgcagcacctcgctgtggccctggacttcagcggcaattccctgagccag
atgtggctgagggagaccttatctccgttccaaggcctgagaagcctaattccgcttagacctgtcccg
aatcgtctgcataccctctgcattgcacccctggcaaccccccacagacttgagctgcgtgcgtctccgttaac
aattacctggcccttcaattggagcagcctgaccctcctgcacccacccctggaaaccctggacctggctggaaaac
cagctgaaggctctgagcaatggcagcctgccttgcacccagctccagaggctggacgtcagcaggaacagc
atcatttcggtccctggttcttgctctggccacgaggctgcagagactcaacctcagtggcaacgcgcctc
10 aggacagaggagccctccgtgttggttcttagcaggctccctgaagtcttagatgtgagcggcaaccctctg
cactgcgcctgtggggcagcccttggacttcctgcaggctcaggctgcgtgcctgtgcggccagccgc
gtcaagtgtggcagtccggccagctccaggccgcagcatctcgacacaagacctgcgcctgcctggacaac
tccctctctggactgtttggctctcattgtgttgcggccctggcgcattgcctatgtgcaccac
ctctgcggctgggacctctggactgtttccacccggccctggcgcggcgcggggggcggcggcagcggggc
15 gggatgcctgagctatgtatgccttggcttcgacaaggcacagagcgcagtgccactgggttgcataat
gaactgcgggtgcggctagaggagccgtggccggccgtccgcctgtgtctggaggagcgtactggct
cctggcaagacgcgttgcggccgttgcgtccgcctgtgtctggccctggcgcggccactgggttgcataat
acggaccaggctcgtggcccttgcgtccgcagcttgcgtccgcctggccgcggccactgggttgcataat
gttgcgtggatctctggactgtggccctgcacgcggccgttgcgtggccctggcgcggccactgggttgcataat
20 cagagtgtcccttctggcccccaccagcctagtgccagcgcagcttcgtggccactggcgttgcgtggcc
aggacaaccgcacttcataaccagaacttcgtccggggccgcacgtatggctgaggtagcacagagtcacagcc
tggcatgtacaacccccccagccctgaccctgcctctgcctatgtgcctcacttcgtgcaccc
tgctgcctccgcaccctcaccctggcatacagcaggcactcaataatgccactggcaggccaaacagcca
aaaaaaaaaaaaaaaaaaaa

25

SEQ ID NO:16 (Equine TLR9)

- 17 -

cagggtcaggctgccgtgcctggctgtcccagccgcgtcaagtgtggcagtcggccagctccagggccgcagc
atcttcgcacaagacacctgcgcctctgcctggacaagtccctctcctggactgttttgt

SEQ ID NO:17 (Ovine TLR9)

5 MGPYCAPHPLSLLVQAAAALAAAALAQGTLPAFLPCELQPRGKVNWCNLFLKSVPFRSAGAPRANVTSLSLISNRIH
HLHDSDFVHSNLRVLNWKNCPPAGLSPMHPCRMIEPNFLAVPTLEELNSYNGITTVPALPSSLVSLSLSR
RTSILVLGPTHFTGLHALRFLYMDGNYYKNPCQQAVEVAPGALLGLGNLTHLSKYNNLTEVPRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLDVGNCRRCDHARNPCRECPKFKLHPDTSFLSRLLEGVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF
10 RSLTNTTLLRPLTQLPKLQSLSQLNFINQAELSIFGAFPSLLFVDLSDNRIISGAARPVAALGEVDSGVVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPFMCGVGHNLFSVAQLPSRLYLSAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGLYLCFFKGLRNVLQQLDLSKNHLHTLLPRHLDNLPKSLRQLRLDNNLAFFNWSSLTVLP
QLEALDLAGNQLKALSNGSLPPGTRLKLDVSSNSIGFVTPGFFVLANRKELNLSANALKTVDPPFWGRLTETL
15 NILDVSANPLHCACGAASFVDFLLEMQAAPGLSRRVTCGSPGQLQGRSIFAQDRLCLDETLSDLCFGFSLLMVA
LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAFVVFDKAQSADWVYNELRVQLEERRGRRAL
RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQLLEDRKDVVVVLVILRPAAYRSR
YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGMALTRDNRFHYNRNFCRGPTTAE

20 **SEQ ID NO:18 (Ovine TLR9)**

MGPYCAPHPLSLLVQAAAALAAAALAQGTLPAFLPCELQPRGKVNWCNLFLKSVPFRSAGAPRANVTSLSLISNRIH
HLHDSDFVHSNLRVLNWKNCPPAGLSPMHPCRMIEPNFLAVPTLEELNSYNGITTVPALPSSLVSLSLSR
RTSILVLGPTHFTGLHALRFLYMDGNYYKNPCQQAVEVAPGALLGLGNLTHLSKYNNLTEVPRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLDVGNCRRCDHARNPCRECPKFKLHPDTSFLSRLLEGVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF
25 RSLTNTTLLRPLTQLPKLQSLSQLNFINQAELSIFGAFPSLLFVDLSDNRIISGAARPVAALGEVDSGVVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDSLRSNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPFMCGVGHNLFSVAQLPSRLYLSAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGLYLCFFKGLRNVLQQLDLSKNHLHTLLPRHLDNLPKSLRQLRLDNNLAFFNWSSLTVLP
30 QLEALDLAGNQLKALSNGSLPPGTRLKLDVSSNSIGFVTPGFFVLANRKELNLSANALKTVDPPFWGRLTETL
NILDVSANPLHCACGAASFVDFLLEMQAAPGLSRRVTCGSPGQLQGRSIFAQDRLCLDETLSDLCFG

SEQ ID NO:19 (Ovine TLR9)

35 gtcggcacggaaagttagcgccaaagcatcttccctgcagctggccccaacttgcggccagaccctctggaga
agccgcattccctgccccatggcccccactgtgccccgcaccccccctttctctctgtgcaggccggccgcgtggc
agcagccctggcccaggccacccctgcctgccttcctgcctgtgagctccagcccccgggtaaggtgaactgcaa
ctggctttctgaagtctgtccgcgtttcggccggagccccccggccaatgtcaccagccctctcctaatt
ctccaaccgcatccaccacttgacgactctgacttcgtccacctgtccaaacctgcgggtctcaacctcaagtg
gaactgcccgcggccggcctcagccccatgcacttccctggccatgaccatcgagcccaacaccccttcgtgc
40 tggcccaccctggaggagctgaaacctgactacaatggcatcacgaccgtgcctgcctgcccagttctctgt
atccctgtcgctgagccgcaccagcatctggctgtaggccccacccacttcaccggcctgcacccctgcgt
tctgtacatggacggcaactgactataagaaccttgcacggcggatgtggggcggccctgcgt
tggcctggcaacctcacgcacccctgtcgctcaagtacaacaacctcaccggcggatgtggggcggccctc
cctggacaccctgtgactgtccataaccacatcatcaccctggccaccggaggacctggccaaatctgactgcct
45 gcgtgtctgtatgtggcgaaaactggccgcgtgcgaccacccgcacccctgcaggagtgcccaaaagaa
cttcccaagctgcaccctgacacccctgagccacccctgagccgcctcgaaaggcctgttgaaggacagtct
ctacaaaactagagaaagactgggtccgcggcctggcaggctcaagtgcgtcgaccctgactgagaacttcctca
tgactacatcaccaagaccaccatcttcaggaaacctgaccctgacccctgcgcacactcaacctgtccctcaattacca
caagaagggtgtccctcgccaccctgcaactggcaccccttggggcctgtccctggagaagctggacat
50 gcacccgcaccccttcgtccctcaccacaccacgcgtccggccgtgaccctgcggccagctggccaaagctccagat
gagctgcagctgaacttcatcaaccaggccgagctcagcatcttggggcctccggcggctgactgtccctgt
cctgtcgacaccgcacccctgcggaggctgcgaggccggatgtggcccccctggggaggatgtggacagcgggggtggaa
ctggcggtggccaccggccctgcgtccaggccgcgtggccgcgtcagcgcacccatgcgtccaaaggacttcatgc

- 18 -

5 cctcaacttcaccttgccacctgtcacggacaacactggtgacgatccagcaggagatgttaccgcctctcccg
cctccagtgcctgcgcctgagccacaacagcatctcgccaggcggttaatggctcgccagttcgccgtgaccgg
cctgcgagtgcctgcacctgtctacaacaagctggacctgtaccatggccgtcgacggagactgcgcgcaact
ggaggcactggacctcagctacaacagccagccccatgcagggcggtggccacaacactcagttcgccg
ccagctgccgtccctgcgtcacctcagccgtgcgcacaacggcatccacagccgtgtcacagaagactcagcc
cgccctcgctgcgcgcctggacttcagccgaactccctgagccagatgtggccgaggagactctatctctg
cttcttcaaaggcttgaggaacctgtccagctggacctgtccaagaaccacactgcacaccctctgcctcgta
cctggataacactgcccagagactgcggcagctgcgtctccggacaataacctggcccttcaactggagcc
cctgactgttctgccccagcttggaaagccctggatctggccggaaaccagactgaaggccctgagcaacggcagcc
gccacactggcaccggcgtccagaagactggacgtgagcagcaacagcatccggctttgtgaccctggctttgt
ccttgccaacggcgtgaaagagacttaacctcagccgaacgcctgaagacagactggatcccttctgggtcggtcg
cttaacagagaccctgaatatccttagacgtgagccgaacccgctccactgtgcctgcggggggcccttggta
cttctgtggagatgcaggccgtgcctggctgtccaggcgcgtcacgtgtggcagttccggccagctcc
ggccgcagcatctcgacaggactgcgcctgcctggatgagacccttcctggactgccttggcttc
gctgtaatgtggcgtggccctggccgtgcccattgcacggccgcggcagccggccgaggacaccctgtctacatgccttc
ccacctgtgtggccattgcacggccgcggcagccggccgaggacaccctgtctacatgccttc
ggcttcgacaaggcgcagactgtcagttggccactgggttacaacgcgactccgcgtgcagctggagggcc
cgccgcggccgcgtccgccttcgcctggaggagcggactggctccctggcaagacgccttcgagaaccctgt
ggcctcggttacagcagccgtaaagaccatgttgcgtggaccacacggaccggccgtggcccttcgccc
cagttcctgtggcccaagcagccgttggaggaccgcagggatgtcgtgggtatcctgcgccttc
cccttaccgggtcccgctacgtgcgggtgcgcgcagcccttcgcgcctggcccaagcgcgtcccttc
cagttggccaggtagcttctggccaaacctggccatggccctgaccaggacaaccgcacttcataaccggaa
cttctgcggggcccaacgcagccgaatagcacaaggactgtactggccag

25 SEQ ID NO:20 (Ovine TLR9)

atggggccccctactgtgccccgcacccccccttctctcctggcggcggcgctggcagcagccccctggccagg
ggcacccctgcctgccttcctgcccgtgagctcagccccggggtaaggtaactgcaactggctgttccctgaa
tctgtgccgcgctttcggccggagccccccggccaatgtcaccagcctctcttaatctccaaaccgcacccac
cacttgacgactctgacttgcgtccacccgtccaaacctgcgggtcctcaacctaagtggaaactgcccgcggcc
30 ggctcagccccatgcacttcccgtccgcacatgaccatcgagccccaaacacccctcctggctgtgcccaccctggag
gagctgaacctgagctacaatggcatcagcaccgtgcctgcctgcaccaggctctctctgtatccctgtcgctgagc
cgaccaggcatcctgggtctaggccccaccacttcaccggcctgcacgcctgcgccttcgtatccatggacggc
aactgtactataagaacccctgcccggcagggcgtggagggtggccccaggcgccctccttggctggcaaccc
acgcacccgtgcgtcaagtgactacaacacccatcagggagggtggcccgccctgcggccaggccctggacaccctgt
35 ctgtcctacaaccacatcatcaccctggcaccggaggacccgtccaaactgtactgcctgcgtgtgtatgt
ggcgggaaactgcgcgcgtgcgaccacgcgcacaccctgcaggagggtggccaaagaacttccccaagctgcac
cctgacacccctcagccacccgtggccctgcagggcctgggttgaaggacagttctcttacaaaactagagaaa
gactgggttccgcggcctggcaggcgtccaaactgtcgacccgtggccctatgactacatcaccac
40 accaccatctcaggaacccgtggcaccctccttggggcctgggtgtccctggagaagctggacatgcacggcatcttc
gcccacccgtcaactggcaccctccttggggcctgggtgtccctggagaagctggacatgcacggcatcttc
cgtccctcaccacaccacgcgtccggcgtgaccaggcgtcccaagctccagatgtgagttgcagctgaac
ttcatcaaccaggccgagctcagcatcttggggcctcccgagccctgtctcgtggaccctgtcgacacc
45 atcagcggagctgcgaggccgggtggccctcggggagggtggacagcgggggtggaaagtctgggggtggccagg
ggcctcgtccaggccccctggccggcgtcagcgtccaaaggacttcatgccaagctgcaacctcaacttcaccc
gacccgtcagggaaactggtgacgatccaggcaggagatgttaccggccttcggccctccggccctcaagtgcctgc
50 ctgagccacaacaggcatcgcaggcgttaatggctcgagttcgtggccctgaccggcctgcggagtgctcgac
ctgtcctacaacaagctggacccgttaccatgggcgtcgttacggagctgcgcagctggaggactggaccc
actacaacagccaggccctcagcatgcagggcgtggccacaacccgttccgtggccctggccctcaacttcaccc
cgttacccgtccgtgcacacccgcacccgcgttccgttccgttccgtgc
55 ctggacttcagcggcaactccctgagccagatgtggggcggaggagacccttatctctgttcttcaaaggctt
aggAACCTGGTCCAGCTGGACCTGTCCAAGAACCCACTGCACACCCCTCCTGCCTCGTACCTGGATAACCTGGCC
AAGAGCCTGCGGAGCTGCGTCTCCGGGACAATAACCTGGCCTTCAACTGGAGCAGCCTGACTGTTCTGGCC
CAGCTGGAAAGCCCTGGATCTGGGGAAACCAGCTGAAGGCCCTGAGCAACGGCAGCCTGCCACCTGGCACCCGG
CTCCAGAAGCTGGACGTGAGCAGCAACAGCATCGGCTTGTGACCCCTGGCTTCTTGTCTTGCAACCGGGCTG
AAAGAGCTTAACCTCAGCGCCAACGCCCTGAAGACAGTGGATCCCTTCTGGTTGGTCTGGCTTAACAGAGACCC
55 ATATCCTAGACGTGAGCGCCAACCCGCTTCACTGTGCTGCGGGCGGGCTTGTGGACTTCCTGCTGGAGATG

- 19 -

caggcggccgtgcctggctgtccaggcgctcacgtgtggcagtccggccagtcacggccgacatcttc
gcacaggacacctgcgcctctgcctggatgagacccttccttgactgcttggc

Complete nucleotide and amino acid sequences for canine and feline TLR9 are
5 publicly available. For example, an amino acid sequence for canine TLR9 is available as
GenBank accession number BAC65192 and its corresponding nucleotide sequence is
available as GenBank accession number AB104899. An amino acid sequence for feline
TLR9 is available as GenBank accession number AAN15751 and its corresponding
nucleotide sequence is available as GenBank accession number AY137581.

10 Complete nucleotide and amino acid sequences for canine and feline TLR9 were also
determined independently from those available from public databases.

An amino acid sequence of canine TLR9 is provided as SEQ ID NO:21. Based on
comparison with known amino acid sequences of human and murine TLR9, it appears that
SEQ ID NO:21 includes sequence for at least a majority of the extracellular domain, all of the
15 transmembrane domain, and at least a portion of the intracellular domain of canine TLR9
(See Figure 1). Amino acids numbered 1-822 of SEQ ID NO:21 are presumptively
extracellular domain and correspond to SEQ ID NO:22. SEQ ID NO:23 is a nucleotide
sequence of canine TLR9 cDNA having an open reading frame corresponding to nucleotides
91-3186. SEQ ID NO:24 is a nucleotide sequence of canine cDNA encoding amino acids 1-
20 822 of SEQ ID NO:21.

An amino acid sequence of feline TLR9 is provided as SEQ ID NO:25. Based on
comparison with known amino acid sequences of human and murine TLR9, it appears that
SEQ ID NO:25 includes sequence for at least a majority of the extracellular domain, all of the
transmembrane domain, and at least a portion of the intracellular domain of feline TLR9 (See
25 Figure 1). Amino acids numbered 1-820 of SEQ ID NO:25 are presumptively extracellular
domain and correspond to SEQ ID NO:26. SEQ ID NO:27 is a nucleotide sequence of feline
TLR9 cDNA having an open reading frame corresponding to nucleotides 87-3179. SEQ ID
NO:28 is a nucleotide sequence of feline cDNA encoding amino acids 1-820 of SEQ ID
NO:25.

30

SEQ ID NO:21 (Canine TLR9)

MGPCRGALHPLSLLVQAAALALALAQQGTLPAFLPCELQPHGLVNWCNWLFLKSVPRFSAAAPRGNVTSLSLYSNRH
HHLHDYDFVHFVHLRLNLKNCCPPASLSPMHFPCHMTIEPNTFLAVPTLEDLNLSYNSITTVPALPSSLVSLSL
SRTNILVLDPATLAGLYALRFLFLDGNCYYKNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYL

- 20 -

LLSYNHIIITLAPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD
 PRWFHGLGNLMVLDLSLENFLYDCITKTAKAFYGLARLRLNLNFNYHKKVSFAHLHASSFGSLLSLQELDIHGIF
 FRSLSKTTLQSLAHLPMQLRLHLQLNFIISQAQLSIFGAFPGLRYVDSLSDNRISGAAEPAATGEVEADCGERVWP
 QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLSRNNLVTVQPEMFVRLARLQCLGLSHNSISQAVNGSQFVPLSNL
 5 RVLDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFMSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA
 SLRALDFSGNTLSQMWAEGDLYLRFQGLRSVLQQLDSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSL
 ALLPKLEALDLAGNQLKALSNGSLPNTGQLQRLDLSGNSIGFVVPSFFALAVRLRELNLSANALKTVEPSWFGSL
 AGALKVLDVTANPLHCACGATFVDFLLEVQAAVPGLPSRVKCGSPGQLQGRSIFAQDILRLCLDEALSWVCFSL
 10 LAVALSLAVPMLHQLCGWDLWYCFHCLAWLPRRGRRGVDALAYDAFVFDFDKAQSSVADWVYNELRVQLEERG
 RRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLARTDRVSGLLRASFLLAQQLLEDRKDVVVLVILCPDA
 HRSRYVRLRQLRCQSVLLWPHQPSGQRSFWAQLGTALTRDNRHFYNQNFCRGPTTA

SEQ ID NO:22 (Canine TLR9)

MGPCRGALHPLSLLVQAAALALALAQGTLPAFLPCELQPHGLVNCNWFLKSVPFRSAAPRGNVTSLSLYSNRI
 15 HHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNFTFLAVPTLEDNLNSYNSITTVPALPSSLVSSL
 SRTNLVLDPATLAGLYAARFLFLDGNCYKNPCQQALQVAPGALLGLGNLTHLSLKYNNTLTVVPRGLPPSLEYL
 LLSYNHIIITLAPEDLANLTALRVLVDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD
 PRWFHGLGNLMVLDLSLENFLYDCITKTAKAFYGLARLRLNLNFNYHKKVSFAHLHASSFGSLLSLQELDIHGIF
 FRSLSKTTLQSLAHLPMQLRLHLQLNFIISQAQLSIFGAFPGLRYVDSLSDNRISGAAEPAATGEVEADCGERVWP
 20 QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLSRNNLVTVQPEMFVRLARLQCLGLSHNSISQAVNGSQFVPLSNL
 RVLDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFMSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA
 SLRALDFSGNTLSQMWAEGDLYLRFQGLRSVLQQLDSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSL
 ALLPKLEALDLAGNQLKALSNGSLPNTGQLQRLDLSGNSIGFVVPSFFALAVRLRELNLSANALKTVEPSWFGSL
 AGALKVLDVTANPLHCACGATFVDFLLEVQAAVPGLPSRVKCGSPGQLQGRSIFAQDILRLCLDEALSWVCFS
 25

SEQ ID NO:23 (Canine TLR9)

aggaaggggctgtgagctccaagcatctttccctgcagctgtcccagccgcacccctctggagaag
 cccccgcctccctgtcatggccctgcgtggccctgcacccctgtctctccctgtgcaggctgccgccta
 gcccggccctggcccagggcacccctgcctgccttcgtggccatccctgtgcaccccgccgtaaacgtcaccaggcccttccttg
 30 aactggctgttctcaagtccgtgccccgttctcggcagctgcaccccgccgttacatccctgtgcaccccgccgttacatcccttg
 tactccaaccgcatccaccacccatgactatgactttgtccacttcgtccacccctgcggccgttcaatcccttg
 tggactgcccggccgcagcctcagccccatgcactttccctgtcacatgaccattgagccaaacaccccttcctg
 gctgtgcccaccctagaggacctgaatctgagctataacagcatcacgactgtgcccgcctgcccagttcgctt
 gtgtccctgtccctgagccgcaccaacatccctggctggaccctgcccacccctggcaggcccttatgcccctgc
 35 ttccctgtccctggatggcaactgctactacaagaacccctgcacccgcaggccctgcagggtggcccccagggtgcccctc
 ctggccctggcaacccatcacacacccatgtcactcaagtacaacaacacctcaccgtggtgccgcggggccctgcccccc
 agcctggagtagctgttgcctacaaccacatcatcacccctggcacctgaggaccctggcaatctgactgcc
 ctgcgtgcctcgatgtggggactgtgcgcgtgtgaccatgcccgtacccctgcagggtggcccaag
 ggctccccccagctgcaccccaacacccctggccacccctgaggccacccctgcgaaggccctgggttggaggacagctt
 40 ctctacagcctgaccccaaggtggttccatggcctggcaacctcatggtgctggacactgagtgagaacttcctg
 tatgactgcatcacaaaaccaaagcccttctacggcctggccggctgcgcagactcaacccctgtccctcaattat
 cataagaaggtgtccttgcacccatctggcattccctccctggagccactgttccctgcaggagctggac
 atacatggcatcttcctccgtcgactcgcaagaccacgcctccatgtcgctggccacccatgtccagcgt
 ctgcgtcgacttgcaggccacccctgcaggccatgtcgacttgcggccctccctggacttgcgttacgt
 45 gacttgtcagacaaccgcacccatgtggagctgcagagccgcggctgcccacaggggaggtagaggcagactgtgg
 gagagactgtggccacaggccggacttgcgtctggccactggcaccccccggctcagaggcccttcatgc
 agctgcaggaccctcaacttccatgtggccactgtcgacccatgtcgactgttgcaggccggatgtttgtc
 cggctggccgcctccactgtggccctggacttgcggccacccatgtcgacttgcggccatgtggacttgc
 cctctgaggcaacctgggggtctggacccctgtcccataacaactgtggacccctgtaccacggccgtcgaccc
 50 ctgcgcggctggaggcccttggacccctgcacccatgcgcacccctgcgtggccacttgcggccatccatgtgg
 agctttgtggcacaaggccctgcacccctgcgtggccacttgcgtggccataccctgcaggccatgtggcc
 cagctccgcagccctcgctccggccctggacttgcgtggccataccctgcaggccatgtggccggaggagac
 ctctatctcccttccatggcaaggccctgagaaggccctgggttgcgtggccactgtccctggccatcc
 ctgcacccatggacaacctcccaaggccctgcggccctgcggccctccgtgacaattacccctggcttcc
 55 aactggaggccctggcccttgcacccatggagccctggacccctggccggaaaccagctgaaggccctgagc

- 21 -

aatggcagctgcccacccgcacccagctccagggctggacactcgccggcaacagcatcggttcgtggcccc
agctttttggccctggccgtgaggctcgagactcaacctcagcggcaacgcctctaagacggtgagccctcc
tggtttggttccctggcgggtgccctgaaagtcttagacgtgaccgcaccccttgcattgcgttgccggca
accttcgtggacttcttgcggaggtgcaggctggccctgcctagccgtgtcaagtgcggcagcccg
5 gcccagctccaggggccgoagcatcttcgcacaggacactgcgcctctgcctggacgaagcgctctccctgggtctgt
ttcagcctctcgctgtggctgtggccctgagcctggctgtgcctatgtgcaccagctctgtgtggacactc
tggtaactgttccacctgtgcctggccctggctgccccggcggggggcggcgggggtgtggatgcctggccat
gacgccttcgtggcttcgacaaggcgcagagctcggtggccgactgggtgtacaatgagctgcgggtacagcta
gaggagcggcgtggcgcgggcgtacgcctgtgtctggaggaacgtgactgggtacccggaaaaacccttc
10 gagaacctctggccctcagttacagcagccgaagacgcgtttgtctggccgcacggacagagtcagccgc
ctcctgcgtgccagcttctgtggcccaacagcgcctgtggaggaccgcagggacgtcggtgtctggatgc
ctgtgcggccgcacccgcacccgcgtatgtgcggctgcggccagcgcctctggcccaagagtgtccctctgg
ccccaccagccgcgtggcgcagcgcgcgttctggcccaagctggccacggccctgaccaggacaaccgcacttc
15 tacaaccagaacttctgcggggcccccacgcacagcctgtatggcagacagccgcacccgcgttgcggcc
ctgcctgtctgtggatgcggccacctgtggcttgcacccgcgtctgtccctacaccgcaccctggca
taaagcggccgtcaataatgtgtggtagac

SEQ ID NO:24 (Canine TLR9)

SEQ ID NO:25 (Feline TLR9)

MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRHHHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPTHELAVPTIIEELNLSYNSITTVPALPSSIVSISL

- 22 -

SRTNIVLDLDPANLAGLHSRLFLFDGNCYKNNPCPQALQVAPGALLGLGNLTHLSLKYNNLTA
5 PRWFHALGNLMVLDSLENFLYDCITKTTFQGLAQLRRLNLSFNYHKKVSFAHLIAPSGSLLSLQQQLDMHGIF
FRSLSETTLRSLVHLPLMQLSFLHQLMNFINQAQLSIFGAFCGFLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS
5 GDLALGPPGTPSSEGFMPCGCKTLNFTLDLSRNNLVTIQPEMFARLSRLQCQLLRSNSISQAVNGSQFMPLTSQV
LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQFSMQGVGHNLFSVAQLPALRYLSLAHNDIHSRVSQQLCSASL
RALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLLDSQNRLHTLLPRTLDNLPKSLRLLRLRDNYLAFFNWSSLVL
LPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG
10 TLKVLDVTGNPLHCACGAAFVDFLLEVQAAVPGLPGHVKCGSPGQLQGRSISFAQDRLCLDEALSWDCFGSLLT
VALGLAVPMHLHLCGWDLWYCFHLCIWLPRRGRRRGADALPYDAFVVFDKAQSavadwvynelrvleerrgrr
ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQRILLEDRKDVVVLVILRPDAHR
SRYVRLRORLCROSVLLWPHOPSGORSFWAOLGTALTRDNOHFYNQNFCRGPTTAE

SEQ ID NO:26 (Feline TLR9)

15 MGPCHGALHPPLSLLVQAAALAVALAAGTLPFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRHHHLHDSDFVHLSLRLNLWNCPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTPALPSSLVSLSL
SRTNILVLDPANLAGLHSRLFLFDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVERPRLPPSLEYLLLSYNNHIIITLAPEDLANLTLRVLDVGNCRRCDHARNPCMCEPKGFPHLHPDTFSHLNHLEGVLKDSSLYNLN
PRWFHALGNLMVLDLSENFPLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSFGSLLSLQQLDMHGIF
20 FRSLSETTLRSLVHLPMLQSLHQMFNINQAQLSIFGAFFPGLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS
GDLALGPGPGTPSSEGFMPCGKTLNFTLDLSRNLLNTIQPEMFARLSRLQCLLSSRNSTSQAVNGSQFMPQLTSLOV
LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMQGVGHNLFSVVAQLPALRYSLAHNDIHSRVSQQLCSASL
RALDFSGNALSRMWAEGDLYLHFFRGLRSVLRLDSLQSNRLHLLPRTLDLNLPKSLRLLRLRDNYLAFFNWSSLVL
25 LPRLEALDLAGNQLKALSNGLSPNGTQLQRLDLSNSNISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG
TLKVLDVTGNPLHCACGAAFVDFLLEVOAAVPGLPGHVKCGSPGQLOGRSIFAQDRLCLDEALSWDCFG

SEQ ID NO:27 (Feline TLR9)

30 agggctcgagctccaggcattctctgcacatcgctgcccagtctccatccagaccctctggagaagcccc
cactccctgtcatgggcccctgcattggccctgcacccctgtctctctggcaggctggcgctggccg
tggccctggcccagggcacccctgccttcgccttgcggcactgtgagctccagcgcacggcctggtaattgcact
ggctgttcccaagtcctgcggcacttctcgccggcagcgcggcgtgtacatgcaccagccttcctgtact
ccaaccgcatccaccacccacccactccacgactccgactttgtccacccgtccagccctgcggcgctcaacctaattgg
actgcccaccggccaggctcagcccatgcactccctgtcacatgaccattgagccccacaccccttcctggccg
tgccccccctggaggagctgaacctgagctacaacagcatcagcagacttccgcctgcccagttccctgtgt
35 ccctgtccctggagccgtaccaacatccctgggtctggaccctgcacccctgcaggcgtcactccctgcgettc
tggccctggatggcaactgtactacaagaaccctgcggcaggccctgcaggtggcccccggggccctcttgc
gcctggcaacccctacgcacccgtcactcaagtacaacaacccactcactgcggtgcggccggcctggcccccaccc
tggagtacccgttattgtccataaccacatcatcaccctggcacctgaggacccctggccaaacctgtaccgcctgc
gtgtgtcgatgtgggtgggaaactggcgtcgctgtgaccacgcccgaacccctgtatggagtggcccaagggt
40 tcccgcacctgcaccctgacacccttcagccacccatgaaaccacccctcgaaaggcctgggtgaaggacagctctct
acaacccatgaaaccctggatggttccatgcctggcaacccctatgggtctggaccctgagtgagaacttcttatatg
actgcacccatggccacccacccatgcacccctggccaggccctggccagctgcgcagactcaacttgccttcaattaccaca
agaagggtgtcccttgcacccatgcacccatggcgccttcctggagccctgtctccctgcagcagctggacatgc
atggcatcttcccgctcgctcaggcagaccacgcctccggcgtcgctggccacccatgcctccagatgtc
45 acctgcagatgaacttcatcaatcaggcccgatgcacccatgcacccatggggccctccctggcctgegatcgtgacc
tgtcagacaaccgcataaagtggagccatggagatggggctggccacccggggaggtggatggggagagatgtcc
ggctgcacccatggggacccatgcacccatggggccacccctagctcccgagggcctatgcacccatgc
ccctcaacttcacccatggacccatgcacccatggggccacccctagctcccgagggcctatgcacccatgc
50 gcttcacccatggggccctgcacccatggggccacccctagctcccgagggcctatgcacccatgc
gcttcacccatggggccctgcacccatggggccacccctagctcccgagggcctatgcacccatgc
gcttcacccatggggccctgcacccatggggccacccctagctcccgagggcctatgcacccatgc
gcttcacccatggggccctgcacccatggggccacccctagctcccgagggcctatgcacccatgc
55 gcttcacccatggggccctgcacccatggggccacccctagctcccgagggcctatgcacccatgc
tgaggccctggacccatgcacccatggggccctgcacccatggggccacccctagctcccgagggcctatgcacccatgc
cacagctgccccccctgcgtatctcagccctggccacccatccacagccgtgtgtcccgagccatgc
gcccctgcgtggggccctggacttcagccgtgtgtcccgatgtggggccagggagacccatgtatctcc
acttctcccgaggccctgaggagccctggatctgtcccaatgcacccatgc
ccctggacaacccatcccaagagccctggcgtgtgtcccgatgtggccacccatgc

- 23 -

5 gcctggtcctcccccaggctggaagccctggacactggcgaaaaccagctgaaggccctgagcaacggcagct
 tcctaatggaaacccagctccagaggctggacactcagcagcaacagatcagcttcgtggctccagcttttg
 ctctggccaccaggctcgagagctcaacctcagtgccaacgcctcaagacggtgagccctctgggtcggt
 ctctagcgggaccctgaaagtcttagatgtactggcaacccctgcaactgcgcctgtggggcggttcgtgg
 10 acttcttgcggagggtcaggctgcagtgcggccctggcaggccacgtcaagtgtggcagtcagctcc
 agggccgcagcatcttgcgcaggatctgcgcctctgcctggatgaggccctctctggactgtttggcctc
 cgctgtgaccgtggccctgggcctggccatgtgcaccacccctgtggctggacctctggactgt
 tccacctgtgcctggcctggctgccccgggggggggggggggggggggggggggggggggggggg
 15 tggcttcgacaaggcacagagcgcggtgccgactgggtgtacaacagactgcggtaacggctagaggagcgg
 gtggacgccgagccctggcgtgcctggaggaacgtgactggctacccggtaaaacgcctttgagaacacgt
 gggccctcagttacagcagccgcagatgtgttgtgtgcggccacacagacagggtcagcggccttgcgc
 ccagcttcgtgcggccagcagccgcctgtggaggaccgcaggacgttgtgtgcggatgcctgcgc
 acgcccaccgcctccgcataatgtgcggctgcgcaggccctgcgcggccagacgcgtcctctggcc
 ccagtgccagcgcagttctggccagctggcaccggccctgaccaggacaaccacacttctataaccaga
 20 acttctgcggggccccacgacggcagactgaccggccagcacccttcacccctgtctgcctgg
 ggtatgcgggg

SEQ ID NO:28 (Feline TLR9)

20 atggggccctgcacatggcgccctgcaccccccgtctctctctggtcaggctgcgcgtggccgtggccctggcc
 cagggcaccctgcctgcctttctgcctctgtgagctccagcgcacggcctggtaattgcactggctgttcc
 aagtccgtgcccacttctccggcgcagcgcggccatgttgcacccctgtcagccgcggcgtctcaaccc
 caccacccacgcactccgcactttgttgcacccctgtcagccgcggcgtctcaaccc
 gccagccctcagcccatgcacttccctgtcataatgcggccatgttgcaccc
 gaggagctgaacctgagctacaacagcatcagcagacttccctgcgtgtccctgtccttgc
 25 agccgtaccaacatcctgggtctggacccctgccaacccctgcaggcgttgcactccctgcgttgc
 ggcaactgtactacaagaacccctgcggccgcaggccctgcagggtggcccccggggcc
 cttacgcacctgtcactcaagtacaacaacccctcactgcgggtgcggccctgc
 ctattgtcctacaaccacatcatcaccctggcacctgaggacctggcaacact
 gtgggtggaaactgcgtcgtgaccacgcggcaacccctgtatggagtgcccaagg
 30 caccctgacacccctgcacccctgcacccctgcacccctgcacccctgcaccc
 cccagatggttccatgcctggcaacccctcatgggtctggacccctgcagg
 tttgcacccctgcacccctgcacccctgcacccctgcacccctgcaccc
 ttccgcgtcgtcagcggacccacgcgtccggcgtggccacccctgcaccc
 35 aacttcatcaatcaggcccagctcagcatcttcggggccctccctggc
 cgcataagtggagccatggagctggcggtgcacggggggagggtggatgg
 ggggacccatgtctggcccacccggccaccccttagtccgcagg
 accttggacccctgtcaggaacaacccctgtatggacatcc
 ctgtccctgagccgcaacccatctcgacggcgttgcaccc
 40 ctggacccctgtccataacaagctggacccctgttccatggcgcttcc
 gacccctgcgtatccgcgtccgcaccc
 gcccctgcgtatccgcgtccgcaccc
 cgggcctggacttgcggcaatgccttgcaggccatgtgg
 ggcctgaggagccctgggtccggatctgtcc
 45 ctcccccaagccctgcggctgtgcgtccctgacaattatctgg
 ctcccccaggctggaaaggccctggacccctggcgaaaacc
 accccagctccagaggctggacccctcagc
 aggctgcgagagctcaaccc
 accctgaaaggcccttagatgtactgg
 50 gaggtgcaggctgcaggccctgcaggccacgtcaagtgtgg
 atcttgcgcaggatctgcgcctctgcctggatgagg
 ccctctctggactgttttgg

Complete nucleotide and amino acid sequences for murine and human TLR9 are publicly available. For example, an amino acid sequence of murine TLR9 is available as

- 24 -

GenBank accession no. AAK29625, provided as SEQ ID NO:29. Amino acids numbered 1-821 of SEQ ID NO:29 presumptively include the entire extracellular domain and correspond to SEQ ID NO:30. SEQ ID NO:31 corresponds to GenBank accession number AF348140, which is a nucleotide sequence of murine TLR9 cDNA. SEQ ID NO:32 is a nucleotide sequence of murine cDNA encoding amino acids 1-821 of SEQ ID NO:29.

An amino acid sequence of human TLR9 is available as GenBank accession no. AAF78037, provided as SEQ ID NO:33. Amino acids numbered 1-820 of SEQ ID NO:33 presumptively include the entire extracellular domain and correspond to SEQ ID NO:34. SEQ ID NO:35 corresponds to GenBank accession number AF245704, which is a nucleotide sequence of human TLR9 cDNA. SEQ ID NO:36 is a nucleotide sequence of human cDNA encoding amino acids 1-820 of SEQ ID NO:33.

SEQ ID NO:29 (Murine TLR9)

MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPFRSAAACSNITRLSLISNRI
 15 HHLHNSDFVHLSNLRQLNLKWNCPPGTGSPHLFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL
 SHTNLVLDANSLAGLYSLRVLFDMDGCYKNPCTGAVKVTGALLGSLNLTHLSLKYNNLTKVPRQLPPSLEYL
 LVSYNLIVKLGPEDLANLTSRVLVDVGNCRRCDHAPNPCTIECGQKSLHLPETFHHLSHLEGVLVKDSSLHTLN
 SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRRKLNLSTNYRKVSFARLHASSFKNLVSLQELNMNGIF
 FRSLNKYTLRWLADLPKLHTLHQMNFINQAOQLSIFTGTFRALRFVDSLSDNRISGPSTISETPEEADDAEQEELL
 20 SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ
 VLDLSHNKLDLYHWKSFSELPOQLQALDLSYNSQPFMSMKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLNSNS
 VRFLDFSGNGMGRMWDEGGYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSL
 25 FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNIKTVDRSWFGPIV
 MNLTVDVRSNPLHCACGAAFDLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFGLSLL
 AVAVGMVVPILHHLCGWDVYCFHLCIAWLPLLARSRRSAQALPYDAFVVFDKAQSavadwvynelrvrleerrg
 RRALRLCLEDRDWLPGQTLFENLWASITYGSRKTLFVLAHTDRVSGLLRTSFLLAQQRILLEDRKDVVVLVILRPDA
 HRSRYVRLRQRLCRQSVLFWPQQPNGQGGFWAQLSTALTRDNRHFYQNQNFRCRGPTAE

SEQ ID NO:30 (Murine TLR9)

MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPFRSAAACSNITRLSLISNRI
 30 HHLHNSDFVHLSNLRQLNLKWNCPPGTGSPHLFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL
 SHTNLVLDANSLAGLYSLRVLFDMDGCYKNPCTGAVKVTGALLGSLNLTHLSLKYNNLTKVPRQLPPSLEYL
 LVSYNLIVKLGPEDLANLTSRVLVDVGNCRRCDHAPNPCTIECGQKSLHLPETFHHLSHLEGVLVKDSSLHTLN
 SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRRKLNLSTNYRKVSFARLHASSFKNLVSLQELNMNGIF
 FRSLNKYTLRWLADLPKLHTLHQMNFINQAOQLSIFTGTFRALRFVDSLSDNRISGPSTISETPEEADDAEQEELL
 35 SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ
 VLDLSHNKLDLYHWKSFSELPOQLQALDLSYNSQPFMSMKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLNSNS
 VRFLDFSGNGMGRMWDEGGYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSL
 FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNIKTVDRSWFGPIV
 40 MNLTVDVRSNPLHCACGAAFDLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFG

SEQ ID NO:31 (Murine TLR9)

tgtcagaggggagccctgggagaatcctccatctcccaacatgtttctccgtcgaaggactctgcaccccttgc
 ctccctggtagaggctgcagtgcggctgagactctggccctggtagccctgcctaccctgtgagctg

- 25 -

SEQ ID NO:31 (Murine TLR9)

45 atggttctccgtcgaggactctgcaccccttgccttcctgtacaggctgcagtgcggctgagactctggc
ctgggtaccctgcctgccttcacctgtgagctgaagctcatggcctggactgcaattggctgttctg
aagtctgtacccgttctctgcggcagcatctgtccaaatcaccgccttccttgatctccaaccgtatc
caccacctgcacaactccgacttcgtccacctgtccaaacctgcggcagctgaacctcaagtggaaactgtccacc
actggccttagccccctgcacttcttgcacatgaccatgtgagccagaaccttctggctatgcgtacactg
50 gaggagctgaacctgagctataatggtatcaccactgtgcccggactgcccagctccctggtaatctgaggctg
agccacaccaacatctgttcttagatgtctaaccgcctcgccggctatacagcctgcgcgttcttcatggc
gggaaactgtactacaagaacccctgcacaggagcggtaaggtgaccggcgcctctggcctgagaat
ctcacccatctgtctctgaaagtataacaacccatcacaagggtgcccggccactgccccccagctggagttacctc
ctggtgtctataacccatgtcaagctggggctgaagacctggccatctgaccccttcgagttacttgat
55 gtgggtgggaaattgccgtcgctgcgaccatgcccccaatccctgtatagaatgtggccaaaagtcctccacactg
caccctgagacccatcacctgagccatctgaaaggcctggctgctgaaggacagctctccatcacactgaaac
tcttcctggttccaaggctggtaacccctcggctggacctaagcgagaacttctcttatgaaagcatcaac
cacaccaatgccttcagaacctaaccqccctqcqcaqctcaacctgtcctcaattaccggaaagaaggatcc

- 26 -

tttggccgcctcaccctggcaaggtaacttccttcaagaacactgggtcactgcaggagctgaacatgaacggcatcttc
 ttccgctcgctcaacaaggtaactacgctcagatggctggccgatctgcccactccacactctgcacatcttcaaat
 aacttcataccaggcacagctcagatcttgcacccctcgccatctgcggacttgtcagacaat
 cgcattcaggcttcaacgcgtcagaaggccaccctgaagaggcagatgtcagagcaggaggagctgt
 5 tctgcggatcctcaccctggacttcactgagcacccctgcattcaagaacttcataggacaggtaagaacttcac
 ttcaccatggacctgtctcgaaacaactggtaactatcaagccagagatgttgcattctcagccctccag
 tgtcttagcctgagccacaactccattgcacaggctgtcaatggctctcagttccgcctgactaatctgcag
 gtgctggacctgtcccataacaaaactggacttgtaccactggaaatcgatcgtgagctaccacagttgcaggcc
 ctggacctgagctacaacagccagcccttagcatgaaggataggccacaatttcagtttgccatctg
 10 tccatgtctacacacgccttagcctggcacacaatgcacattcataccgtgtcctcacatctcaacagcaactca
 gtgagggtttcttgacttcagcggcaacggtatggccgcattgtggatggggcccttatctccattctc
 caaggcctgagttggcctgctgaagctggacctgtctcaaaaataacctgcatactcccccggccagaacccct
 aaccccccagagcctgaagctgtcagccctcgagacaactacctatctttaactggaccagtctgtcc
 15 ttcctgcccacactggaaactggcttagacactggcaggcaaccagctaaggccctgaccaatggcaccctgcctaaat
 ggcaccctcctccagaaactggatgtcagcagcaacagtatgtctctgtggcccttcgtctggc
 gtcgagctgaaagaggtcaacctcagccacaacattctcaagacggtgatcgtctggatggccattgt
 atgaacctgacagttctagacgtgagaagcaacccctctgcactgtgcctgtggccagccctcgtagacttactg
 ttggaggtgcagaccaaggcctggcctggctaatgggtgaaagtgtggcagccccggccagctgcagggccgt
 agcatcttcgcacaggcacctggcggctgtgcctggatgaggccctcttgactgcttggc
 20

SEQ ID NO:33 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFKSVPHFSMAAPRGNVTSLSLSSNRI
 HHLHDSDFAHPLPSRLRHLNLKWNCPVGSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSSNRI
 SHTNILMDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNTVVPRNLPSSLEYL
 25 LLSYNRIVKLAPEDLANLTALRVLVDGGNCRRCDHAPNPMCEPCRHFQPLHPDTFSHLSRLEGVLKDSSLWSLN
 ASWFRGLGNLRLVLDLSENFLYKCIKTKAFQGLTQLRKLNLSFNYQKRVSAHLSLAPSFGSLVALKEELDMHGIF
 FRSLETTLRPLARLPMQLQTLRLQMNFINQAQLGIIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQP
 GDLAPAPVDTPSSEDFRPNCSTLNFTLDSLRSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
 LDLSRNKLDLYHEHSFTELPRLEALDLSSYNSQPGFMQGVGHNFVFVAHLRTLRLSLAHNNIHSQVSQQLCSTSL
 30 RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVRLRDNYLAFFKWWSLHF
 LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLAS
 ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGPLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLA
 VALGLGVPMHLHLCWDLWYCFHLCIWLWPWRGRQSGRDEDALPYDAVVFDKTQSADWVYNELRGQLEECRG
 RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDG
 35 RRSRYVRLQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHFYNRNFCQGPTAE

SEQ ID NO:34 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFKSVPHFSMAAPRGNVTSLSLSSNRI
 HHLHDSDFAHPLPSRLRHLNLKWNCPVGSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSSNRI
 SHTNILMDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNTVVPRNLPSSLEYL
 LLSYNRIVKLAPEDLANLTALRVLVDGGNCRRCDHAPNPMCEPCRHFQPLHPDTFSHLSRLEGVLKDSSLWSLN
 ASWFRGLGNLRLVLDLSENFLYKCIKTKAFQGLTQLRKLNLSFNYQKRVSAHLSLAPSFGSLVALKEELDMHGIF
 FRSLETTLRPLARLPMQLQTLRLQMNFINQAQLGIIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQP
 GDLAPAPVDTPSSEDFRPNCSTLNFTLDSLRSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
 45 LDLSRNKLDLYHEHSFTELPRLEALDLSSYNSQPGFMQGVGHNFVFVAHLRTLRLSLAHNNIHSQVSQQLCSTSL
 RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVRLRDNYLAFFKWWSLHF
 LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLAS
 ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGPLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFA

50 SEQ ID NO:35 (Human TLR9)

aggctggtataaaaatcttacttccttattctctgagccgctgtggccctgtggaaaggacctcgagtgtga
 agcatcccttcctgttagctgtccagtcgtccatctgcggccatcatgtggccatgaccctggccctgggt
 ttctgcggcagccctgcaccctgtcttcctggcagggccatcatgtggccatgaccctggccctgggt

- 27 -

SEQ ID NO:36 (Human TLR9)

45 atgggtttctgcgcagggccctgcacccgctgtctctcttggtcaggccatcatgtggccatgaccctggc
ctgggtacctgcctgccttcacctgtgagctccagccccacggctgtgaactgcacttgctttctgt
aagtctgtccccacttctccatggcagcacccctggcaatgtcaccacgccttcattgtccccaaccgcac
caccacccatgattctgactttgcccacctggccagcctggcatcaacctaagtggaaactgcccggc
gttggcctcagccccatgcacttccctgccacatgaccatcgagccccagcaccttctggctgtgcccaccc
50 gaagagactaaacctgagctacaacaacatcatgactgtgcctgcgtgccaatccctcatatccctgtccctc
agccataccacatcctgtatgtagactctgcagcctgcggccctgcatgccctgcgttccattatggac
ggcaactgttattacaagaacccctgcaggcaggcaactggagggtggcccccgggtgcctccctggc
ctcacccacctgtcaactcaagtacaacaacactactgtggtgcggcccaacctgcctccagcctggagtatctg
55 ctgttgtccataaccgcacatgtcaactggccctgaggacactggccaaatctgaccgcctgcgtgtgc
gtggggcggaaattggccgcgctgcgaccacgctccaaacccctgcatggagtgcctcgtacttcccc
catcccgataccctcagccacctgagccgtcttgaaggcctgggtgtgaaggacagtctctcc
gcaacttccatcaaaaatgcacact

- 28 -

aaaaccaaggccttccagggcctaacacagctgcgaagcttaacctgtccttcaattaccaaaagagggtgtcc
tttgcccacctgtctctggcccttccttcggagcctggctgcgcctgaaggagctggacatgcacggcatcttc
ttccgctactcgatgagaccacgctccggccactggcccctgcgcctgcgcctgcgcactgtggacactgtcgcatgc
aacttcataaccaggcccagctggcatcttcaggcccttcctggcctgcgcactgtggacactgtcgcatgc
cgcatcagcggagcttcggagctgacagccaccatggggagggcagatggaggggagaaggctgtgcagc
ggggaccttgcctccggccccagttggacactcccagctctgaagacttcaggcccaactgcagcacccctcaacttc
accttggatctgtacggacaacactgtgtgaccgtgcagccggagatgttgcctccagttctgcgcactgtgc
ctgcgcctgagccacaactgcacatctgcaggcagtcaatggctccagttctgcgcactgtgcaggtg
ctagacactgtcccgcaataagctggacacttaccacagcactcattcacggagctaccgcacttgaggccctg
gacactcagctacaacagccagcccttggcatgcaggcgtggccacaacttcagcttcgtggctcacctgcgc
accctgcgccacccctcagctggcccacaacaaacatccacagccaactgtcccagcagctctgcagta
cgccgcctggacttcagcgcaatgcactggccatatgtggccgagggagacctctatctgcacttctccaa
ggctgagcggtttgatctggctggacttgtccagaaccgcctgcacacccttcgtggcccaaaccctgcgc
ctcccaagagcctacaggtgctgcgtctccgtgacaattacttgccttcattgtggtgaggccctccacttc
ctgcccuaacttggaaacttgcgtccgcggctgaaaccggctgaaaggccctgaccaatggcagc
accggctccggaggctggatgtcagctgcacagcatcagcttcgtggcccccggcttcatttccaaggccaag
gagctgcgagagactcaaccttagcgccaaacgcctcaagacagtgaccacttcgtggccctggcgag
gcctgccaaataactagatgtaaagcgccaaacccttcgcactgcgcctgtggccggcttattggacttctgc
gaggtgcaggctgcgtggccgtctgcccagccgggtgaagtgtggcagttccggccagctccaggccctc
atcttgcacaggacactgcgccttcgcctggatgaggcccttcctggactgtttcgcc

In addition to the foregoing native rat, porcine, bovine, equine, and ovine TLR9 polypeptides and nucleic acid molecules encoding them, chimeric TLR9 polypeptides and nucleic acid molecules encoding them are provided by the invention. The chimeric polypeptides include at least one amino acid substitution based on a comparison of conserved and non-conserved amino acids among at least two of rat, murine, porcine, bovine, equine, ovine, canine, feline, and human TLR9. The information contained in a multiple sequence alignment of these various TLR9 polypeptide sequences, provided for example in Figure 1, can be used to identify and select individual amino acid positions and even individual amino acids to substitute in designing a chimeric TLR9. The substitution or substitutions can be effected using methods known to those of ordinary skill in molecular biology. Nucleic acids encoding the native or chimeric polypeptides of the invention can be inserted into an expression vector and used to express TLR9 polypeptide.

A conservative amino acid substitution shall refer to a substitution of a first amino acid for a second amino acid, wherein side chains of the first amino acid and the second amino acid share similar features in terms of hydrophobicity, size, aromaticity, or tendency to alter conformation. For example, conservative amino acid substitutions generally may be made between members within each of the following groups: hydrophobic (A, I, L, M, V), neutral (C, S, T), acidic (D, E), basic (H, K, N, Q, R), and aromatic (F, W, Y). A non-conservative amino acid substitution refers to any other amino acid substitution.

- 29 -

An expression vector for TLR9 will include at least a nucleotide sequence coding for a TLR9, or a fragment thereof coding for a functional TLR9 polypeptide, operably linked to a gene expression sequence which can direct the expression of the TLR9 nucleic acid within a eukaryotic or prokaryotic cell. A "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked.

With respect to TLR9 nucleic acid, the "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the TLR9 nucleic acid to which it is operably linked.

The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPRT), adenosine deaminase, pyruvate kinase, β -actin promoter, and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus (e.g., SV40), papillomavirus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), cytomegalovirus (CMV), the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase (TK) promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art.

The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein (MT) promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined nucleic acid coding sequence for a TLR9 polypeptide. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

- 30 -

Generally a nucleic acid coding sequence and a gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or control of the gene expression sequence. Thus the TLR9 nucleic acid coding sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the TLR9 nucleic acid coding sequence under the influence or control of the gene expression sequence. If it is desired that the TLR9 sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the TLR9 sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the TLR9 sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a TLR9 nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that TLR9 nucleic acid sequence such that the resulting transcript might be translated into the desired TLR9 protein or polypeptide.

A "TLR9 ligand" as used herein refers to a molecule that specifically binds a TLR9 polypeptide. In one embodiment the TLR9 ligand specifically binds a TLR9 polypeptide corresponding to at least a ligand-binding portion of the extracellular domain of TLR9. In most instances a TLR9 ligand will also induce TLR9 signaling when contacted with TLR9 under suitable conditions. TLR9 signaling refers to TLR/IL-1R signal transduction mediated through the TLR9, as described in further detail elsewhere herein. As mentioned above, CpG nucleic acids have been reported to be TLR9 ligands, but TLR9 ligands may include other entities as well, including, for example, small molecules. As also previously mentioned, there appears to be a species-specific preference for at least certain TLR9s and certain CpG motifs. As used herein, a species-preferred CpG DNA refers to a particular CpG DNA that is optimized for signal induction by a TLR9 of a particular species. A CpG DNA that is optimized for signal induction by a TLR9 of a particular species refers to a CpG DNA having a sequence that preferentially binds to and/or induces signaling by TLR9 of that species. For example, a human-preferred CpG DNA shall refer to a CpG DNA that optimally stimulates human TLR9 to signal through its TIR domain. Likewise, a murine-preferred CpG DNA

- 31 -

shall refer to a CpG DNA that optimally stimulates murine TLR9 to signal through its TIR domain. Examples of human-preferred and murine-preferred CpG DNA are ODN 2006 (SEQ ID NO:58) and 1668 (SEQ ID NO:60), respectively.

The binding and species specificity of TLR9s are believed to be influenced by key 5 amino acids present in the extracellular domain of TLR9. Key amino acids in a TLR9 as used herein refer to those amino acids which contribute significantly to ligand binding and ligand specificity of a particular TLR9 polypeptide.

A "CpG nucleic acid" or a "CpG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine 10 dinucleotide sequence, i.e., "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanine and linked by a phosphate bond) which activates a component of the immune system. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

In one embodiment a CpG nucleic acid is represented by at least the formula:

15 $5'-N_1X_1CGX_2N_2-3'$

wherein X_1 and X_2 are nucleotides, N is any nucleotide, and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

20 Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Pat. Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe 25 immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

An immunostimulatory nucleic acid molecule, including for example a CpG DNA, 30 may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base. As

- 32 -

used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base-containing polymer. The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

The substituted purines and pyrimidines of the immunostimulatory nucleic acids include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The immunostimulatory nucleic acid is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' to 3' (or equivalent) order from left to right and that "A" denotes adenine, "C" denotes cytosine, "G" denotes guanine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

- 33 -

Immunostimulatory nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g., genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g., produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

The immunostimulatory nucleic acids can be produced on a large scale in plasmids, (see *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, 10 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

15 For use in the instant invention, the immunostimulatory nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the β-cyanoethyl phosphoramidite method (Beaucage SL and Caruthers MH, *Tetrahedron Lett* 22:1859 (1981)); nucleoside H-phosphonate method (Garegg et al., *Tetrahedron Lett* 27:4051-4054 (1986); Froehler et al., *Nucl Acid Res* 14:5399-5407 (1986); 20 Garegg et al., *Tetrahedron Lett* 27:4055-4058 (1986); Gaffney et al., *Tetrahedron Lett* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

25 The immunostimulatory nucleic acid may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Immunostimulatory nucleic acids can be produced on a large scale in plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

A “stabilized immunostimulatory nucleic acid” shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endo-nuclease). 30 Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an

oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

- Some stabilized immunostimulatory nucleic acids have a modified backbone. It has
5 been demonstrated that modification of the oligonucleotide backbone provides enhanced
activity of the immunostimulatory nucleic acids when administered *in vivo*. Nucleic acids,
including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and
multiple phosphorothioate linkages at the 3' end, preferably 5, may provide maximal activity
and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.
10 Other modified oligonucleotides include phosphodiester modified oligonucleotide,
combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate,
methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these
combinations and their particular effects on immune cells is discussed in more detail in U.S.
Pat. Nos. 6,194,388 and 6,207,646, the entire contents of which are incorporated herein by
15 reference. It is believed that these modified oligonucleotides may show more stimulatory
activity due to enhanced nuclease resistance, increased cellular uptake, increased protein
binding, and/or altered intracellular localization. Both phosphorothioate and phosphodiester
nucleic acids are active in immune cells.

Other stabilized immunostimulatory nucleic acids include: nonionic DNA analogs,
20 such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by
an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged
oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol
or hexaethyleneglycol, at either or both termini have also been shown to be substantially
resistant to nuclease degradation.

25 Phosphorothioate nucleic acid molecules may be synthesized using automated
techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and
alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and
alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S.
Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid
30 phase synthesis using commercially available reagents. Methods for making other DNA
backbone modifications and substitutions have been described. Uhlmann E and Peyman A
(1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165.

- 35 -

Other sources of immunostimulatory nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty 5 vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene 10 be expressed in the cell.

Nucleic acid-binding fragments of TLRs are believed to include the extracytoplasmic (extracellular) domain or subportions thereof, such as those which include at least an MBD motif, a CXXC motif, or both an MBD motif and a CXXC motif.

Both mouse and human TLR9 have an N-terminal extension of approximately 180 15 amino acids compared to other TLRs. An insertion also occurs at amino acids 253-268, which is not found in TLRs 1-6 but is present in human TLR7 and human TLR8. This insert has two CXXC motifs which participate in forming a CXXC domain. The CXXC domain resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g., methyl-CpG binding protein-1 (MBD-1). Fujita N et al. (2000) 20 *Mol Cell Biol* 20:5107-18. Both human and mouse TLR9 CXXC domains occur at aa 253-268:

CXXC motif:	GNCXXCXXXXXXCXXC	SEQ ID NO:62
Human TLR9:	GNCRRCDHAPNPCM	SEQ ID NO:63
25 Murine TLR9:	GNCRRCDHAPNPCM	SEQ ID NO:64

An additional motif believed to be involved in CpG binding is the MBD motif, also found in MBD-1, listed below as SEQ ID NO:53. Fujita, N et al.(2000) *Mol Cell Biol* 20:5107-18; Ohki I et al. (1999) *EMBO J* 18:6653-61. Amino acids 524-554 of hTLR9 and 30 aa 525-555 of mTLR9 correspond to the MBD motif of MBD-1 as shown:

MBD motif:

- 36 -

MBD-1	R-XXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:65
hTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:66
mTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:67
5	hTLR9 Q-VLDLSRN-K-L-D-L-Y-HEHSFTELP-R-L-EALDLS-Y	SEQ ID NO:68
	mTLR9 Q-VLDLSHN-K-L-D-L-Y-HWKSFSELP-Q-L-QALDLS-Y	SEQ ID NO:69

Although the signaling functions of MBD-1 and TLR9 are quite different, the core D-X-Y is conserved and is believed to be involved in CpG binding.

10 According to another aspect of the invention, a screening method is provided for identifying an immunostimulatory compound. The method according to this aspect of the invention involves contacting a functional TLR9 with a test compound; detecting presence or absence of a response mediated by a TLR9 signal transduction pathway in the presence of the test compound arising as a result of an interaction between the functional TLR9 and the test compound; and determining the test compound is an immunostimulatory compound when the presence of a response mediated by the TLR9 signal transduction pathway is detected.

15 An immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell. A TLR9 ligand that is an immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell that expresses TLR9. A 20 TLR9 ligand that is an immunostimulatory compound is also a natural or synthetic compound that is capable of inducing a TLR/IL-1R signal transduction pathway when contacted with a TLR9. Immunostimulatory compounds include but are not limited to immunostimulatory nucleic acids. The immunostimulatory compound can be, for example, a nucleic acid 25 molecule, polynucleotide or oligonucleotide, a polypeptide or oligopeptide, a lipid or lipopolysaccharide, a small molecule.

30 A basis for certain of the screening assays is the presence of a functional TLR9 in a cell. The functional TLR9 in some instances is naturally expressed by a cell. In other instances, expression of the functional TLR9 can involve introduction or reconstitution of a species-specific TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an

- 37 -

immunostimulatory nucleic acid. In yet other instances, expression of the functional TLR9 can involve introduction of a chimeric or modified TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact
5 with an immunostimulatory nucleic acid. Examples of cell lines lacking TLR9 or immunostimulatory nucleic acid responsiveness include, but are not limited to, 293 fibroblasts (ATCC CRL-1573), MonoMac-6, THP-1, U937, CHO, and any TLR9 knock-out. The introduction of the species-specific, chimeric or modified TLR9 into the cell or cell line is preferably accomplished by transient or stable transfection of the cell or cell line with a
10 TLR9-encoding nucleic acid sequence operatively linked to a gene expression sequence (as described above). Methods for transient and for stable transfection of a cell are well known in the art.

The screening assays can have any of a number of possible readout systems based upon either TLR/IL-1R signaling pathway or other assays useful for assessing response to
15 immunostimulatory nucleic acids. It has been reported that immune cell activation by CpG immunostimulatory sequences is dependent in some way on endosomal processing.

In certain embodiments, the readout for the screening assay is based on the use of native genes or, alternatively, cotransfected or otherwise co-introduced reporter gene constructs which are responsive to the TLR/IL-1R signal transduction pathway involving
20 MyD88, TRAF, p38, and/or ERK. Häcker H et al. (1999) *EMBO J* 18:6973-6982. These pathways activate kinases including κB kinase complex and c-Jun N-terminal kinases. Thus reporter genes and reporter gene constructs particularly useful for the assays can include a reporter gene operatively linked to a promoter sensitive to NF-κB. Examples of such promoters include, without limitation, those for NF-κB, IL-1 β , IL-6, IL-8, IL-12 p40, CD80,
25 CD86, and TNF- α . The reporter gene operatively linked to the TLR-sensitive promoter can include, without limitation, an enzyme (e.g., luciferase, alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase (CAT), etc.), a bioluminescence marker (e.g., green-fluorescent protein (GFP, U.S. Pat. No. 5,491,084), blue fluorescent protein, etc.), a surface-expressed molecule (e.g., CD25), and a secreted molecule (e.g., IL-8, IL-12 p40, TNF- α). In
30 certain embodiments the reporter is selected from IL-8, TNF- α , NF-κB-luciferase (NF-κB-luc; Häcker H et al. (1999) *EMBO J* 18:6973-6982), IL-12 p40-luc (Murphy TL et al. (1995)

- 38 -

Mol Cell Biol 15:5258-5267), and TNF-luc (Häcker H et al. (1999) *EMBO J* 18:6973-6982). At least one of these reporter constructs (NF-κB-luc) is commercially available (Stratagene, La Jolla, CA). In assays relying on enzyme activity readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, 5 color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using FACS analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many such readout systems are well known in the art and are commercially available.

10 According to one embodiment of this method, comparison can be made to a reference immunostimulatory nucleic acid. The reference immunostimulatory nucleic acid may be any suitably selected immunostimulatory nucleic acid, including a CpG nucleic acid. In certain embodiments the screening method is performed using a plurality of test nucleic acids. In certain embodiments comparison of test and reference responses is based on comparison of 15 quantitative measurements of responses in each instance.

In another aspect the invention provides a screening method for identifying species specificity of an immunostimulatory nucleic acid. The method involves contacting a TLR9 of a first species with a test immunostimulatory nucleic acid; contacting a TLR9 of a second species with the test immunostimulatory nucleic acid; measuring a response mediated by a 20 TLR signal transduction pathway associated with the contacting the TLR9 of the first species with the test immunostimulatory nucleic acid; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the TLR9 of the second species with the test immunostimulatory nucleic acid; and comparing the two responses. The TLR9 may be expressed by a cell or it may be part of a cell-free system. The TLR9 may be part of 25 a complex, with either another TLR or with another protein, e.g., MyD88, IRAK, TRAF, IκB, NF-κB, or functional homologues and derivatives thereof. Thus for example a given ODN can be tested against a panel of human fibroblast 293 fibroblast cells transfected with TLR9 from various species and optionally cotransfected with a reporter construct sensitive to TLR/IL-1R activation pathways. Thus in another aspect, the invention provides a method for 30 screening species selectivity with respect to a given nucleic acid sequence.

Test compounds can include but are not limited to peptide nucleic acids (PNAs), antibodies, polypeptides, carbohydrates, lipids, hormones, and small molecules. Test

- 39 -

compounds can further include variants of a reference immunostimulatory nucleic acid incorporating any one or combination of the substitutions described above. Test compounds can be generated as members of a combinatorial library of compounds.

In preferred embodiments, the screening methods can be performed on a large scale
5 and with high throughput by incorporating, e.g., an array-based assay system and at least one automated or semi-automated step. For example, the assays can be set up using multiple-well plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening
10 assay are well known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are well known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the
15 throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

20 The following examples are provided for illustrative purposes and are not meant to be limiting in any way.

Examples

25 Example 1. Cloning and Sequencing of Rat, Porcine, Bovine, Equine, Ovine, Canine, and Feline TLR9

Cells and Tissues. Lymphoid tissues, primarily spleen or blood mononuclear cells (PBMC) from five mammalian species were collected: mouse, pig, bovine, rat and horse. Spleen samples were collected in RNAlater™ (Ambion®, Austin, TX, USA), stabilized at
30 4°C overnight and stored at -70°C. Blood samples were centrifuged at 500 x g for 25 min at room temperature and the buffy coat, containing enriched PBMC, was then removed and stored at -70°C. The mouse specimen was used as a comparative positive control.

- 40 -

First-strand cDNA synthesis. Total RNA from the spleen and PBMC samples was isolated using a monophasic solution of phenol and guanidine isothiocyanate: TRIzol™ reagent (GIBCO BRL®, Burlington, ON, Canada) according to the manufacturer's instructions. First-strand cDNA was synthesized from the total RNA using 5 SUPERSCRIPT™ II reverse transcriptase (GIBCO BRL®, Burlington, ON, Canada). Approximately 3 µg of total RNA was added to 50 pmoles of oligo(dT) primer [poly T₍₁₈₎]; the mixture was heated to 70°C for 10 min and subsequently chilled on ice. The following was added to the cooled reaction mixture: 1 µl of mixed dNTP stock containing 10 mM each dATP, dCTP, dGTP and dTTP (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) at 10 neutral pH, 1X first strand buffer (50 mM Tris-HCl pH 8.3/ 75 mM KCl/ 3 mM MgCl₂) and 2 µl of 0.1 M DTT. The mixture was subsequently heated to 42°C for 2 min, followed by addition of 200 units of SUPERSCRIPT™ II reverse transcriptase. The reaction was carried out at 42°C for 50 min, followed by 70°C for 15 min. The first-strand cDNA was used as the template for subsequent polymerase chain reaction (PCR) amplifications.

15 *PCR amplification.* TLR9 gene was PCR amplified from each of the above-mentioned species using primers designed from known mouse and human TLR9 sequence in Genbank: Accession AF314224 and AF259262, respectively. The primers were designed using the primer design software, Clone Manager 5 (Scientific and Educational Software, Durham, NC, USA). TLR9 gene-specific primers used were:

20 forward primer 5'-ACCTTGCCTGCCTTCCTACCCTGTGA-3' (SEQ ID NO:37) and reverse primer 5'-GTCCGTGTGGGCCAGCACAAA-3' (SEQ ID NO:38).

The 2.7 Kbp fragment was PCR amplified using Advantage® 2 DNA polymerase mix (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. PCR reaction volumes of 25 µl contained 15 pmoles of each primer, 0.2 mM of dNTP mix 25 and 1 µl of reverse transcription reaction. PCR amplification was conducted by initial denaturation at 94°C for 1 min followed by 30 cycles of 94°C denaturation (15 sec), 65°C annealing (45 sec) and 72°C extensions (2 min), with a final extension at 72°C for 5 min.

30 *Cloning and sequencing.* The PCR amplified fragment was treated with 500 units of T4 DNA polymerase (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) for 15 min at room temperature prior to cleaning the reaction with QIAquick PCR purification kit (QIAGEN Inc., Mississauga, ON, Canada). The fragment was then ligated to pZErO™ - 2

- 41 -

vector (Invitrogen™ Life Technologies, Burlington, ON, Canada), treated with *Eco RV* restriction enzyme, using T4 DNA Ligase (GIBCO BRL®, Burlington, ON, Canada). *E. coli* TOP 10 chemically competent cells (Invitrogen™ Life Technologies, Burlington, ON, Canada) were used to transform ligated products. Plasmids containing the 2.7 Kbp fragment 5 were sequenced using an automated DNA sequencer, CEQ™ 2000XL DNA analysis system (Beckman Coulter Inc., Fullerton, CA, USA).

Sequences of the 2.7 Kbp fragment were derived from three clones of each species selected from independent PCR reactions to account for errors that may have been incurred during the PCR amplifications and to confirm the sequence data.

10 Nucleotide sequences of the rat, porcine, bovine, equine, ovine, canine, and feline TLR9 were extended and completed using standard 5' and 3' RACE PCR and primers designed using the sequences obtained from the 2.7 Kbp fragments.

15 *Results.* Nucleotide sequences of rat, porcine, bovine, equine, canine, and feline TLR9 cDNA obtained by the methods above are provided as SEQ ID NOs 3, 7, 11, 15, 19, 23, and 27, respectively. Dduced amino acid sequences are provided as SEQ ID NOs 1, 5, 9, 13, 17, 21, and 25, respectively. Dduced amino acid sequences of full-length murine and human TLR9 are provided as SEQ ID NOs 29 and 33, respectively.

Example 2. Comparison of Aligned Sequences for TLR9 from Various Mammalian Species.

20 Multiple sequence alignment of deduced amino acid sequences for feline, canine, bovine, mouse, ovine, porcine, horse, human, and rat TLR9 polypeptides was performed using Clustal W 1.82 (see, for example, www.cmbi.kun.nl/bioinf/tools/clustalw.shtml). In addition, paired sequence alignment of deduced amino acid sequences for murine and human TLR9 polypeptides was performed using Clustal W 1.82. The results of the multiple 25 sequence alignment are presented in **Figure 1**. As will be appreciated from Figure 1, certain amino acids are highly conserved across all species examined. Similarly, certain amino acids differ only by conservative amino acid substitutions among the various species. In addition, it is evident that certain amino acids which are conserved between murine and human TLR9 are not conserved in other species. Furthermore, Figure 1 also indicates that certain amino 30 acids are highly divergent across various species. The information provided by the comparison of multiple species adds significantly to the information available by comparison between only murine and human TLR9 sequences.

- 42 -

The putative transmembrane regions of the TLR9 polypeptides are indicated in boxes in Figure 1. Sequence upstream of each transmembrane region is extracellular domain and is believed to include sequence primarily responsible for binding to TLR9 ligands, including CpG DNA. The extracellular domains of feline, canine, bovine, mouse, ovine, porcine, 5 horse, human, and rat TLR9 correspond to amino acids numbered 1-820, 1-822, 1-818, 1-821, 1-818, 1-819, 1-820, 1-820, and 1-821, respectively, as shown in Figure 1.

Figure 2 presents an evolutionary relatedness tree for six TLR9 polypeptides examined. The cladogram in Figure 2 was prepared using Clustal W (see above). As can be appreciated from this figure, murine and human TLR9 are nearly the most divergent TLR9s 10 in this group. Surprisingly, human and horse TLR9 appear relatively closely related.

Example 3. Reconstitution of TLR9 Signaling in 293 Fibroblasts.

Mouse TLR9 cDNA (SEQ ID NO:31) and human TLR9 cDNA (SEQ ID NO:35) in pT-Adv vector (from Clonetech) were individually cloned into the expression vector 15 pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

20 Since NF- κ B activation is central to the IL-1/TLR signal transduction pathway (Medzhhitov R et al. (1998) *Mol Cell* 2:253-258; Muzio M et al. (1998) *J Exp Med* 187:2097-101), cells were transfected with hTLR9 or co-transfected with hTLR9 and an NF- κ B-driven luciferase reporter construct. Human fibroblast 293 cells were transiently transfected with hTLR9 and a six-times NF- κ B-luciferase reporter plasmid (NF- κ B-luc) or with hTLR9 alone. 25 After stimulus with CpG-ODN (2006, 2 μ M, TCGTCGTTTGTCGTTTGTCGTT, SEQ ID NO:58), GpC-ODN (2006-GC, 2 μ M, TGCTGCTTTGTGCTTTGTGCTT, SEQ ID NO:59), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results representative of three independent experiments showed that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

30 Independently, human fibroblast 293 cells were transiently transfected with mTLR9 and the NF- κ B-luc construct or with mTLR9 alone. After stimulation with CpG-ODN (1668, 2 μ M; TCCATGACGTTCCCTGATGCT, SEQ ID NO:60), GpC-ODN (1668-GC, 2 μ M;

- 43 -

TCCATGAGCTTCCTGATGCT, SEQ ID NO:61), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results showed that expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG-DNA stimulation.

5 To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- κ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2×10^6 cells/plate) with 16 μ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe, Germany). Clones were tested for TLR9 expression by RT-PCR. The clones were also screened for IL-8 production or NF- κ B-luciferase activity after stimulation with
10 ODN. Four different types of clones were generated.

15 293-hTLR9-luc: expressing human TLR9 and 6-fold NF- κ B-luciferase reporter
293-mTLR9-luc: expressing murine TLR9 and 6-fold NF- κ B-luciferase reporter
293-hTLR9: expressing human TLR9
293-mTLR9: expressing murine TLR9

Results indicated that stable clones also responded to CpG-ODN.

Example 4. Similar ODN Sequence Specificity of TLR9 of Human and Equine TLR9.

20 3×10^6 293T cells were electroporated with 5 μ g NF- κ B-luc plasmid and 5 μ g of either horse TLR9-pcDNA3.1 plasmid or humanTLR9-pcDNA3.1 plasmid at 200V, 975 μ F. After the electroporation the cells were plated in 96-well cell culture plates at 2.5×10^4 cells per well and grown overnight at 37°C. The cells were stimulated with the indicated concentration of ODN for 16h, after which the supernatant was removed and the cells lysed in lysis buffer and
25 frozen for at least 2 hours at -80°C. Luciferase activity was measured by adding Luciferase Assay substrate from Promega. Values are given as fold specific induction over non-stimulated control. Results are shown in Figure 3.

As shown in Figure 3, ODN 2006 (TCGTCGTTTGTCTCGTTTGTGTT; SEQ ID NO:58) has a strong specificity for human TLR9. ODN 1982 (TCCAGGACTTCTCTCAGGTT; SEQ ID NO:70) was the negative control ODN. ODN 5890 (TCCATGACGTTTGATGTT; SEQ ID NO:39) has a strong specificity for mouse

- 44 -

TLR9. This experiment demonstrates the similarity of horse TLR9 to human TLR9 in binding specificity, a result predicted by the evolutionary relatedness of horse TLR9 to human TLR9. Mouse TLR9 is more distant from horse TLR9 and human TLR9 in sequence homology, and ODN 5890 was not detected by either human or horse TLR9.

5

Example 5. Non-human, Non-murine Native Mammalian TLR9 Useful in Screening for Human-Preferred CpG DNA.

Native rat, porcine, bovine, equine, and ovine TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 10 2006). Rat, porcine, bovine, equine, or ovine TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The 15 cells expressing the selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

20 Example 6. Chimeric TLR9 Useful in Screening for Human-Preferred CpG DNA.

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector 25 containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

30

Example 7. Chimeric TLR9 Responsive to Both Human-Preferred and Murine-Preferred CpG DNA.

- 45 -

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006) and also screened for binding or TLR9 signaling activity when contacted with murine-preferred CpG DNA (ODN 1668). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in each of these assays are then used as the basis for screening for additional human-preferred CpG DNA and for screening for additional murine-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA or candidate murine-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA. Candidate murine-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as murine-preferred CpG DNA.

15

Equivalents

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages of the invention are not necessarily encompassed by each embodiment of the invention.

25 All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

- 46 -

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

5

2. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.

3. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a
10 polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ
ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

4. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a
polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ
15 ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.

5. A vector comprising the nucleic acid of any of claims 3-4.

6. A cell comprising the vector of claim 5.

20

7. An antibody or fragment thereof that binds specifically to the polypeptide of any of
claims 1-2.

8. A method for identifying key amino acids in a TLR9 of a first species which
25 confer specificity for CpG DNA optimized for TLR9 of the first species, comprising:
aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and
TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a
signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than
when contacted with a CpG DNA optimized for TLR9 of the second species;
30 generating an initial set of candidate amino acids in the TLR9 of the first species by
excluding each amino acid in the TLR9 of the first species which (a) is identical with the

- 47 -

TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution;

generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

10 9. A method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9, comprising:

aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9;

generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution;

20 generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids.

25

10. The method according to claim 9, performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight, said weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

- 48 -

11. An isolated polypeptide comprising an amino acid sequence identical to SEQ ID NO:30 except for substitution of at least one key amino acid identified according to the method of any of claims 9 or 10.
- 5 12. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide according to claim 11.
- 10 13. A vector comprising the nucleic acid of claim 12.
14. A cell comprising the vector of claim 13.
- 15 15. An antibody that binds specifically to the polypeptide of claim 14.
16. A screening method to identify a TLR9 ligand, comprising:
15 contacting a polypeptide according to any of claims 1, 2, or 11 with a candidate TLR9 ligand;
 measuring a signal in response to the contacting; and
 identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling.
- 20 17. The method of claim 16, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.
- 25 18. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF-κB.
19. The method of claim 17, wherein the candidate TLR9 ligand is an immunostimulatory nucleic acid.
- 30 20. The method of claim 19, wherein the immunostimulatory nucleic acid is CpG DNA.

- 49 -

21. A screening method to identify species-specific CpG-motif preference of an isolated polypeptide of claim 2 or claim 11, comprising:

contacting an isolated polypeptide of claim 2 or claim 11 with a CpG DNA comprising a hexamer sequence selected from the group consisting of GACGTT, AACGTT, 5 CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACTTT, GACGCT, GACGAT, GACGGT, GACGTC, GACGTA, and GACGTG;

measuring a signal in response to the contacting; and

10 identifying a species-specific CpG-motif preference when the signal in response to the contacting is consistent with TLR9 signaling.

22. The method of claim 21, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.

15 23. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF- κ B.

24. The method of claim 21, wherein the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

20 TCCATGACGTTTGATGTT (SEQ ID NO:39),
TCCATAACGTTTGATGTT (SEQ ID NO:40),
TCCATCACGTTTGATGTT (SEQ ID NO:41),
TCCATTACGTTTGATGTT (SEQ ID NO:42),
TCCATGGCGTTTGATGTT (SEQ ID NO:43),
25 TCCATGCCGTTTGATGTT (SEQ ID NO:44),
TCCATGTCGTTTGATGTT (SEQ ID NO:45),
TCCATGATGTTTGATGTT (SEQ ID NO:46),
TCCATGAAGTTTGATGTT (SEQ ID NO:47),
TCCATGAGGTTTGATGTT (SEQ ID NO:48),
30 TCCATGACATTTGATGTT (SEQ ID NO:49),
TCCATGACCTTTGATGTT (SEQ ID NO:50),
TCCATGACTTTGATGTT (SEQ ID NO:51),
TCCATGACGTTTGATGTT (SEQ ID NO:52),
TCCATGACGATTTGATGTT (SEQ ID NO:53),
35 TCCATGACGGTTTGATGTT (SEQ ID NO:54),
TCCATGACGCTTGATGTT (SEQ ID NO:55),
TCCATGACGTATTGATGTT (SEQ ID NO:56), and
TCCATGACGTGTTGATGTT (SEQ ID NO:57).



Figure 1
(1/3)

feline	MGPCHGALHPLSLLVQAAALAVALAOGTLPFLPCELQRHGLVNCDWLFLKSVPHFSAAA	60
canine	MGPCRGALHPLSLLVQAAALALALAOGTLPFLPCELQPHGLVNCNWLFLKSVPRFSAAA	60
bovine	MGP-YCAPHPLSLLVQAAALAAAEGTLPFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
mouse	MGP-YCAPHPLSLLVQAAALAAAEGTLPFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
ovine	MGP-YCAPHPLSLLVQAAALAAAEGTLPFLPCELQPRGKVNCNWLFLKSVPRFSAGA	59
porcine	MGP-RCTLHPLSLLVQVTALAAAQGRLPFLPCELQPHGLVNCNWLFLKSVPHFSAAA	59
horse	MGPCHGALQPLSLLVQAAMLAVALAOGTLPFLPCELQPHGLVNCNWLFLKSVPHFSAAA	60
human	MGFCRSALHPLSLLVQAIMLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA	60
rat	MVLCRTLHPLSLLVQAAVLAEEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAE	60
	* : *****. ** :** * *.*****: :* *;*****:*** .	
feline	PRGNVTSLSLYSNRRIHHLDSDFVHLSSLRRLNWKWCNPASLSPMHFPCHMTIEPHTFL	120
canine	PRGNVTSLSLYSNRRIHHLDYDFVHLRRRLNWKWCNPASLSPMHFPCHMTIEPNFL	120
bovine	PRANVTSLSLISNRRIHHLDSDFVHLNSNLRKWNCPAGLSPMHFPCCRMTIEPNFL	119
mouse	PRANVTSLSLISNRRIHHLDSDFVHLNSNLRKWNCPAGLSPMHFPCCRMTIEPNFL	119
ovine	PRANVTSLSLISNRRIHHLDSDFVHLNSNLRKWNCPAGLSPMHFPCCRMTIEPNFL	119
porcine	PRDNVTSLSLSSNRRIHHLDSDFAQLSNLQKLNWKWNCPAGLSPMHFPCHMTIEPNFL	120
horse	PRGNVTSLSLSSNRRIHHLDSDFAHPLPSLRHLNWKWNCPVGLSPMHFPCHMTIEPNTFL	120
human	PRSNITSLSLIANRIHHLDNFVHLNVRQLNLWKWCNPAGLSPMHFPCHMTIEPKTFL	120
rat	** *:***** :*****: *.: : *:***** .*:.*:***** ***	
feline	AVPTLEELNLSYNSITTVPALPSSLVSLSLSRNTNILVLDPANLAGLHSIRFLFLDGNCY	180
canine	AVPTLEDLNLSYNSITTVPALPSSLVSLSLSRNTNILVLDPATLAGLYALRFLFLDGNCY	180
bovine	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRNTSILVLGPTHFTGLHALRFLYMDGNCY	179
mouse	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRNTSILVLGPTHFTGLHALRFLYMDGNCY	179
ovine	AVPTLEELNLSYNSITTVPALPDSLVSLSRSRTNILVLDPTHTLTGLHALRYLYMDGNCY	179
porcine	AVPTLEELNLSYNSITTVPALPDSLVSLSRSRTNILQLDPTSLTGLHALRFLYMDGNCY	180
horse	AVPTLEELNLSYNGITTVPALPSSLVSLSLSRNTNILMDSASLAGLHALRFLFMDGNCY	180
human	AMRMLEEELNLSYNGITTVPRLPSLTSNLSSHTNLVLDASSLAGLHSIRVLFLMDGNCY	180
rat	*: *:*****. * * * . * * .: *;*:*** *;*****	
feline	KNPCPQALQVAPGALLGLGNLTHLSLKYNNTAVPRGLPPSLEYLLSYNHIITLAPEDL	240
canine	KNPCQALQVAPGALLGLGNLTHLSLKYNNTVPRGLPPSLEYLLSYNHIITLAPEDL	240
bovine	MNPCPRALEVAPGALLGLGNLTHLSLKYNNTTEVPRRLPPSLDTLLSYNHIITLAPEDL	239
mouse	MNPCPRALEVAPGALLGLGNLTHLSLKYNNTTEVPRRLPPSLDTLLSYNHIITLAPEDL	239
ovine	KNPCQQADEVAPGALLGLGNLTHLSLKYNNTTEVPRSLPPSLDTLLSYNHIITLAPEDL	239
porcine	KNPCQQADEVAPGALLGLGNLTHLSLKYNNTTEVPRSLPPSLEYLLSYNHIITLAPEDL	239
horse	KNPCGRALEVAPGALLGLGNLTHLSLKYNNTTVPRLPSLTSNLSSHTNLVLDASSLAGLHSIRVLFLMDGNCY	240
human	KNPCRQALELEVAPGALLGLGNLTHLSLKYNNTVPRNLPSSLEYLLSYNRIVKLAPEDL	240
rat	KNPCNGAVNVTPDAFLGLSNLTHLSLKYNNTTEVPRQLPPSLEYLLSYNLIVKLGAEDL	240
	*** *:*.*****.*****:***** *** *.*:***** *:.***	
feline	ANLTALRVLDVGNCRRCDHARNPCMECPKGFPFLHPDTFSHLNHLGVLKDSSLYNL	300
canine	ANLTALRVLDVGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGVLVLRDSSL	300
bovine	ANLTALRVLDVGNCRRCDHARNPCRECPKNFKLHPDTFSHLRSLEGVLKDSSLYKLE	299
mouse	ANLTALRVLDVGNCRRCDHARNPCRECPKNFKLHPDTFSHLRSLEGVLKDSSLYKLE	299
ovine	ANLTALRVLDVGNCRRCDHARNPCRECPKDHPKLHSDFSHLSRLEGVLKDSSLYNLD	299
porcine	ANLTALRVLDVGNCRRCDHARNPCVECPHKFPQLHSDFSHLSRLEGVLKDSSLYQLN	300
horse	ANLTALRVLDVGNCRRCDHARNPCMCECPRFQQLHPDTFSHLRSLEGVLKDSSLSWLN	300
human	ANLTSLRMLDVGGNCRRCDHAPDLCTECRQKSSDLHPQTFFHLHSLEGVLKDSSLHSLN	300
rat	*****:*****:***** : * * : .*:.*:*****:***** *:	
feline	PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSAHLHLAPS	360
canine	PRWFHGLGNLMVLDLSENFLYDCITKTFKFYGLARLRRRNLSFNYHKKVSAHLHLASS	360
bovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSAHLHLASS	359
mouse	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSAHLHLASS	359
ovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSAHLQLAPS	359
porcine	TRWFRLGRLQVLDLSENFLYDCITKTTAFQGLARLRSNLSFNYHKKVSAHLHLAPS	359
horse	PRWFRLGRLQVLDLSENFLYDCITKTFKFQGLAQLRRLNLSFNYHKKVSAHLLAPS	360
human	ASWFRLGRLVLDLSENFLYKCIKTKAFQGLTQLRKLNLSFNYQKRVSAHLSLAPS	360
rat	SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTLLRKLDSLFSFNYCKKVSFARLHLASS	360
	:*. *:**. *.*:*****:***** *:*****:*** .***	

Figure 1
(2/3)

Figure 1
(3/3)

feline	SFFALATRLRELNLSANALKTVEPSWFGSLAGTLKVLVDVTGNPLHCACGAAFVDFLLEVO	778
canine	SFFALAVRLRELNLSANALKTVEPSWFGSLAGALKVLDVTANPLHCACGATFVDFLLEVO	780
bovine	GFFVRATRLIELNLSANALKTVDPFWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERQ	776
mouse	GFFVRATRLIELNLSANALKTVDPFWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERQ	776
ovine	GFFVLANRLKELNLSANALKTVDPFWFGRLTEFLNILDVSANPLHCACGAAFVDFLLEMQ	776
porcine	GFFALAKQLEELNLSANALKTVEPSWFGMVGNLKVLVDVSANPLHCACGATFVGFLLEVO	777
horse	GFFALATRLRELNLSANALRTEEPFWFGFLAGSLEVLVDVSANPLHCACGAAFVDFLQQVQ	778
human	GFFSKAKELRELNLSANALKTVDSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVO	778
rat	AFFALAVELKEVNLSHNIKTVDRSWFGPIVMNLTVDVSSNPLHCACGAPFVDLLEVO	779
	*** * . * :*** * * : * : *** : . * :*** : ***** : * : * :	
feline	AAVPGLPGHVKGSPGQLOGRSIFAQDLRLCLDEALSWDCFG	838
canine	AAVPGLPSRVKGSPGQLOGRSIFAQDLRLCLDEALSWVCFS	840
bovine	EAVPGLSRRVTCGSPGQLOGRSIFTQDRLRLCLDETLSDCFG	836
mouse	EAVPGLSRRVTCGSPGQLOGRSIFTQDRLRLCLDETLSDCFG	836
ovine	AAVPGLSRRVTCGSPGQLOGRSIFAQDLRLCLDETLSDCFG	836
porcine	AAVPGLPSRVKGSPGQLOGRHSIFAQDLRLCLDETLSWNCFG	837
horse	AAVPGLPSRVKGSPGQLOGRSIFAQDLRLCLDKSLSDCFG	838
human	AAVPGLPSRVKGSPGQLOGRSIFAQDLRLCLDEALSWDCFG	838
rat	TKVPLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFG	839
	***** . * .***** **** :***** : * . :*** : * : * : * :	
feline	CGWDLWYCFHLCLAWLPRRGRR--RGADALPYDAFVVFDKAQSAVADWVYNELRVLEER	896
canine	CGWDLWYCFHLCLAWLPRRGRR--RGVDALAYDAFVVFDKAQSSAVADWVYNELRVQLEER	898
bovine	CGWDLWYCFHLCLAHLPRRRQ--RGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEER	894
mouse	CGWDLWYCFHLCLAHLPRRRQ--RGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEER	894
ovine	CGWDLWYCFHLCLAHLPRRRQ--RGEDTLLYDAFVVFDKAQSAVADWVYNELRVQLEER	894
porcine	CGWDLWYCFHLCLAWLPHRGQR--RGADALFYDAFVVFDKAQSAVADWVYNELRVQLEER	895
horse	CGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEEC	896
human	CGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEEC	898
rat	CGWDWVYCFHLCLAWLPLLTRGR-RSAQALPYDAFVVFDKAQSAVADWVYNELRVLEER	898
	***** :***** * * * . : * : * . * :***** : * :***** : ***	
feline	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQLR	956
canine	RGRRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLARTDRVSGLLRASFLLAQQLR	958
bovine	RGRRALRLCLEERDWVPGKTLFENLWASVYSSRKTMFVLDDHTDRVSGLLRASFLLAQQLR	954
mouse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDDHTDRVSGLLRASFLLAQQLR	954
ovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDDHTDRVSGLLRASFLLAQQLR	954
porcine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAAHTDRVSGLLRASFLLAQQLR	955
horse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAAHTDRVSGLLRASFLLAQQLR	956
human	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAAHTDRVSGLLRASFLLAQQLR	958
rat	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAAHTDRVSGLLRASFLLAQQLR	958
	***** :***** :***** :***** :***** :***** :***** :***** :*****	
feline	LEDRKDVVVLVILRPDAHRSRYVRLQRQLCRQSVLWPHQPSGQRSFWAQLGTALTRDNQ	1016
canine	LEDRKDVVVLVILCPDAHRSRYVRLQRQLCRQSVLWPHQPSGQRSFWAQLGTALTRDNR	1018
bovine	LEDRKDVVVLVILRPAAYRSRYVRLQRQLCRQSVLWPHQPSGQGSFWANLGIALTRDNR	1014
mouse	LEDRKDVVVLVILRPAAYRSRYVRLQRQLCRQSVLWPHQPSGQGSFWANLGIALTRDNR	1014
ovine	LEDRKDVVVLVILRPAAYRSRYVRLQRQLCRQSVLWPHQPSGQGSFWANLGMALTRDNR	1014
porcine	LEDRKDVVVLVILRDAYRSRYVRLQRQLCRQSVLWPHQPSGQGSFWAQLGTALTRDNH	1015
horse	LEDRKDVVVLVILSPDARRSRYVRLQRQLCRQSVLWPHQPSGQGSFWAQLGMALTRDNR	1016
human	LEDRKDVVVLVILSPDGRRSRYVRLQRQLCRQSVLWPHQPSGQRSFWAQLGMALTRDNH	1018
rat	LEDRKDVVVLVILRPDAHRSRYVRLQRQLCRQSVLWPHQPSGQGSFWAQLSTALTRDNH	1018
	***** :***** * . ***** :***** :***** :***** :***** :*****	
feline	HFYNQNFCRGPTTAE-----	1031
canine	HFYNQNFCRGPTTA-----	1032
bovine	HFYNRNFCRGPTTA-----	1029
mouse	HFYNRNFCRGPTTA-----	1032
ovine	HFYNRNFCRGPTTA-----	1029
porcine	HFYNRNFCRGPTTA-----	1030
horse	HFYNRNFCRGPTMAE-----	1031
human	HFYNRNFCQGPTAE-----	1032
rat	HFYNRNFCRGPTAE-----	1032
	***** :***** :*****	

Figure 2**Figure 3**

SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH
University of Saskatchewan
Qiagen GmbH

<120> TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES

<130> C1041.70040W000

<150> US 60/412,479
<151> 2002-09-19

<160> 70

<170> PatentIn version 3.1

<210> 1
<211> 1032
<212> PRT
<213> Rattus norvegicus

<400> 1

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn
50 55 60

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn
65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro
180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser
260 265 270

Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe
290 295 300

Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu
370 375 380

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr
420 425 430

Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val
435 440 445

Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser
450 455 460

Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp
515 520 525

Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser
565 570 575

Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val
580 585 590

Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly
595 600 605

Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe

610

615

620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu
645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser
660 665 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn
675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Pro Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser
805 810 815

Arg Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Thr Val
820 825 830

Leu Pro Leu Leu Gln His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
835 840 845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Thr Arg Gly Arg Arg Ser
850 855 860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
900 905 910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Lys Val Ser
930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
980 985 990

Leu Phe Trp Pro His Gln Pro Asn Gly Gln Gly Ser Phe Trp Ala Gln
995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
1025 1030

<210> 2
<211> 821
<212> PRT
<213> Rattus norvegicus

<400> 2

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn
50 55 60

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn
65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro
180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser
260 265 270

Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe
290 295 300

Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu
370 375 380

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr
420 425 430

Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val
435 440 445

Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser
450 455 460

Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp
515 520 525

Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser
565 570 575

Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val
580 585 590

Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly
595 600 605

Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe
610 615 620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu
645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser
660 665 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn
675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn

725

730

735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
 740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly
 755 760 765

Ala Pro Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly
 770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg
 785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser
 805 810 815

Arg Asp Cys Phe Gly
 820

<210> 3
<211> 3099
<212> DNA
<213> Rattus norvegicus

<400> 3		
atggttctct gtcgcaggac cctgcacccc ttgtctctcc tggtacaggc cgca	gtgc	60
gctgaggctc tggccctggg taccctgcct gccttcctac cctgtgaact gaagc	cctcat	120
ggccttggtag actgcaactg gctcttcttg aagtctgtgc ctca	cttctc	180
ccccgttcca acatcaccag ccttccttg atcgccaaacc gcatccacca cctgcaca	accac	240
ctcgactttg tccacctgccc caacgtgcga cagctgaacc tca	actggaa	300
ctgtccggccc		
cctggcctca gccccttgca cttctcctgc cgcatgacca ttgagccaa aac	cttctc	360
gctatgcga tgcttggaaa gctgaacctg agtataacg gtatcac	accac	420
tgtgc	ccccgc	
ctgcccagct ccctgacgaa tctgaggcta agccacacca acatc	cctgggt	480
ctcgatgcc		
agcagcctcg ctggcctgca cagcctgcga gttcttca tggacggaa ctg	ctactac	540
aagaacccct gcaacggggc ggtgaacgtg accccggacg cttc	cctgggg	600
ttca tggagcaac		
ctcaccact tgc	ccccggcc	660
ttttaaa gtataacaac ctcacagagg tgccccggca actg	cccccc	
agcctggagt acctcctgct gtcctataac ctcatgtca agct	ggggc	720
ggggc cgaagaccta		
gccaacctga cttcccttcg aatgctgtat gtgggtggga att	gtcg	780
gtcgatcac		

gcccccgacc tctgtacaga atgccggcag aagtcccttg atctgcaccc tcagactttc	840
catcacctga gccaccttga aggcctggtg ctgaaggaca gttctctcca ctcgctgaac	900
tccaaagtggt tccagggtct ggcaacacctc tcgggtctgg acctaaggcga gaactttctc	960
tacgagagca tcaacaaaac cagcgccctt cagaacactga cccgtctgcg caagctcgac	1020
ctgtccttca attactgcaa gaaggtatcg ttgcggcc tccacctggc aagttccctc	1080
aagagcctgg tgtcgctgca ggagctgaac atgaacggca tcttcttccg cttactcaac	1140
aagaacacgc tcaggtggct ggctggctcg cccaagctcc acacgctgca ccttcaaattg	1200
aatttcatca accaggcgca gtcagcgctc ttttagtacct tccgagccct tcgctttgtg	1260
gacctgtcca ataatcgcat cagcgccctt ccaacgctgt ccagagtcgc ccccggaaaag	1320
gcagacgagg cggagaaggg ggttccatgg cctgcaagtc tcaccccagc tctcccgagc	1380
actccgtct caaagaactt catggtcagg tgtaagaacc tcagattcac catggacactg	1440
tctcggaca accaggtgac tatcaagcca gagatgttcg tcaacctctc ccattctccag	1500
tgtctgagcc tgagccacaa ctgcacgcg caggctgtca atggctctca gttcctgccc	1560
ctgaccaacc tgaaggtgct ggacctgtcc tataacaagc tggacctgtta ccattcgaaa	1620
tcgttcagtg agctccacaa gttgcaggcc ctggacactga gctacaacag ccagccattc	1680
agcatgcagg ggataggcca caacttcagt tttctggcca atctgtccag gttacagaac	1740
cttagcctgg cacacaatga cattcacagc cgctgtccct cacgcctcta cagcacctca	1800
gtggagtatc tggacttcag cgcaacgggt gtggggcgca tgtgggacga ggaggacatt	1860
tacctctatt tcttccaaga cctgagaagc ctgattcatac tggacctgtc tcagaataag	1920
ctgcacatcc tccggcccca gaacctcaac tacctccccca agacgcgtac gaagctgagt	1980
ttccgtgaca atcacctctc tttcttaac tggagcagtc tggccttcct gccaaatctg	2040
cgagacctgg acctggcagg caatctacta aaggccctga ccaacggcac cctgcctaatt	2100
ggcacgctcc tccagaaaact ggatgtcagt agcaacagta tcgtctttgt ggtcccgagcc	2160
ttcttgctc tggcggtaga gctaaaagag gtcaacactca gccataacat cctcaagact	2220
gtggatcgct cctgggttgg gcccattgtg atgaacactga cggttctaga cgtgagcagc	2280
aaccctctgc attgtgcctg cggtgacccc tttgttagact tactgctgga agtgcagacc	2340
aagggtcctg gcctggctaa cggtgtgaag tggcggcagtc cccgcccacgt gcagggccgc	2400
agcatcttg cgcaagaccc tggcgtgtgc ctggatgacg tcctttctcg ggactgcttt	2460
ggccttcac tcctggctgt ggccgtggc acgggtttgc cttaactgca gcatctctgc	2520
ggctgggacg tctggtactg tttccatctg tgctggcat ggctaccctt gctgaccctgt	2580

ggccggcgca gcgcccaagc tctcccttat gatgccttcg tgggtttcga taaggcgcag	2640
agcgcgggttgc tgactgggt gtataacgag cttcgagtgc ggctagagga gcggcgcgg	2700
cggcggcccc tacgcttgcg tctggaggac cgagattggc tgcctggcca gacactcttc	2760
gagaacctct gggcctccat ctatggcagc cgcaagactc tgggttgct ggcccacacg	2820
gacaagggtca gtggcctcct gcgcaccaggc ttccctgctgg ctcagcagcg cctgctggag	2880
gaccgcaagg acgtgggtgt gttggtgatc ctgcgcctg atgcccacccg ctcccgtac	2940
gtgcgactgc gccagcgcct ctgcgcctag agtgtgctct tctggcccca tcagccaaac	3000
gggcaggcga gcttctggc ccagctgagt acagccctga cttagggacaa ccaccacttc	3060
tataaccgga acttctgccg gggacctaca gcagaatag	3099

<210> 4
<211> 2463
<212> DNA
<213> Rattus norvegicus

<400> 4 atggttctct gtcgcaggac cctgcacccc ttgtctctcc tggtaacaggc cgcaagtgc	60
gctgaggctc tggccctggg taccctgcct gccttcctac cctgtgaact gaagcctcat	120
ggcctggtag actgcaactg gctttccctg aagtctgtgc ctcaacttctc tgccgcagaa	180
ccccgttcca acatcaccag cctttccctg atgcacaacc gcatccacca cctgcacaac	240
ctcgactttg tccacctgcc caacgtgcga cagctgaacc tcaagtggaa ctgtccgccc	300
cctggcctca gcccattgca cttctcctgc cgcatgacca ttgagcccaa aacttccctg	360
gctatgcgcga tgctggaaga gctgaacctg agtataacg gtatcacccac tggccccgc	420
ctgcccagct ccctgacgaa tctgaggcta agccacacca acatcctggt actcgatgcc	480
agcagcctcg ctggcctgca cagcctgcga gttctttca tggacgggaa ctgctactac	540
aagaacccct gcaacggggc ggtgaacgtg accccggacg cttccctggg cttgagcaac	600
ctcacccact tggcccttaa gtataacaac ctcacagagg tggcccccca actgcccccc	660
agcctggagt acctcctgct gtcctataac ctcatcgta agctggggc cgaagaccta	720
gccaacctga cttccctcg aatgcttgat tggggggaa attgcgtcg ctgtgatcac	780
gcccccgacc tctgtacaga atgcggcag aagtcccttg atctgcaccc tcagactttc	840
catcacctga gccacccctga aggccctggc ctgaaggaca gttctctcca ctcgtgaaac	900
tccaagtggc tccagggtct ggcgaacctc tcgggtctgg acctaagcga gaactttctc	960
tacgagagca tcaacaaaac cagcgccttt cagaacctga cccgtctgcg caagctcgac	1020

ctgtccttca	attactgcaa	gaaggatatcg	ttcgcccgcc	tccacctggc	aagttccttc	1080
aagagcctgg	tgtcgctgca	ggagctgaac	atgaacggca	tcttcttccg	cttactcaac	1140
aagaacacgc	tcaggtggct	ggctggtctg	cccaagctcc	acacgctgca	ccttcaaatg	1200
aatttcatca	accaggcgca	gctcagcgtc	tttagtacct	tccgagccct	tcgctttgtg	1260
gacctgtcca	ataatcgcat	cagcgggcct	ccaacgctgt	ccagagtcgc	ccccgaaaag	1320
gcagacgagg	cggagaaggg	ggttccatgg	cctgcaagtc	tcaccccagc	tctcccgagc	1380
actcccgct	caaagaactt	catggtcagg	tgtaagaacc	tcagattcac	catggacctg	1440
tctcgaaca	accaggtgac	tatcaagcca	gagatgttcg	tcaacctctc	ccatctccag	1500
tgtctgagcc	tgagccacaa	ctgcatcgcg	caggctgtca	atggctctca	gttccctgccc	1560
ctgaccaacc	tgaaggtgct	ggacctgtcc	tataacaagc	tggacctgtta	ccattcgaaa	1620
tcgttcagt	agctccacaca	gttgcaggcc	ctggacctga	gctacaacag	ccagccattc	1680
agcatgcagg	ggataggcca	caacttcagt	tttctggcca	atctgtccag	gttacagaac	1740
cttagcctgg	cacacaatga	cattcacagc	cgcgtgtcct	cacgcctcta	cagcacctca	1800
gtggagtatc	tggacttcag	cggcaacgggt	gtggggccgca	tgtgggacga	ggaggacctt	1860
tacctctatt	tcttccaaga	cctgagaagc	ctgattcatc	tggacctgtc	tcagaataag	1920
ctgcacatcc	tccggcccca	gaacctaacc	tacctcccca	agagcctgac	gaagctgagt	1980
ttccgtgaca	atcacctctc	tttcttaac	tggagcagtc	tggccttcct	gcccaatctg	2040
cgagacctgg	acctggcagg	caatctacta	aaggccctga	ccaacggcac	cctgcctaatt	2100
ggcacgctcc	tccagaaact	ggatgtcagt	agcaacagta	tcgtctttgt	ggtcccagcc	2160
ttctttgctc	tggcggtaga	gctaaaagag	gtcaacctca	gccataacat	cctcaagact	2220
gtggatcgct	cctggtttgg	gcccattgtg	atgaacctga	cgtttctaga	cgtgagcagc	2280
aaccctctgc	attgtgcctg	cggtgacacc	ttttagact	tactgctgga	agtgcagacc	2340
aaggtgcctg	gcctggctaa	cggtgtgaag	tgtggcagtc	cccgccagct	gcagggccgc	2400
agcatcttg	cgcaagacct	gcggctgtgc	ctggatgacg	tcctttctcg	ggactgcttt	2460
ggc						2463

<210> 5
 <211> 1030
 <212> PRT
 <213> Sus scrofa

<400> 5

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val
 1 5 10 15

Thr Ala Leu Ala Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu
 20 25 30

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe
 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Ala Asn Val
 50 55 60

Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp Ser
 65 70 75 80

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn
 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr
 100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
 115 120 125

Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu
 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr
 145 150 155 160

His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn
 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly
 180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
 195 200 205

Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu
 210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala
 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro
260 265 270

Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg
290 295 300

Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Cys Ile Thr Lys Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg
325 330 335

Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln
370 375 380

Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn
385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu
405 410 415

Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro
435 440 445

Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp
450 455 460

Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg
465 470 475 480

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg
485 490 495

Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn
500 505 510

Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser
515 520 525

His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro
530 535 540

Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met
545 550 555 560

Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu
565 570 575

Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln
580 585 590

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp
595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln
610 615 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His
625 630 635 640

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His
645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu
660 665 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu
675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg
690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe

705	710	715	720
Ala Leu Ala Lys Gln Leu Glu Glu Leu Asn Leu Ser Ala Asn Ala Leu			
725		730	735
Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys			
740		745	750
Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr			
755		760	765
Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro			
770		775	780
Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile			
785		790	795
800			
Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn			
805		810	815
Cys Phe Gly Ile Ser Leu Leu Ala Met Ala Leu Gly Leu Val Val Pro			
820		825	830
Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu			
835		840	845
Cys Leu Ala Trp Leu Pro His Arg Gly Gln Arg Arg Gly Ala Asp Ala			
850		855	860
Leu Phe Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val			
865		870	875
880			
Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg			
885		890	895
Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro			
900		905	910
Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg			
915		920	925
Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu Leu			
930		935	940

Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys
 945 950 955 960

Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala Tyr Arg Ser Arg
 965 970 975

Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp
 980 985 990

Pro His Gln Pro Arg Gly Gln Gly Ser Phe Trp Ala Gln Leu Gly Thr
 995 1000 1005

Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg Asn Phe Cys
 1010 1015 1020

Arg Gly Pro Thr Thr Ala Glu
 1025 1030

<210> 6
 <211> 819
 <212> PRT
 <213> Sus scrofa

<400> 6

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val
 1 5 10 15

Thr Ala Leu Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu
 20 25 30

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe
 35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Ala Asn Val
 50 55 60

Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp Ser
 65 70 75 80

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn
 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr
 100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr
145 150 155 160

His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro
260 265 270

Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg
290 295 300

Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Cys Ile Thr Lys Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg
325 330 335

Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln
370 375 380

Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn
385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu
405 410 415

Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro
435 440 445

Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp
450 455 460

Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg
465 470 475 480

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg
485 490 495

Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn
500 505 510

Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser
515 520 525

His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro
530 535 540

Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met
545 550 555 560

Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu
565 570 575

Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln
580 585 590

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp
595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln
610 615 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His
625 630 635 640

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His
645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu
660 665 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu
675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg
690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe
705 710 715 720

Ala Leu Ala Lys Gln Leu Glu Leu Asn Leu Ser Ala Asn Ala Leu
725 730 735

Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys
740 745 750

Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr
755 760 765

Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro
770 775 780

Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile
785 790 795 800

Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn
805 810 815

Cys Phe Gly

<210> 7
<211> 3352
<212> DNA
<213> Sus scrofa

<400> 7
gagcacgaac atccttcaact gtagctgctg cccggctctgc cagccagacc ctggagaa 60
gaccccaactc cctgtcatgg gcccccgctg caccctgcac ccccttctc tcctggtgca 120
ggtgacagcg ctggctgcgg ctctggccca gggcaggctg cctgccttcc tgccctgtga 180
gctccagccc cacggcctgg tgaactgcaa ctggctcttc ctgaagtccg tgcccccactt 240
ctcgccggca gcgcgggggg ccaacgtcac cagectctcc ttactctcca accgcatcca 300
ccacctgcac gactccgact tcgtccaccc gtccagccta cgaactctca acctcaagtg 360
gaactgccccg ccggctggcc tcagccccat gcacttcccc tgccacatga ccatcgagcc 420
caacaccccttc ctggccgtgc ccaccctgga ggagctgaac ctgagctaca acagcatcac 480
gaccgtgcct gccctgcccc actccctcggt gtccctgtcg ctgagccgca ccaacatcct 540
ggtgctagac cccacccacc tcactggcct acatgccctg cgctacctgt acatggatgg 600
caactgctac tacaagaacc cctgccaggg ggcgctggag gtggtgcggg gtgcctcct 660
cggcctgggc aacctcacac atctctcaact caagtacaac aatctcacgg aggtgccccg 720
cagcctgccc cccagcctgg agaccctgct gtgtcctac aaccacattt tcaccctgac 780
gcctgaggac ctggccaatc tgactgcct ggcgtgttt gatgtggggg ggaactgccc 840
ccgctgtgac catgcccgcac acccctgcag ggagtgcaca aaggaccacc ccaagctgca 900
ctctgacacc ttcagccacc tgagccgcct cgaaggcctg gtgttggaaag acagttctct 960
ctacaacctg gacaccagggt ggttccgagg cctggacagg ctccaagtgc tggacctgag 1020
tgagaacttc ctctacgact gcatcacca gaccacggcc ttccaggggcc tggcccgact 1080
gcccggccctc aacctgtccct tcaattacca caagaagggtg ttccaggccc acctgcaccc 1140
ggcacccctcc tttgggcacc tccggccct gaaggagctg gacatgcattt gcatcttctt 1200
ccgctcgctc agttagacca cgttccaaacc tctggtccaa ctgcctatgc tccagaccct 1260
gcccggccatg atgaacttca ttaaccaggc ccagctcage atctttgggg cttccctgg 1320
cctgtgtac gtggacccat cggacaaccg catcagcggg gtcgtcaaggc cagtggccat 1380
tactagggag gtggatggta gggagagggt ctggctgcct tccaggaacc tcgtccacg 1440
tccactggac actctccgct cagaggactt catgccaaac tgcaaggcct tcagcttcac 1500

cttggacctg tctcggaaca acctggtgac aatccagtcg gagatgtttg ctcgcctctc	1560
acgcctcgag tgccctgcgcc tgagccacaa cagcatctcc caggcggtca atggctctca	1620
gtttgtgcgg ctgaccagcc tgcgggtgct ggacctgtcc cacaacaagc tggacctgta	1680
tcacgggcgc tcgttcacgg agctgcccg cctggaagca ctggacctca gctacaatag	1740
ccagcccttt accatgcagg gtgtgggcca caacctcagc ttctgtggcc agctgcccgc	1800
cctgcgctac ctcagcctgg cgccacaatga catccatagc cgagtgtccc agcagctctg	1860
tagcgcttca ctgtgcgccc tggactttag cggcaacgat ctgagccgga tgtggctga	1920
gggagacetc tatctccgct tcttccaagg cctaagaagc ctatctggc tggacctgtc	1980
ccagaaccac ctgcacaccc tcctgccacg tgccctggac aacccccc aaaggcctgaa	2040
gcatctgcat ctccgtgaca ataacctggc ttcttcaac tggagcagcc tgaccctct	2100
gccccaaagctg gaaaccctgg acttggctgg aaaccagctg aaggccctaa gcaatggcag	2160
cctgccatct ggccatccaggc tgccggaggct ggacctcagt ggcaacagca tcggcttgc	2220
gaaccctggc ttctttgccc tggccaagca gttagaagag ctcaacctca ggcgcacatgc	2280
cctcaagaca gtggagccct cctgggtttgg ctgcgtggc ggcaacactga aagtccctaga	2340
cgtgagcgc aaccctctgc acttgtccctg tggggcacc ttctgtggct ttctgtggc	2400
ggtagcaggct gccgtgcctg ggctgcccag ccgcgtcaag tgtggcagtc cggggcagct	2460
ccaggggccat agcatctttg cgcaagaccc gcgcctctgc ctggatgaga ccctctctgc	2520
gaactgtttt ggcatttcgc tgctggccat ggccctgggc ctgggtgtgc ccatgtgc	2580
ccacacctgc ggctgggacc tctggtaactg ctccacctg tgctggccct ggctgcccc	2640
ccgagggcag cggcgccccg cagacccct gttctatgat gccttcgtgg tctttgacaa	2700
agctcagagt gctgtggccg actgggtgta caacgagctg cgggtgcagc tggaggagcg	2760
ccgtggggcgc cgccactgc gcctgtgcct ggaggagcga gactggttac ctggcaagac	2820
gctcttcgag aacctgtggg cctcagtcta cagcagccgc aagaccctgt ttgtgtggc	2880
ccacacggac cgtgtcagcg gcctctgcg tgccagtttc ctgctggccc agcagcgcct	2940
gctggaggac cgcaaggacg ttgttagtgc ggtgatcctg cggcccgatg cctaccgc	3000
ccgctacgtg cggctgcgcc agcgccctcg ccggccagagt gtcctccct ggccccacca	3060
gccccgtggg cagggcagct tctggggcca gctgggcaca gcccgtacca gggacaacca	3120
ccacttctat aaccggaaact tctgcccccc cccacgaca gccgaatagc actgagtgac	3180
agcccagttg ccccagcccc cctggatttg cctctctgc tgggggtggcc caacctgctt	3240
tgctcagcca caccactgct ctgctccctg ttccccaccc caccggccag cctggcatgt	3300

aacatgtgcc	caataaatgc	taccggaggg	ccaagaaaaaa	aaaaaaaaaa	aa	3352
<210>	8					
<211>	2457					
<212>	DNA					
<213>	Sus scrofa					
<400>	8					
atggggccccc	gctgcaccct	gcacccctt	tctctcctgg	tgcaggtgac	agcgctggct	60
gcggctctgg	cccagggcag	gctgcctgcc	ttcctgcctt	gtgagctcca	gcuccacggc	120
ctggtaact	gcaactggct	cttcctgaag	tccgtcccc	acttctcgcc	ggcagcgccc	180
cgggccaacg	tcaccaggct	ctccttactc	tccaaccgca	tccaccacct	gcacgactcc	240
gacttcgtcc	acctgtccag	cctacgaact	ctcaacctca	agtggaaactg	cccgccggct	300
ggcctcagcc	ccatgcactt	cccctgccac	atgaccatcg	agccaaacac	cttcctggcc	360
gtgcccaccc	tggaggagct	gaacctgagc	tacaacagca	tcacgaccgt	gcctgccttg	420
cccgactccc	tcgtgtccct	gtcgctgagc	cgcaccaaca	tcctggtgct	agacccccacc	480
cacctcaactg	gcctacatgc	cctgcgtac	ctgtacatgg	atggcaactg	ctactacaag	540
aaccctgccc	agggggcgct	ggaggtggtg	ccgggtgccc	tcctcgccct	ggcaacctc	600
acacatctct	cactcaagta	caacaatctc	acggaggtgc	cccgcagcct	gcucccccagc	660
ctggagaccc	tgctgttgtc	ctacaaccac	attgtcaccc	tgacgcctga	ggacctggcc	720
aatctgactg	ccctgcgcgt	gcttgatgtg	ggggggaaact	gccgcccgtg	tgaccatgcc	780
cgcaacccct	gcagggagtg	cccaaaggac	caccccaagc	tgcactctga	cacccctcagc	840
cacctgagcc	gcctcgaagg	cctgggtttg	aaagacagtt	ctctctacaa	cctggacacc	900
aggtggttcc	gaggcctgga	caggctccaa	gtgctggacc	tgagtgagaa	cttcctctac	960
gactgcatca	ccaagaccac	ggccttccag	ggcctggccc	gactgcgcag	cctcaacctg	1020
tccttcaatt	accacaagaa	ggtgtccttt	gcccacctgc	acctggcacc	ctcctttggg	1080
cacctccgggt	ccctgaagga	gctggacatg	catggcatct	tcttcgcctc	gctcagttag	1140
accacgctcc	aacctctggt	ccaaactgcct	atgctccaga	ccctgcgcct	gcagatgaac	1200
ttcattaacc	aggcccagct	cagcatcttt	ggggccttcc	ctggcctgct	gtacgtggac	1260
ctatcgacca	accgcacatcg	cggagctgca	aggccagtgg	ccattactag	ggaggtggat	1320
ggtagggaga	gggtctggct	gccttccagg	aacctcgctc	cacgtccact	ggacactctc	1380
cgctcagagg	acttcatgcc	aaactgcaag	gcctttagct	tcaccttggaa	cctgtctcg	1440
aacaacctgg	tgacaatcca	gtcggagatg	tttgcgtgcc	tctcacgcct	cgagtgcctg	1500

cgcctgagcc acaacagcat	ctcccaggcg gtcaatggct	ctcagttgt gccgctgacc	1560
agcctgcggg tgctggacct	gtccccacaac aagctggacc	tgtatcacgg gcgctcggttc	1620
acggagctgc cgccgcctgga	agcaactggac ctcagctaca	atagccagcc ctttaccatg	1680
cagggtgtgg gccacaacct	cagcttcgtg gcccagctgc	ccgcctgcg ctacccatgc	1740
ctggcgcaca atgacatcca	tagccgagtg tcccagcagc	tctgttagcgc ctcactgtgc	1800
gccctggact tttagcggcaa	cgtatctgagc cggatgtggg	ctgagggaga cctctatctc	1860
cgcttcttcc aaggcctaag	aaggcctaag aaggcctaag	tggctggacc tgtcccagaa ccacccgcac	1920
accctcctgc cacgtgcctt	ggacaacctc cccaaaagcc	tgaagcatct gcacatccgt	1980
gacaataacc tggccttctt	caactggagc agcctgaccc	tcctgcccaa gctggaaacc	2040
ctggacttgg ctggaaacca	gctgaaggcc ctaagcaatg	gcagcctgcc atctggcacc	2100
cagctgcgga ggctggacct	cagtgccaa acgcattggct	tttgtgaaccc tggcttcttt	2160
gccctggcca agcagttaga	agagctcaac ctcagcgc	atgcctcaa gacagtggag	2220
ccctcctgggt ttggctcgat	ggtggcaac ctgaaagtcc	tagacgtgag cgccaaaccct	2280
ctgcactgtg cctgtggggc	gaccttcgtg ggcttcctgc	tggaggtaca ggctgcgtg	2340
cctggctgc ccagccgcgt	caagtgtggc agtccggggc	agctccaggg ccatagcatc	2400
tttgcgcaag acctgcgcct	ctgcctggat gagaccctct	cgtggaaactg ttttggc	2457

<210> 9
<211> 1029
<212> PRT
<213> Bos taurus

<400> 9

Met	Gly	Pro	Tyr	Cys	Ala	Pro	His	Pro	Leu	Ser	Leu	Leu	Val	Gln	Ala
1					5				10				15		

Ala	Ala	Leu	Ala	Ala	Ala	Leu	Ala	Glu	Gly	Thr	Leu	Pro	Ala	Phe	Leu
								20		25			30		

Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Gln	Val	Asp	Cys	Asn	Trp	Leu	Phe
					35			40			45				

Leu	Lys	Ser	Val	Pro	His	Phe	Ser	Ala	Gly	Ala	Pro	Arg	Ala	Asn	Val
					50			55			60				

Thr	Ser	Leu	Ser	Leu	Ile	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp	Ser
65					70				75			80			

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr

305	310	315	320
Asp Tyr Ile Thr Lys Thr Thr Ile Phe Asn Asp Leu Thr Gln Leu Arg			
325		330	335
Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His			
340		345	350
Leu His Leu Ala Ser Ser Phe Gly Ser Leu Val Ser Leu Glu Lys Leu			
355		360	365
Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Ile Thr Leu Gln			
370		375	380
Ser Leu Thr Arg Leu Pro Lys Leu Gln Ser Leu His Leu Gln Leu Asn			
385		390	395
400			
Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu			
405		410	415
Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Thr Pro			
420		425	430
Ala Ala Ala Leu Gly Glu Val Asp Ser Arg Val Glu Val Trp Arg Leu			
435		440	445
Pro Arg Gly Leu Ala Pro Gly Pro Leu Asp Ala Val Ser Ser Lys Asp			
450		455	460
Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn			
465		470	475
480			
Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu			
485		490	495
Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly			
500		505	510
Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser His			
515		520	525
Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln			
530		535	540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
660 665 670

Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Ile Arg Leu Gln Lys Leu
690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Ile Pro Gly Phe Phe Val
705 710 715 720

Arg Ala Thr Arg Leu Ile Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu Lys Ile
740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
755 760 765

Val Asp Phe Leu Leu Glu Arg Gln Glu Ala Val Pro Gly Leu Ser Arg
770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Thr Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
805 810 815

Phe Gly Leu Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met
820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys
835 840 845

Leu Ala His Leu Pro Arg Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu
850 855 860

Leu Tyr Asp Ala Val Val Phe Asp Lys Val Gln Ser Ala Val Ala
865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly
885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly
900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys
915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg
930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp
945 950 955 960

Val Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr
965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro
980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Ile Ala
995 1000 1005

Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg
1010 1015 1020

Gly Pro Thr Thr Ala Glu
1025

<210> 10
<211> 818
<212> PRT
<213> Bos taurus

<400> 10

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala
1 5 10 15

Ala Ala Leu Ala Ala Ala Leu Ala Glu Gly Thr Leu Pro Ala Phe Leu
20 25 30

Pro Cys Glu Leu Gln Pro His Gly Gln Val Asp Cys Asn Trp Leu Phe
35 40 45

Leu Lys Ser Val Pro His Phe Ser Ala Gly Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser
65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Tyr Ile Thr Lys Thr Ile Phe Asn Asp Leu Thr Gln Leu Arg
325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu His Leu Ala Ser Ser Phe Gly Ser Leu Val Ser Leu Glu Lys Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Ile Thr Leu Gln
370 375 380

Ser Leu Thr Arg Leu Pro Lys Leu Gln Ser Leu His Leu Gln Leu Asn
385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu
405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Thr Pro

420

425

430

Ala Ala Ala Leu Gly Glu Val Asp Ser Arg Val Glu Val Trp Arg Leu
435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Asp Ala Val Ser Ser Lys Asp
450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn
465 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu
485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser His
515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln
530 535 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
 660 665 670

Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
 675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Ile Arg Leu Gln Lys Leu
 690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Ile Pro Gly Phe Phe Val
 705 710 715 720

Arg Ala Thr Arg Leu Ile Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
 725 730 735

Thr Val Asp Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu Lys Ile
 740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
 755 760 765

Val Asp Phe Leu Leu Glu Arg Gln Glu Ala Val Pro Gly Leu Ser Arg
 770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
 785 790 795 800

Thr Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
 805 810 815

Phe Gly

<210> 11
 <211> 3191
 <212> DNA
 <213> Bos taurus

<400> 11		
gggaagtggg cgccaaggcat cttccctgc agtcgcctcc caacctgccc gccagaccct		60
ctggagaagc cgcattccct gtcatgggcc cctactgtgc cccgcacccc ctttctctcc		120
tggtgcaaggc ggcggcactg gcagcggccc tggccgaggg caccctgcct gccttcctgc		180
cctgtgagct ccagccccat ggtcaggtgg actgcaactg gctgttcctg aagtctgtgc		240
cgcacttttc ggctggagcc ccccgggcca atgtcaccag ccttcctta atctccaacc		300

gcatccacca	cttgcatgac	tctgacttcg	tccacacctgtc	caacacctgcgg	gtcctcaacc	360
tcaagtggaa	ctgcccggccg	gccggcctca	gccccatgca	cttccctgtc	cgtatgacca	420
tcgagccaa	caccccttcgt	gctgtgccc	ccctggagga	gctgaacctg	agctacaacg	480
gcatcacgac	cgtgcctgccc	ctgcccagtt	ccctcggtc	cctgtcgctg	agccacacca	540
gcatcctgggt	gctaggcccc	acccacttca	ccggcctgca	cggccctgcgc	tttctgtaca	600
tggacggcaa	ctgtctactac	atgaacccct	gcccggggc	cctggaggtg	gccccaggcg	660
ccctcctcgg	cctggggcaac	ctcacgcacc	tgtcgctcaa	gtacaacaac	ctcacggagg	720
tgccccggcg	cctgcccccc	agcctggaca	ccctgctgtc	gtcctacaac	cacattgtca	780
ccctggcacc	cgaggacactg	gccaacctga	ctggccctgcg	cgtgcttgac	gtgggtggga	840
actgcccgg	ctgcgaccat	gcccgcacc	cctgcaggga	gtgccccaaag	aacttccccca	900
agctgcaccc	tgacaccccttc	agtcacactga	gcccgcctga	aggcctggtg	ttgaaggaca	960
gttctctcta	caaactagag	aaagatttgt	tccgcggcct	gggcaggctc	caagtgcgtg	1020
acctgagtga	gaacttccttc	tatgactaca	tcaccaagac	caccatottc	aacgacactga	1080
cccagctgcg	cagactcaac	ctgtccttca	attaccacaa	gaaggtgtcc	ttcgcccacc	1140
tgcaccttagc	gtcctccttt	gggagcttgg	tgtccctgga	gaagctggac	atgcacggca	1200
tcttottccg	ctccctcacc	aacatcacgc	tccagtcgt	gaccggctg	cccaagctcc	1260
agagtcgtca	tctgcagctg	aacttcatca	accaggccca	gctcagcatc	tttggggcct	1320
tcccgagcct	gctttcgtg	gacctgtcgg	acaaccgcatt	cagcggagcc	gcgacgcccag	1380
cgcccgccct	gggggaggtg	gacagcagg	tggaaagtctg	gcgattgccc	agggggctcg	1440
ctccaggccc	gctggacgccc	gtcagctcaa	aggacttcat	gccaagctgc	aacctcaact	1500
tcaccccttgg	cctgtcacgg	aacaacctgg	tgacaatcca	gcaagagatg	tttacccgcc	1560
tctcccgccct	ccagtgcctg	cgccctgagcc	acaacagcat	ctcgcaggcg	gttaatggct	1620
cccagttcgt	ggcgctgacc	agcctgcgag	tgctcgacct	gtcccacaac	aagctggacc	1680
tgtaccatgg	gcgctcattc	acggagctgc	cgcagctgga	ggcactggac	ctcagctaca	1740
acagccagcc	ttcagcatg	cagggcgtgg	gccacaacct	cagcttcgtg	gcccagctgc	1800
cctccctgcg	ctacctcagc	tttgcgcaca	atggcatcca	cagccgcgtg	tcacagaagc	1860
tcagcagcgc	ctcggtgcgc	gcccctggact	tcagcggcaa	ctccctgagc	cagatgtggg	1920
ccgagggaga	cctcttatctc	tgcttttca	aaggcttgag	gaacctggtc	cagctggacc	1980
tgtcccgagaa	ccatctgcac	accctcctgc	ctcgaccc	ggacacaacctg	cccaagagcc	2040

tgccggcagct	gctgtctccgg	gacaataacc	tggccttctt	caactggagc	agcctgaccg	2100
tcctggccccg	gcttggaaagcc	ctggatctgg	caggaaacca	gctgaaggcc	ctgagcaacg	2160
gcagcctgcc	gcctggcatc	cggtccaga	agctggacgt	gagcagcaac	agcateggct	2220
tcgtgatccc	cggcttcttc	gtccgcgcga	ctcggctgat	agagcttaac	ctcagcgcca	2280
atgccctgaa	gacagtggat	ccctccttgt	tccgttcctt	agcagggacc	ctgaaaatcc	2340
tagacgtgag	cgcacacccg	ctccactgca	cctgcggggc	ggcctttgtg	gacttcctgc	2400
tggagagaca	ggaggccgtg	cccgggctgt	ccaggcgcgt	cacatgtggc	agtccgggccc	2460
agctccaggg	ccgcagcatc	ttcacacagg	acctgcgcct	ctgcctggat	gagaccctct	2520
ccttgactg	ctttggcctc	tcactgctaa	tggtggcgt	gggcctggca	gtgcccattgc	2580
tgcaccacct	ctgtggctgg	gacctcttgt	actgcttcca	cctgtgtctg	gcccatattgc	2640
cccgacggcg	goggcagcgg	ggcgaggaca	ccctgctcta	tgtgcgcgtc	gtggctttcg	2700
acaaggtgca	gagtgcagtg	gctgattggg	tgtacaacga	gctccgcgtg	cagctggagg	2760
agcgccgggg	gcccggggcg	ctccgcctct	gcctggagga	gcgagactgg	ctccctggta	2820
agacgctctt	cgagaacctg	tgggcctcg	tctacagcag	ccgcaagacc	atgttcgtgc	2880
tggaccacac	ggaccggggtc	agcggctcc	tgcgcgcag	cttcctgtg	gcccagcagc	2940
gcctgttgg	ggaccgcaag	gacgtcgtag	tgctgggtat	cctgcgcctcc	gccgcctatc	3000
ggtcccgcta	cgtgcggctg	cgccagcgcc	tctgcgcctca	gagcgtcctc	ctctggcccc	3060
accagccca	tggccagggt	agtttctggg	ccaacctggg	catagccctg	accagggaca	3120
accgtcactt	ctataaccgg	aacttctgcc	ggggccccac	gacagccgaa	tagcacagag	3180
tgactgccc	g					3191

<210> 12
<211> 2454
<212> DNA
<213> Bos taurus

<400> 12						
atggggccct	actgtgcccc	gcacccctt	tctctcctgg	tgcaggcggc	ggcactggca	60
gcggccctgg	ccgagggcac	cctgcctgcc	ttcctgcctt	gtgagctcca	gccccatggt	120
caggtggact	gcaactggct	gttccctgaag	tctgtgcgc	acttttcggc	tggagcccc	180
cgggccaatg	tcaccaggct	ctccttaatc	tccaaaccgca	tccaccactt	gcatgactct	240
gacttcgtcc	acctgtccaa	cctgcggggtc	ctcaacctca	agtggaaactg	cccgccggcc	300
ggcctcagcc	ccatgcactt	ccccctgcgt	atgaccatcg	agcccaacac	cttcctggct	360

gtgcccaccc tggaggagct gaacctgagc tacaacggca tcacgaccgt gcctgccctg	420
cccagttccc tcgtgtccct gtcgctgagc cacaccagca tcctggtgct agggcccacc	480
cacttcaccc gcctgcacgc cctgcgcctt ctgtacatgg acggcaactg ctactacatg	540
aaccctgcc cgccccccct ggaggtggcc ccaggcgccc tcctcgccct gggcaacctc	600
acgcacactgt cgctcaagta caacaaccc acggaggtgc cccgcgcct gccccccagc	660
ctggacacccc tgctgctgtc ctacaaccac attgtcaccc tggcacccga ggacctggcc	720
aacctgactg ccctgcgcgt gcttgacgtg ggtggaaact gccgcgcgtg cgaccatgcc	780
cgcaacccct gcagggagtg cccaaagaac ttccccaagc tgcaccctga caccctcagt	840
cacctgagcc gcctcgaagg cctgggttg aaggacagtt ctctctacaa actagagaaa	900
gattggttcc gcggcctggg caggctccaa gtgctcgacc tgagtgagaa cttcccttat	960
gactacatca ccaagaccac catttcaac gacctgaccc agctgcgcag actcaacctg	1020
tccttcaatt accacaagaa ggtgtccctc gcccacctgc acctagcgac ctccttggg	1080
agtctggtgt ccctggagaa gctggacatg cacggcatct tcttcgcgtc ctcaccaac	1140
atcacgctcc agtcgctgac cggcgtcccc aagctccaga gtctgcacatc gcagctgaac	1200
ttcatcaacc aggcccagct cagcatctt gggcccttcc cgagcctgct cttcggtggac	1260
ctgtcggaca accgcatcag cggagccgcg acgccagcgg cggccctggg ggaggtggac	1320
agcaggggtgg aagtctggcg attgcccagg ggcctcgctc cagggccgct ggacgcgc	1380
agctcaaagg acttcatgcc aagctgcaac ctcaacttca cttggacact gtcacggaac	1440
aacctggta caatccagca agagatgttt acccgccctct cccgcctcca gtgcctgcgc	1500
ctgagccaca acagcatctc gcagggcggtt aatggctccc agttcgtgcc gctgaccagc	1560
ctgcgagtgc tcgacctgtc ccacaacaag ctggacctgt accatggcgc ctcattcacg	1620
gagctgccgc agctggaggc actggacctc agctacaaca gccagccctt cagcatgcag	1680
ggcgtggccc acaacctcag cttcggtggcc cagctgcctt ccctgcgtcta ctcagccctt	1740
gcbcacaatg gcatccacag ccgcgtgtca cagaagctca gcagccctc gttgcgcgc	1800
ctggacttca gcggcaactc cctgagccag atgtggcccg agggagacct ctatctgtc	1860
ttttcaaag gcttgaggaa cctgggtccag ctggacctgt ccgagaacca tctgcacacc	1920
ctcctgcctc gtcacctggca aacctgccc aagagcctgc ggcagctgcg tctccggac	1980
aataacctgg cttttcaaa ctggagcagc ctgaccgtcc tgcccccgt ggaagccctg	2040
gatctggcag gaaaccagct gaaggccctg agcaacggca gcctgcgcgc tggcatccgg	2100
ctccagaagc tggacgtgag cagcaacagc atcggcttcg tgatccccgg cttttcgtc	2160

cgcgcgactc ggctgataga gcttaacctc agcgccaatg ccctgaagac agtggatccc	2220
tccctggttcg gttccttagc agggaccctg aaaatcctag acgtgagcgc caacccgctc	2280
cactgcgcct gcggggcggc ctgtgtggac ttccctgctgg agagacagga ggccgtgccc	2340
gggctgtcca ggcgcgtcac atgtggcagt cggggccagc tccagggccg cagcatcttc	2400
acacaggacc tgcgccctcg cctggatgag accctctctt tggactgctt tggc	2454

<210> 13
<211> 1031
<212> PRT
<213> *Equus caballus*

<400> 13

Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
 35 40 . 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Asp Asn
50 55 60

Val	Thr	Ser	Leu	Ser	Leu	Leu	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp
65					70					75					80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn	Leu	Ser	Tyr	Asn	Gly	Ile	Thr	Thr	Val	Pro	Ala	Leu	Pro	Ser	Ser
130						135						140			

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro
145 150 155 160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe
260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu
370 375 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly
405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu
420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu
435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe
610 615 620

Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln
645 650 655

Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu
740 745 750

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp
805 810 815

Asp Cys Phe Gly Leu Ser Leu Leu Val Val Ala Leu Gly Leu Ala Met
820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
835 840 845

Leu Gly Leu Ala Trp Leu Pro Arg Arg Gly Trp Gln Arg Gly Ala Asp
850 855 860

Ala Leu Ser Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala

865	870	875	880
Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg			
885	890	895	
Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu			
900	905	910	
Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser			
915	920	925	
Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Gln Val Ser Gly Leu			
930	935	940	
Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg			
945	950	955	960
Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Ala Arg Arg Ser			
965	970	975	
Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Phe			
980	985	990	
Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly			
995	1000	1005	
Met Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln Asn Phe			
1010	1015	1020	
Cys Arg Gly Pro Thr Met Ala Glu			
1025	1030		
<210> 14			
<211> 820			
<212> PRT			
<213> Equus caballus			
<400> 14			
Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln			
1	5	10	15
Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe			
20	25	30	
Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu			

35

40

45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Asp Asn
50 55 60

Val Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro
145 150 155 160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe
260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu
370 375 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly
405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu
420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Val Trp Leu
435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe
610 615 620

Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln
645 650 655

Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu
740 745 750

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp
805 810 815

Asp Cys Phe Gly
820

<210> 15
<211> 3391
<212> DNA
<213> Equus caballus

<400> 15
ctctgttctc tgagctgttg ccgcgtgaag ggactgctgag cacaaagcat cctccctctgc 60
agctgctgcc cagtgtgcca gctggaccct ctggatcatc tcccactccc tgtcatggc 120
ccttgcacatg gtgcctgtca gccccctgtct ctccctggtgc aggccggccat gctggccgtg 180
gctctggccc aaggcacccct gcctcccttc ctgcccctgtg agctccagcc ccacggccctg 240
gtgaactgca actggctgtt cctgaagtcc gtgccttact tctcagcagc agcaccctcg 300
gacaatgtca ccagccttcc ttgtctctcc aaccgcacatcc accacactcca cgactccgac 360
tttgccttcaac tgcataacttgc acatccaaat ggaactgccc gccagccggc 420
ctcagcccca tgcacttccc ctgccacatg accatcgagc ccaacacttt cctggctgtta 480
cccaccctgg aggagctgaa cctgagctac aacggcatca cgactgtgcc tgccctgccc 540
agctccctcg tgcataacttgc acatccaaat ggaactgccc gccagccggc 600
ctcacggggcc tgcataacttgc acatccaaat ggaactgccc gccagccggc 660
ccctgcggggc gggccctggg ggtggccccc ggcgcctcc ttggccctggg caacccatcc 720
cacctgtcac tcaagtacaa caacccatcc acgggtggccccc gcagccctgcc ccctgcctg 780
gagttacccatcc tgcataacttgc acatccaaat ggcgcctcc ttggccctggg caacccatcc 840
ctgactgccc tgcgtgtgtct cgtatgtgggt ggaaaactgccc ggcgcctgtga ccatgcacgc 900
aacccctggc tggagtggccc acataaaattt ccccaagctgc actccqacac cttcagccac 960

ctaagccgcc tagaaggcct cgtgttgaag gatagtctc tctaccagct gaaccccaga	1020
tggttccgtg gcctggcaa cctcacagtg ctcgacctga gtgagaactt cctctacgac	1080
tgcacatcacca aaaccaaggc attccagggc ctggcccagc tgcgaagact caacttgtcc	1140
ttcaattacc ataagaaggt gtccttcgcc cacctgacgc tggcaccctc cttcgggagc	1200
ctgctctccc tgcaggaact ggacatgcat ggcacatcttct tccgctcaact cagccagaag	1260
acgctccagc cactggcccg cctgcccattg ctccagcgtc tgtatctgca gatgaacttc	1320
atcaaccagg cccagctcg catcttcaag gacttccctg gtctgcgcta catagacctg	1380
tcagacaacc gcatcagtgg agctgtggag ccggtgccca ccacagggga ggtggatgg	1440
ggaaagaagg tctggctgac atccaggac ctcaactccag gcccactgga caccggcagc	1500
tctgaggact tcatgccaag ctgcaagaac ctcaagttca ccttggaccc gtcacggAAC	1560
aacctggtaa cagtccagcc agagatgttt gcccagctct cgccgccttca gtgcctgcgc	1620
ctgagccaca acagcatctc gcaggcggtc aatggctcac agttcgtgcc actgaccagc	1680
ctgcagggtgc tggacctgtc ccataacaaa ctggacctgt accatggcg ctgcgttacg	1740
gagctgcccc gactggaggc cctggacctc agtacaaca gccagccctt cagcatgcgg	1800
ggtgtgggcc acaaccttag ctttgggcc cagctgccc ccctgcgcta cctcagccctg	1860
gcacacaatg gcatccacag ccgtgtgtcc cagcagctct gcagcacctc gctgtgggcc	1920
ctggacttca gcggcaattc cctgagccag atgtgggctg agggagaccc ctatctccgc	1980
ttcttccaag gcctgagaag cctaattccgg ctagacctgt cccagaatcg tctgcataacc	2040
ctccctgccat gcaccctggg caaccccccc aagagcttc agctgctgcg tctccgtAAC	2100
aattacctgg ctttcttcaa ttggagcagc ctgaccctcc tgcccaacct ggaaaccctg	2160
gacctggctg gaaaccagct gaaggctctg agcaatggca gcctgccttc tggcacccag	2220
ctccagagggc tggacgtcag caggaacagc atcatcttcg tggcccttgg cttctttgt	2280
ctggccacga ggctgcgaga gctcaacctc agtgccaaacg ccctcaggagc agaggagccc	2340
tcctggtttg gtttccctagc aggctccctt gaagtcctag atgtgagcgc caaccctctg	2400
cactgcgcct gtggggcagc ctttggac ttccctgtgc aggttcaggc tgccgtgcct	2460
ggtctgccc gccgcgtcaa gtgtggcagt ccggggccagc tccagggccg cagcatcttc	2520
gcacaagacc tgccgcctcg cctggacaag tccctctccct gggactgttt tggctctca	2580
ttgctggttg tggccctggg cctggccatg cctatgttgc accacctctg cggctgggac	2640
ctctggtaact gtttccaccc gggcctggcc tggctgcctt ggcgggggtg gcagcggggc	2700

gcggatgccc ttagctatga tgcccttgtg gtcttcgaca aggcacagag cgca	2760
gactgggtgt acaatgaact ggggtgcgg ctagaggagc gccgtggcg cggcgctc	2820
cgcctgtgtc tggaggagcg tgactggcta cctggcaaga cgctgttgcg aaacctgtgg	2880
gcctcagtct acagcagccg caagatgctg tttgtctgg cccacacgga ccaggtcagt	2940
ggcctcttgc gtgccagctt cctgtggcc cagcagcgctc tgctggagga ccgcaaggac	3000
gttgtggtgc tgtaatcct gagccctgac gcccgcgtt cccgttacgt gggctgcgc	3060
cagcgcctct gcgcgcagag tgcctcttc tggccccacc agcctagtgg ccagcgcagc	3120
ttctggcccc agctaggcat ggccctgacc agggacaacc gccacttcta taaccagaac	3180
ttctggccgg gcccgcgat ggctgagtag cacaggtga cagcctggca tgtacaaccc	3240
ccagccctga cttgcctct ctgcctatga tgcccagtct gcctcactct gtgacgcccc	3300
tgctctgcct ccgcacccct caccctggc atacagcagg cactcaataa atgccactgg	3360
caggccaaac agccaaaaaaaaaaaaaaa a	3391

<210> 16
<211> 2460
<212> DNA
<213> Equus caballus

<400> 16	
atggggccctt gccatggtgc cctgcagccc ctgtctctcc tgggtgcaggg gcgcattgtg	60
gcgcgtggctc tggcccaagg caccctgcct cccttcctgc cctgtgagct ccagccccac	120
ggcctggta actgcaactg gctgttcctg aagtccgtgc cccacttctc agcagcagca	180
ccccgggaca atgtcaccag ctttccttg ctctccaacc gcatccacca cttccacgac	240
tccgactttg cccaactgtc caacctgcag aaactcaacc tcaaattggaa ctgcccgcct	300
gccggccctca gccccatgca cttccctgc cacatgacca tcgagccaa cactttcctg	360
gctgtaccca ccctggagga gctgaacctg agctacaacg gcatcacgac tgtgcctgcc	420
ctgcccagct ccctcggtgc cctgatcctg agccgcacca acatcctgca gctagacccc	480
accagcctca cgggcctgca tgccctgcgc ttctataca tggatggcaa ctgctactac	540
aagaacccct gggggggggc cctggaggtg gcccaggcg ccctccctgg cctggcaac	600
ctcaccacc tgcactcaa gtacaacaac ctcacaacgg tgccccgcag cctggccct	660
agcctggagt acctgctgtt gtcctacaac cacattgtca ccctggcacc tgaggacctg	720
gccaatctga ctgcccctgca tgcgtcgat gtgggtggaa actgcccggc ctgtgaccat	780
gcacgcaacc cctgcgtgga gtgcccacat aaattccccc agctgcactc cgacacccctc	840

agccaccta gcccctaga aggccctcgta ttgaaggata gttctctcta ccagctgaac 900
cccagatgg tccgtggcct gggcaacctc acagtgcctg acctgagtga gaacttcctc 960
tacgactgca tcacccaaac caaggcattc cagggcctgg cccagctgca aagactcaac 1020
ttgtccttca attaccataa gaagggtgtcc ttgcggccacc tgacgctggc accctccctc 1080
gggagcctgc tctccctgca ggaactggac atgcattggca tcttcttccg ctcaactcaggc 1140
cagaagacgc tccagccact ggccccgcctg cccatgctcc agcgtctgta tctgcagatg 1200
aacttcatca accaggccca gctcggcatc ttcaaggact tccctggtct gcgctacata 1260
gacctgtcag acaaccgcatt cagtgagact gtggagccgg tggccaccac aggggaggtg 1320
gatggtggga agaaggctcg gctgacatcc agggacctca ctccaggccc actggacacc 1380
cccagctctg aggacttcat gccaagctgc aagaacctca gcttcacccctt ggacctgtca 1440
cggaacaacc tggtaacagt ccagccagag atgtttgccc agctctcgca cttccagtg 1500
ctgcgcctga gccacaacag catctcgca gcggtcaatg gctcacagtt cgtgccactg 1560
accagcctgc aggtgctgga cctgtcccat aacaaactgg acctgtacca tggcgcctcg 1620
tttacggagc tgccgcact ggaggccctg gacctcagct acaacagcca gcccttcagc 1680
atgcggggtg tggccacaa cctcagcttt gtggcccage tgcccaccct gcgctacctc 1740
agcctggcac acaatggcat ccacagccgt gtgtcccage agctctcgca cacctcgctg 1800
tggccctgg acttcagcgg caattccctg agccagatgt gggctgaggg agaccttat 1860
ctccgcttct tccaaggcct gagaaggcta atccggctag acctgtccca gaatcgctg 1920
cataaccctcc tgccatgcac cctggcaac ctccccaaaga gcttgcagct gctgcgtctc 1980
cgtaacaatt acctggcctt cttcaattgg agcagcctga ccctcctgca caacctggaa 2040
accctggacc tggctggaaa ccagctgaag gctctgagca atggcagct gccttcgtgc 2100
acccagctcc agaggctgga cgtcagcagg aacagcatca tcttcgtggt ccctggcttc 2160
tttgcctgg ccacgaggct gcgagagctc aacctcagtg ccaacgcctt caggacagag 2220
gagccctcct ggtttggttt cctagcaggc tcccttgaag tccttagatgt gagcgccaaac 2280
cctctgcact ggcgcctgtgg ggcagccctt gtggacttcc tgctgcaggt tcaggctgca 2340
gtgcctggtc tgcccagccg cgtcaagtgt ggcagtcggc gccagctcca gggccgcagc 2400
atcttcgcac aagacactgcg cctctgcctg gacaagtccc tcttcgtggta ctgtttgggt 2460

<210> 17
<211> 1029
<212> PRT
<213> Ovis aries

<400> 17

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala
1 5 10 15

Ala Ala Leu Ala Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu
20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe
35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser
65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr
100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn
115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu
130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr
145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn
165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn
195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu
210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala
225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg
245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro
260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu
275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg
290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr
305 310 315 320

Asp Tyr Ile Thr Lys Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg
325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg
370 375 380

Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn
385 390 395 400

Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu
405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp
435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp
450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn
465 . 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu
485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr
515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln
530 535 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
660 665 670

Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu
690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val
705 710 715 720

Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile
740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
755 760 765

Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg
770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
805 810 815

Phe Gly Phe Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met
820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys
835 840 845

Leu Ala His Leu Pro Arg Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu
850 855 860

Leu Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val Ala
865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly
885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly
900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys
915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg

930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp
945 950 955 960

Val Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr
965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro
980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Met Ala
995 1000 1005

Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg
1010 1015 1020

Gly Pro Thr Thr Ala Glu
1025

<210> 18
<211> 818
<212> PRT
<213> Ovis aries

<400> 18

Ala Ala Leu Ala Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu
20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe
35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val
50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His His Leu His Asp Ser
65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn
85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr

100	105	110
Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn		
115	120	125
Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu		
130	135	140
Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr		
145	150	155
His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn		
165	170	175
Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly		
180	185	190
Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn		
195	200	205
Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu		
210	215	220
Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala		
225	230	235
Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg		
245	250	255
Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro		
260	265	270
Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu		
275	280	285
Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg		
290	295	300
Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr		
305	310	315
Asp Tyr Ile Thr Lys Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg		
325	330	335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His
340 345 350

Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu
355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg
370 375 380

Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn
385 390 395 400

Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu
405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
420 425 430

Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp
435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp
450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn
465 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu
485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly
500 505 510

Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr
515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln
530 535 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln
545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg
565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys
580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu
595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly
610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr
625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu
645 650 655

Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
660 665 670

Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys
675 680 685

Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu
690 695 700

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val
705 710 715 720

Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys
725 730 735

Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile
740 745 750

Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
755 760 765

Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg
770 775 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe
785 790 795 800

Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys
805 810 815

Phe Gly

<210>	19					
<211>	3199					
<212>	DNA					
<213>	Ovis aries					
<400>	19					
gtcggcacgg	gaagtgagcg	ccaagcatcc	ttccctgcag	ctgccgc	acttgcccgc	60
cagaccctct	ggagaagccg	cattccctgc	catggggccc	tactgtgcc	cgcacccccc	120
ttctctcc	gtgcaggcgg	cggcgctggc	agcagccctg	gcccaggca	ccctgcctgc	180
ttccctgccc	tgtgagctcc	agccccgggg	taaggtgaac	tgcaactggc	tgttcctgaa	240
gtctgtgc	cgttttcgg	ccggagcccc	ccgggccaat	gtcaccagcc	tctccttaat	300
ctccaaccgc	atccaccact	tgcacgactc	tgacttcgtc	cacctgtcca	acctgcgggt	360
cctcaacctc	aagtggaaact	gcccgcggc	cggcctcagc	cccatgcact	tcccctgccc	420
catgaccatc	gagcccaaca	ctttcctggc	tgtgcccacc	ctggaggagc	tgaacctgag	480
ctacaatggc	atcacgaccg	tgcctgc	gcccagttt	ctcgatccc	tgtcgctgag	540
ccgcaccagc	atcctggtgc	taggccccac	ccacttcacc	ggcctgcacg	ccctgcgtt	600
tctgtacatg	gacggcaact	gctactataa	gaacccctgc	cagcaggccg	tggaggtggc	660
cccaggcgcc	ctccttgccc	tggcaacct	cacgcacctg	tgcgtcaagt	acaacaacct	720
cacggagg	ccccggcc	tgccccccag	cctggacacc	ctgctgtgt	cctacaacca	780
catcatcacc	ctggcaccccg	aggacctggc	caatctgact	gcccgcgtg	tgcttgatgt	840
ggcgaaaa	tgccgcggc	gcaaccacgc	ccgcaacccc	tgcagggagt	gccccaaagaa	900
cttcccaag	ctgcaccctg	acacccctcg	ccacccctg	cgccctgatgt	960	
gaaggacagt	tctctctaca	aactagagaa	agactggttc	cgccgcctgg	gcaggctcca	1020
agtgcgtc	ctgagtgaga	acttcctcta	tgactacatc	accaagacca	ccatccatcg	1080
gaacctgacc	cagctgcgca	gactcaacct	gtccttcaat	taccacaaga	agggtgcctt	1140
cgccccac	caactggcac	cctccttgg	gggcctgggt	tccctggaga	agctggacat	1200
gcacggc	ttttccgt	ccctcaccaa	caccacgctc	cgccgcgtga	cccagctgcc	1260
caagctcc	agtctgagtc	tgcagctgaa	cttcatcaac	caggccgagc	tcagcatctt	1320
tggggc	ccgagcctgc	tcttcgtgga	cctgtcggac	aaccgcac	gcggagctgc	1380
gaggcc	ggccgcctcg	gggaggtgga	cagcgggggtg	gaagtctggc	ggggccca	1440

gggcctcgct ccaggcccgc tggccgcccgt cagcgcaaag gacttcatgc caagctgcaa	1500
cctcaacttc accttggacc tgtcacggaa caacctggtg acgatccagc aggagatgtt	1560
tacccgcctc tccccctcc agtgcctgctg cctgagccac aacagcatct cgccaggcggt	1620
taatggctcg cagttcgtgc cgctgaccccg cctgcgagtg ctgcacctgt cctacaacaa	1680
gctggacctg taccatgggc gctcggtcac ggagctgccc cagctggagg cactggacct	1740
cagctacaac agccagccct tcagcatgca gggcgtggc cacaaccta gcttcgtggc	1800
ccagctgccc tccctgcgtc acctcagccct tgccacaac ggcataccaca gccgcgtgtc	1860
acagaagctc agcagcgcct cgctgcgcgc cctggacttc agcggcaact ccctgagcca	1920
gatgtgggcc gagggagacc ttatctctg cttttcaaa ggcttgagga acctggtcca	1980
gctggacctg tccaagaacc acctgcacac cctcctgcct cgtcacctgg ataacctgcc	2040
caagagcctg cggcagctgc gtctccggga caataacctg gccttcttca actggagcag	2100
cctgactgtt ctgccccagc tggaaagccct ggatctggcg ggaaaccagc tgaaggccct	2160
gagcaacggc agcctgccac ctggcaccccg gctccagaag ctggacgtga gcagcaacag	2220
catcggttt gtgacccctg gtttttgtt ctttgcac cggctgaaag agcttaacct	2280
cagcgccaaac gcccgtaaaga cagtggatcc cttctggttc ggtcgttaa cagagaccct	2340
aatatccta gacgtgagcg ccaacccgct ccactgtgcc tgcggggcgg cctttgtgga	2400
tttcctgctg gagatgcagg cggccgtgcc tggctgtcc aggccgtca cgtgtggcag	2460
tccggggccag ctccaggggcc gcagcatctt cgcacaggac ctgcgcctct gcctggatga	2520
gaccctctcc ttggactgct ttggcttctc gctgctaattt gtggcgctgg gcctggcggt	2580
gccccatgctg caccacctct gtggctggga cctgtggtaa tgcttccacc tttgtctggc	2640
ccatggccccc cgacggcggc ggcagcccc cgaggacacc ctgtctacg atgcattcgt	2700
ggtcttcgac aaggcgcaga gtgcagtggc cgactgggtg tacaacgagc tccgcgtgca	2760
gctggaggag cgccgcggc gcccggcgct ccgcctctgc ctggaggagc gagactggct	2820
ccctggcaag acgctttcg agaacctgtg ggctcggtc tacagcagcc gtaagaccat	2880
tttcgtgtc gaccacacgg accgggttag tggcttcctg cgccgcgtca tcotgctggc	2940
ccagcagcgc ctgttggagg accgcaagga tgtcggtgt ctgggtatcc tgcggcccccgc	3000
cgccctaccgg tcccgctacg tgccgcgtcg ccagcgccctc tgccgcaga gcgtccctct	3060
ctggcccccac cagcccagtg gccagggtag cttctggcc aacctggca tggccctgac	3120
cagggacaac cgccacttct ataaccggaa ctctgcggg ggccccacga cagccgaata	3180

gcacagagtg actgcccag	3199
<210> 20	
<211> 2454	
<212> DNA	
<213> Ovis aries	
<400> 20	
atggggccctt actgtgcccc gcaccccttt tcttcctgg tgcaggcggc ggcgctggca	60
gcagccctgg cccagggcac cctgcctgcc ttctgcctt gtgagctcca gccccggggt	120
aaggtaact gcaactggct gttcctgaag tctgtgccgc gctttcggc cggagcccc	180
cgggccaatg tcaccagcct ctcccttaatc tccaaaccgca tccaccactt gcacgactct	240
gacttcgtcc acctgtccaa cctgcggggtc ctcaacctca agtggaaactg cccgcgggccc	300
ggcctcagcc ccatgcactt cccctgccgc atgaccatcg agcccaacac cttectggct	360
gtgcccaccc tggaggagct gaacctgagc tacaatggca tcacgaccgt gcctgcctg	420
cccagttctc tcttatccct gtcgctgagc cgccaccagca tcctgggtct aggccccacc	480
cacttcaccc gcctgcacgc cctgcgttt ctgtacatgg acggcaactg ctactataag	540
aaccctgcc agcaggccgt ggaggtggcc ccaggcgccc tcctggcct gggcaacctc	600
acgcacctgt cgctcaagta caacaacctc acggaggtgc cccgcgcct gccccccagc	660
ctggacacccc tgctgctgtc ctacaaccac atcatcaccc tggcaccctga ggacctggcc	720
aatctgactg ccctgcgtgt gcttgatgtg ggcgggaaact gccgcgcgtc cgaccacgccc	780
cgcaacccct gcagggagtg cccaaagaac ttccccaagc tgcaccctga caccttcagc	840
cacctgagcc gcctcgaagg cctgggttt aaggacagt ctctctacaa actagagaaa	900
gactggttcc ggggcctggg caggctccaa gtgctcgacc tgagtgagaa ctccctctat	960
gactacatca ccaagaccac catcttcagg aacctgaccc agctgcgcag actcaacctg	1020
tccttcaatt accacaagaa ggtgtccttc gcccacctgc aactggcacc ctcccttggg	1080
ggcctgggtgt ccctggagaa gctggacatg cacggcatct tcttccgcgc cctcaccaac	1140
accacgctcc ggccgctgac ccagctgccc aagctccaga gtctgagtct gcagctgaac	1200
ttcatcaacc aggccgagct cagcatctt ggggccttcc cgagcctgtct ctgcgtggac	1260
ctgtcggaca accgcattcag cggagctgcg aggccgggtgg ccgcctcgg ggaggtggac	1320
agcgggggtgg aagtctggcg gtggcccagg ggccctcgctc caggcccgct ggccgcgc	1380
agcgcaaagg acttcatgcc aagctgcaac ctcaacttca cttggacact gtcacggaac	1440
aacctggtga cgatccagca ggagatgttt accgcctct cccgcctcca gtgcctgcgc	1500

ctgagccaca acagcatctc gcaggcggtt aatggctgc agttcggtcc gctgaccgc	1560
ctgcgagtgc tcgacacctgc ctacaacaag ctggacactgt accatggcg ctcgttcacg	1620
gagctgccgc agctggaggc actggacctc agctacaaca gccagccctt cagcatgcag	1680
ggcgtggcc acaacacctag cttcggtggcc cagctgcgt ccctgcgcta cctcagccct	1740
gcbcacaacg gcatccacag ccgcgtgtca cagaagctca gcagcgcctc gctgcgcgc	1800
ctggacttca gcggcaactc cctgagccag atgtggcccg agggagacct ctatctctgc	1860
ttcttcaaag gcttgaggaa cctgggtccag ctggacactgt ccaagaacca cctgcacacc	1920
ctcctgcctc gtcacacttga taacctgccc aagagcctgc ggcagctgc tctccggac	1980
aataacctgg ctttcttcaa ctggagcagc ctgactgttc tgccccagct ggaagccctg	2040
gatctggcgg gaaaccagct gaaggccctg agcaacggca gcctgccacc tggcacccgg	2100
ctccagaagc tggacgttag cagcaacagc atcggctttg tgacccctgg cttctttgtc	2160
cttgccaacc ggctgaaaga gcttaacctc agcgccaacg ccctgaagac agtggatccc	2220
ttctggttcg gtcgcttaac agagaccctg aatatcctag acgtgagcgc caacccgctc	2280
cactgtgcct gcggggcggc ctttgtggac ttccctgctgg agatgcaggg gcgcgtgcct	2340
gggctgtcca ggcggtcac gtgtggcagt cggggccagc tccagggccg cagcatctc	2400
gcacaggacc tgccctctg cctggatgag accctctcct tggactgctt tggc	2454

<210> 21

<211> 1032

<212> PRT

<213> Canis familiaris

<400> 21

Met	Gly	Pro	Cys	Arg	Gly	Ala	Leu	His	Pro	Leu	Ser	Leu	Leu	Val	Gln	
1									5					10		15

Ala	Ala	Ala	Leu	Ala	Leu	Ala	Gln	Gly	Thr	Leu	Pro	Ala	Phe
									20		25		30

Leu	Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Leu	Val	Asn	Cys	Asn	Trp	Leu
									35		40		45		

Phe	Leu	Lys	Ser	Val	Pro	Arg	Phe	Ser	Ala	Ala	Pro	Arg	Gly	Asn	
									50		55		60		

Val	Thr	Ser	Leu	Ser	Leu	Tyr	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp
									65		70		75		80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu
115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe
260 265 270

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe
290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu
370 375 380

Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu
385 390 395 400

Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu
420 425 430

Pro Ala Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val
435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly
450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp
465 470 475 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln
500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu
515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr
530 535 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro

545	550	555	560
Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu			
565	570	575	
Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg			
580	585	590	
Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser			
595	600	605	
Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg			
610	615	620	
Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn			
625	630	635	640
Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser			
645	650	655	
Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp			
660	665	670	
Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly			
675	680	685	
Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln			
690	695	700	
Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro			
705	710	715	720
Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala			
725	730	735	
Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly			
740	745	750	
Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys			
755	760	765	
Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro			
770	775	780	

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly
785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu
805 810 815

Ser Trp Val Cys Phe Ser Leu Ser Leu Ala Val Ala Leu Ser Leu
820 825 830

Ala Val Pro Met Leu His Gln Leu Cys Gly Trp Asp Leu Trp Tyr Cys
835 840 845

Phe His Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Arg Gly
850 855 860

Val Asp Ala Leu Ala Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865 870 875 880

Ser Ser Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu
885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
900 905 910

Trp Val Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
915 920 925

Ser Ser Arg Lys Thr Leu Phe Val Leu Ala Arg Thr Asp Arg Val Ser
930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Cys Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
995 1000 1005

Leu Gly Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Thr Ala
1025 1030

<210> 22
<211> 822
<212> PRT
<213> Canis familiaris

<400> 22

Met Gly Pro Cys Arg Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Ala Leu Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu
115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe
260 265 270

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe
290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu
355 360 365

Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu
370 375 380

Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu
385 390 395 400

Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu
420 425 430

Pro Ala Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val
435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly
450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp
465 470 475 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln
500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu
515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr
530 535 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro
545 550 555 560

Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu
565 570 575

Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg
580 585 590

Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser
595 600 605

Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg
610 615 620

Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn
625 630 635 640

Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser
645 650 655

Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp

660 665 670

Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly
675 680 685

Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln
690 695 700

Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro
705 710 715 720

Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala
725 730 735

Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly
740 745 750

Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys
755 760 765

Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro
770 775 780

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly
785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu
805 810 815

Ser Trp Val Cys Phe Ser
820

<210> 23
<211> 3334
<212> DNA
<213> *Canis familiaris*

```
<400> 23  
aggaaggggc tgtgagctcc aagcatcctt tcctgcagct gctgccca 60  
gaccctctgg agaagccccc gctccctgtc atggggccct gccgtggcgc cctgcacccc 120  
ctgtctctcc tggtgcagggc tgcccgcgcta gccctggccc tggcccaggg caccctgcct 180  
gccttcctgc cctgtgagct ccagcccat ggcctggta actgcaactg gctgttcctc 240  
aagtccgtgc cccgcttctc ggcagctgca ccccgccgta acgtcaccag cctttccttq 300
```

tactccaacc	gcatccacca	cctccatgac	tatgactttg	tccacttcgt	ccacacctgcgg	360	
cgtctcaatc	tcaagtggaa	ctgcccgc	cccagcctca	gccccatgca	ctttccctgt	420	
cacatgacca	ttgagccaa	cacccctc	gtgtgccc	ccctagagga	cctgaatctg	480	
agctataaca	gcatcacgac	tgtcccc	ctgcccagtt	cgcttgcgtc	cctgtccctg	540	
agccgacca	acatcc	gtgtggac	gccaccctgg	caggcctta	tgcctgcgc	600	
ttcc	ttcc	tggtatggcaa	ctgctactac	aagaacccct	gccagcaggc	660	
gccccaggt	ccctcc	ttgg	ctggcaac	ctcacacacc	tgtcactcaa	720	
ctcaccgtgg	tgcc	gggg	cctgcccc	agcctggagt	acctgcttt	780	
cacatcatca	ccctggcacc	tgaggac	ctgacc	gtgc	gtgcagg	840	
gtgggtggga	actgtcgccg	ctgtgaccat	gcccgt	gtgcagg	gtgcagg	900	
ggcttcccc	agctgcaccc	caacac	cttc	ggccac	ctcg	aggc	960
ttgagggaca	gctctctcta	cagc	cctgg	cccagg	gtccatgg	ggcaac	1020
atggtgctgg	acctgagtga	gaactt	cctg	tatgactg	ca	aaagc	1080
tacggcctgg	cccggctg	cagact	caac	ctgtc	attatcataa	gaagg	1140
tttgc	ccacc	tgc	atc	ccttc	gggagc	ctac	1200
atacatggca	tcttcttccg	ctcg	ctc	aagacc	acgc	tccag	1260
cccatg	ctcc	agcgt	tgc	tctg	aactt	tatca	1320
ttcggc	ccctgg	tcggt	acgt	gactt	gtc	ggag	1380
gcagag	ccgg	gtgt	ccac	aggagg	gagg	gtgg	1440
cagtc	ccct	ggact	ggcc	gggg	gggg	gggg	1500
agctgc	ccct	caactt	cac	ttgg	act	gtgg	1560
ccggagatgt	ttgtccgg	ggcg	cgcc	cgt	gc	caac	1620
tcgcagg	ccgg	tcaatgg	gtc	gat	ctt	gag	1680
tcccataaca	agctgg	acc	gtacc	acgg	cgctcg	gtcc	1740
gccttggacc	tca	atgg	gtc	gat	cc	ggcgt	1800
agctt	gtgg	cac	agctg	gcc	cc	ccatcc	1860
agccgcgtgt	ccc	aggc	cc	cgcc	cc	ccatcc	1920
accctgagcc	agatgt	gggc	cgagg	gagac	ctctat	ctcc	1980
agcctgg	ttc	agctgg	acc	gtccc	aga	ccatcc	2040
gacaac	ctcc	ccaag	aggc	ctcg	cc	ccatcc	2100

aactggagca gcctggccct cctacccaag ctggaagccc tggacctggc gggaaaccag	2160
ctgaaggccc tgagcaatgg cagcttgcac aacggcaccc agctccagag gctggaccc	2220
agcggcaaca gcatcggttt cgtggcccc agctttttg ccctggccgt gaggcttcga	2280
gagctcaacc tcagcgccaa cgccctcaag acggtgagc cctcctggtt tggttccctg	2340
gcgggtgccc tgaaagtccct agacgtgacc gccaaccctt tgcattgcgc ttgcggcgca	2400
accttcgtgg acttccttgct ggaggtgcag gctgcgggtc ccggcctgccc tagccgtgtc	2460
aagtgcggca gcccgggcca gctccagggc cgcatcttc tcgcacagga cctgcgcctc	2520
tgcctggacg aagcgctctc ctgggtctgt ttcaagcctct cgctgcgtgc tgtggccctg	2580
agcctggctg tgcccatgct gcaccagetc tggctgggg acctctggta ctgcttccac	2640
ctgtgcctgg cctggctgcc ccggcggggg cgccggcggg gtgtggatgc cctggcctat	2700
gacgccttcg tggcttcga caaggcgcag agctcggtgg cgactgggt gtacaatgag	2760
ctgcgggtac agcttagagga gcccgtggg cgccggcgc tacgcctgtg tctggaggaa	2820
cgtgactggg taccggcaa aaccctcttc gagaacctct ggccctcagt ttacagcagc	2880
cgcaagacgc tgtttgtct ggcccgacg gacagagtca gcccctccct gcgtgccagc	2940
ttccctgtgg cccaacagcg cctgctggag gaccgcaagg acgtcggtgt gctgggtatc	3000
ctgtgcctgg acgcccaccc ctcccgctat gtgcggctgc gcccgcct ctgcgcctag	3060
agtgtcttcc tctggccca ccagccctggc ggcagcgca gcttctggc ccagctggc	3120
acggccctga ccagggacaa ccgcacttc tacaaccaga acttctgccc gggcccccacg	3180
acagcctgat aggccagacag cccagcacct tcgcgcctt acaccctgcc tgctgtctg	3240
ggatgcccga cctgctggct ctacaccgccc gctctgtctc ccctacacccc agccctggca	3300
taaagcgacc gctcaataaa tgctgcgtgg agac	3334

<210> 24
<211> 2466
<212> DNA
<213> Canis familiaris

<400> 24 atggggccctt gcccgtggcgcc cctgcacccccc ctgtctctcc tgggtgcaggc tgccgcgtat	60
ggccctggccc tggcccaggc caccctgcctt gccttcctgc cctgtgagct ccagcccccatt	120
ggccctgggtga actgcaactg gctgttccttc aagtccgtgc cccgcttctc ggcagctgca	180
ccccgcggta acgtcaccag cctttccttg tactccaacc gcatccacca cctccatgac	240
tatgacttttgc tccacttcgtt ccacccgtgg cgtctcaatc tcaagtggaa ctgcggccccc	300

gccagcctca	gccccatgca	ctttccctgt	cacatgacca	ttgagccaa	cacccttcgt	360
gctgtgccc	ccctagagga	cctgaatctg	agctataaaca	gcatcacgac	tgtgcccgc	420
ctgcccagtt	cgcttgtgtc	cctgtccctg	agccgcacca	acatcctgg	gctggaccct	480
gccaccctgg	caggccttta	tgccctgcgc	ttcctgttcc	tggatggcaa	ctgctactac	540
aagaacccct	gccagcaggg	cctgcaggtg	gccccaggtg	ccctcctggg	cctgggcaac	600
ctcacacacc	tgtcactcaa	gtacaacaac	ctcaccgtgg	tgggggggg	cctgggggg	660
agcctggagt	acctgcttt	gtcctacaac	cacatcatca	ccctggcacc	tgaggacctg	720
gccaatctga	ctgcccgtcg	tgcctcgat	gtgggtggga	actgtcgccg	ctgtgaccat	780
gcccgttaacc	cctgcaggg	gtgccccaa	ggcttcccc	agctgcaccc	caacaccc	840
ggccacactga	gccacctcg	aggcctgg	ttgagggaca	gctctctcta	cagcctggac	900
cccaggtgg	tccatggcct	gggcaacctc	atggtgctgg	acctgagtga	gaacttcctg	960
tatgactgca	tcaccaaaac	caaagccttc	tacggcctgg	ccggctg	cagactcaac	1020
ctgtccttca	attatcataa	gaaggtgtcc	tttgcacc	tgcatctggc	atcctccttc	1080
gggagcctac	tgtccctgca	ggagctggac	atacatggca	tcttcttccg	ctcgctcagc	1140
aagaccacgc	tccagtcgt	ggcccacctg	ccatgtc	agcgtctgca	tctgcagtt	1200
aactttatca	gccaggccc	gctcagcatc	ttcggcgcct	tccctggact	gcgtacgt	1260
gacttgcag	acaaccgc	cagtggagct	gcagagccc	cggctgccac	aggggaggta	1320
gaggcagact	gtggggagag	agtctggcca	cagtcccgg	accttgc	ggcccactg	1380
ggcacccccc	gctcagaggc	cttcatgccc	agctgcagga	ccctcaactt	caccttggac	1440
ctgtctcgga	acaacctagt	gactgttcag	ccggagatgt	ttgtccggct	ggcgccctc	1500
cagtgcctgg	gcctgagcca	caacagcatc	tgcaggcgg	tcaatggctc	gcagttcg	1560
cctctgagca	acctgcgggt	gctggacctg	tcccataaca	agctggac	gtaccacgg	1620
cgctcggtca	cggagctg	gcccgtggag	gccttgacc	tcaatggctc	gcagttcg	1680
ttcagcatgc	ggggcgtgg	ccacaatctc	agctttgtgg	cacagctgcc	agccctgcgc	1740
tacctcagcc	tggcgcacaa	tggcatccac	agccgcgtgt	ccagcagct	ccgcagcgcc	1800
tcgctccggg	ccctggactt	cagtggcaat	accctgagcc	agatgtggc	cgagggagac	1860
ctctatctcc	gtttttcca	aggcctgaga	agcctggttc	agctggac	gtcccagaat	1920
cgcctgcata	ccctcctg	acgcaacctg	gacaacctcc	ccaagagc	gcggctcctg	1980
cggtcccg	acaattacct	ggcttcttc	aactggagca	gcctggccct	cctacccaag	2040

ctggaagccc tggacctggc gggaaaccag ctgaaggccc tgagcaatgg cagttgccc 2100
 aacggcaccc agctccagag gctggacctc agcgcaaca gcatcggtt cgtggcccc 2160
 agctttttg ccctggccgt gaggottcga gagctcaacc tcagcgccaa cgccctcaag 2220
 acggtgagc ctcctgggt tggttccctg gcgggtgccc taaaagtctt agacgtgacc 2280
 gccaaccct tgcattgcgc ttgcggcgca accttcgtgg acttcttgct ggaggtgcag 2340
 gctgcggtgc cggcctgcc tagccgtgtc aagtgcggca gcccgggcca gctccaggc 2400
 cgcagcatct tcgcacagga cctgcgcctc tgccctggacg aagcgctctc ctgggtctgt 2460
 ttca
 2466

<210> 25
 <211> 1031
 <212> PRT
 <213> Felis catus

<400> 25

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 . 10 15

Ala Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe
 20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu
 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn
 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp
 85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
 100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
 130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe
260 265 270

Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe
290 295 300

His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu
370 375 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu
420 425 430

Leu Ala Ala Ala Thr Gly Glu Val Asp Gly Gly Glu Arg Val Arg Leu
435 440 445

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu
450 455 460

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser
485 490 495

Arg Leu Gln Cys Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe

610 615 620

Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg
645 650 655

Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Val Leu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu
740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
805 810 815

Asp Cys Phe Gly Leu Ser Leu Leu Thr Val Ala Leu Gly Leu Ala Val
820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
835 840 845

'Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Gly Ala Asp
 850 855 860

Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala
 865 870 875 880

Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg
 885 890 895

Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu
 900 905 910

Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser
 915 920 925

Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu
 930 935 940

Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg
 945 950 955 960

Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His Arg Ser
 965 970 975

Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu
 980 985 990

Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly
 995 1000 1005

Thr Ala Leu Thr Arg Asp Asn Gln His Phe Tyr Asn Gln Asn Phe
 1010 1015 1020

Cys Arg Gly Pro Thr Thr Ala Glu
 1025 1030

<210> 26
<211> 820
<212> PRT
<213> Felis catus

<400> 26

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15

Ala Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His His Leu His Asp
65 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser
130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro
145 150 155 160

Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe
260 265 270

Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe
290 295 300

His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Ala Phe Gln Gly Leu Ala Gln Leu
325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala
340 345 350

His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu
370 375 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu
420 425 430

Leu Ala Ala Ala Thr Gly Glu Val Asp Gly Gly Glu Arg Val Arg Leu
435 440 445

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu
450 455 460

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser
485 490 495

Arg Leu Gln Cys Leu Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser
545 550 555 560

Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser
580 585 590

Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg
645 650 655

Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser
660 665 670

Leu Val Leu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln
675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln
690 695 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe
705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala

725

730

735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu
 740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala
 755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
 770 775 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser
 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
 805 810 815

Asp Cys Phe Gly
 820

<210> 27
<211> 3235
<212> DNA
<213> Felis catus

<400> 27	
agggtctgcg agctccaggc attcttctct gccatcgctg cccagtcgtc catccagacc	60
ctctggagaa gccccactc cctgtcatgg gcccctgcca tggcgcctg cacccttgt	120
ctctcctggc gcaggctgcc ggcgtggccg tgccctggc ccagggcacc ctgcctgcct	180
ttctgccttg tgagctccag cgccacggcc tggtaattt cgactggctg ttccctcaagt	240
ccgtgccccca cttctcggcg gcagcgcccc gtggtaacgt caccagcatt tccctgtact	300
ccaaaccgcat ccaccacactc cacgactccg actttgtcca cctgtccagc ctgcggcgctc	360
tcaacctcaa atggaactgc ccacccgcca gcctcagccc catgcacttc ccctgtcaca	420
tgaccattga gccccacacc ttccctggccg tgcccacccct ggaggagctg aacctgagct	480
acaacagcat cacgacagta cccgcctgc ccagttccct cgtgtccctg tccttgagcc	540
gtaccaacat cctggtgctg gaccctgcca acctcgagg gctgcactcc ctgcgttttc	600
tgttcctgga tggcaactgc tactacaaga acccctgccc gcagggccctg caggtggccc	660
cgggcgcctt cttggcctg ggcaacctta cgcacctgtc actcaagtagc aacaacctca	720
ctgcggtgcc cccggccctg ccccoagcc tggagtaccc gctattgtcc tacaaccaca	780

tcatcacccct	ggcacctgag	gacctggcca	acctgaccgc	cctgcgtgt	ctcgatgtgg	840
gtgggaactg	ccgtcgctgt	gaccacgccc	gcaacccctg	tatggagtgc	cccaaggcgt	900
tcccccacct	gcaccctgac	accttcagcc	acctgaacca	cctcgaaggc	ctggtgttga	960
aggacagctc	tctctacaac	ctgaacccca	gatggttcca	tgccctgggc	aacctcatgg	1020
tgctggacct	gagtgagaac	ttcctatatg	actgcatacac	caaaaccaca	gccttccagg	1080
gcctggccca	gctgcgcaga	ctcaacttgt	ctttcaatta	ccacaagaag	gtgtcctttg	1140
cccacacctgca	tctggcgccc	tccttcggga	gcctgctctc	cctgcagcag	ctggacatgc	1200
atggcatctt	cttccgctcg	ctcagcgaga	ccacgctccg	gtcgctggtc	cacctggcca	1260
tgctccagag	tctgcacctg	cagatgaact	tcatcaatca	ggcccagctc	agcatcttcg	1320
gggccttccc	tggcctgcga	tacgtggacc	tgtcagacaa	ccgcataagt	ggagccatgg	1380
agctggcggc	tgccacgggg	gaggtggatg	gtggggagag	agtccggctg	ccatctgggg	1440
acctagctct	gggcccacccg	ggcaccccta	gctccgaggg	cttcatgcca	ggctgcaaga	1500
ccctcaactt	cacttggac	ctgtcacgga	acaacctagt	gacaatccag	ccagagatgt	1560
ttgcccggct	ctcgccgcctc	cagtgcctgc	tcctgagccg	caacagcatc	tcgcaggcag	1620
tcaacggctc	acaattttatg	ccgctgacca	gcctgcaggt	gctggacctg	tcccataaca	1680
agctggacct	gtaccatggg	cgctcttca	cgagactgcc	gcggctggag	gccctggacc	1740
tcaagctacaa	cagccagccc	ttcagcatgc	agggcgtggg	tcacaacctc	agctttgtgg	1800
cacagctgcc	ggccctgcgc	tatctcagcc	tggcgcacaa	cgacatccac	agccgtgtgt	1860
cccagcagct	ctgcagcgc	tcgctgcggg	ccttggactt	cagcggcaat	gccttgcggcc	1920
ggatgtgggc	cgagggagac	ctgtatctcc	acttcttccg	aggcctgagg	agcctgggtcc	1980
ggttggatct	gtcccagaat	cgcctgcata	ccctcttgcc	acgcacccctg	gacaacctcc	2040
ccaagagcct	gcggctgctg	cgtctccgtg	acaatttatct	ggctttcttc	aactggagca	2100
gcctggcct	cctccccagg	ctggaagccc	tggacctggc	ggaaaccag	ctgaaggccc	2160
tgagcaacgg	cagcttgcct	aatggaaccc	agctccagag	gctggacctc	agcagcaaca	2220
gtatcagctt	cgtggcctcc	agcttttttgc	ctctggccac	caggctgcga	gagctcaacc	2280
tcagtgccaa	cgcctcaag	acggtgagc	cctcctggtt	cggttctcta	gcgggcaccc	2340
tgaaagtccct	agatgtgact	ggcaacccccc	tgcactgcgc	ctgtggggcg	gccttcgtgg	2400
acttcttgct	ggaggtgcag	gctgcagtgc	ccggcctgcc	aggccacgtc	aagtgtggca	2460
gtccaggtca	gctccagggc	cgcagcatct	ttgcgcagga	tctgcgcctc	tgccctggatg	2520
aggccctctc	ctgggactgt	tttggcctct	cgctgcgtac	cgtggccctg	ggccctggccg	2580

tgcccatgct	gcaccaccc	tgtggctggg	acctctggta	ctgcttccac	ctgtgcctgg	2640
cctggctgcc	ccggcgaaaa	cggcggcgaa	gcccggatgc	cctgccatc	gatgcctttg	2700
tggtcttcga	caaggcacag	agcgcggtgg	ccgactgggt	gtacaacgag	ctgcgggtac	2760
ggcttagagga	gcccgtggaa	cggcggcgcc	tccgcctgtg	cctggaggaa	cgtgactggc	2820
tacccgtaa	aacgctcttt	gagaacctgt	gggcctcagt	ttacagcagc	cgcaagatgc	2880
tgttgtgtct	ggccccacaca	gacagggtca	gcccgccttt	gcccgcctgc	tttctgtgg	2940
cccagcagcg	cctgctggag	gaccgcaagg	acgttgggt	gctggtgatc	ctgcggcccg	3000
acgcccaccc	ctcccgctat	gtgcggctgc	gccagcgcct	ctgcgcgcag	agcgtccctcc	3060
tctggcccca	ccagcccaagt	ggccagcgca	gcttctggc	ccagctggc	acggccctga	3120
ccaggjacaa	ccagcacttc	tataaccaga	acttctgccc	gggccccacg	acggcagagt	3180
gaccggccag	caccccaaggc	ctcctacacc	ttgcctgtct	gcctggatg	ccggg	3235

<210> 28
<211> 2460
<212> DNA
<213> *Felis catus*

<400> 28						
atggggccct	gccatggcgc	cctgcaccc	ctgtctctcc	tggtgcaaggc	tgccgcgtg	60
gccgtggccc	tggcccaggg	caccctgcct	gcctttctgc	cctgtgagct	ccagcgcac	120
ggcctggta	attgcactg	gctgttcctc	aagtccgtgc	cccacttctc	ggccgcagcg	180
ccccgtggta	acgtcaccag	cctttccctg	tactccaacc	gcatccacca	cctccacgac	240
tccgactttg	tccacctgtc	cagcctgcgg	cgtctcaacc	tcaaattggaa	ctgcccaccc	300
gccagcctca	gccccatgca	cttccctgt	cacatgacca	ttgagcccc	cacccctctg	360
gccgtgccc	ccctggagga	gctgaacctg	agctacaaca	gcatcacgac	agtacccgac	420
ctgcccagtt	ccctcggtgc	cctgtccttg	agccgtacca	acatcctgg	gctggaccct	480
gccaacctcg	cagggctgca	ctccctgcgc	tttctgttcc	tggatggcaa	ctgtactac	540
aagaacccct	gccccagggc	cctgcaggtg	gccccggggc	ccctccttgg	cctggcaac	600
cttacgcacc	tgtcactcaa	gtacaacaac	ctcactgcgg	tgccccgcgg	cctggccccc	660
agcctggagt	acctgctatt	gtcctacaac	cacatcatca	ccctggcacc	tgaggacctg	720
gccaacctga	ccgcccctgog	tgtgctcgat	gtgggtggga	actgcccgtcg	ctgtgaccac	780
gcccccaacc	cctgtatgga	gtgccccaaag	ggcttcccgc	acctgcaccc	tgacaccc	840
agccacacctga	accacctcgaa	aggcctggtg	ttgaaggaca	gctctctcta	caacacctgaac	900

cccagatgg tccatgcctt	960
gggcaacctc atggtgctgg acctgagtga	
gaacttccta tatgactgca tcacccaaac	1020
cacaggcttc cagggcctgg cccagctgcg	
cagactcaac ttgtctttca attaccacaa	1080
gaaggtgtcc tttgccacc tgcatctggc	
gccctccttc gggagcctgc tctccctgca	1140
gcagctggac atgcatggca tcttcttccg	
ctcgctcagc gagaccacgc tccggtcgct	1200
ggtccacctg cccatgtcc agagtctgca	
cctgcagatg aacttcatca atcaggcccc	1260
gctcagcatc ttccggccct tccctggcct	
gcgatacgtg gacctgtcag acaaccgcac	1320
aagtggagcc atggagctgg cggctgccac	
gggggaggtg gatgggtggg agagagtccg	1380
gctgccatct gggcacctag ctctggccc	
accggggcacc cctagctccg agggcttcat	1440
gccaggctgc aagaccctca acttcacett	
ggacctgtca cggaacaacc tagtgacaat	1500
ccagccagag atgtttgccc ggctctgcg	
cctccagtgc ctgctcctga gccgcaacag	1560
catctcgcag gcagtcaacg gtcacaatt	
tatgccgtg accagcctgc aggtgctgga	1620
cctgtcccat aacaagctgg acctgtacca	
tggcgctct ttcacggagc tgcccgccgt	1680
ggaggccctg gacctcagct acaacagcca	
gcccttcagc atgcagggcg tgggtcacaa	1740
cctcagcttt gtggcacagc tgccggccct	
gctatatctc agcctggcgc acaacgcacat	1800
ccacagccgt gtgtcccagc agctctgcag	
cgccctcgctg cggcccttgg acttcagcgg	1860
caatgcctt agccggatgt gggccgaggg	
agacctgtat ctccacttct tccgaggcct	1920
gaggagcctg gtccggttgg atctgtccca	
gaatgcctg cataccctct tgccacgcac	1980
cctggacaac ctccccaaga gcctgcccgt	
gctgcgtctc cgtgacaatt atctggcttt	2040
cttcaactgg agcagcctgg tcctctccc	
caggctggaa cgcctggacc tggcggaaa	2100
ccagctgaag gcctgagca acggcagctt	
gcctaattggg acccagctcc agaggctgga	2160
cctcagcagc aacagtatca gcttcgtggc	
ctccagcttt tttgctctgg ccaccaggct	2220
gctgagagctc aacctcagtg ccaacgcctt	
caagacggtg gagccctcct ggttcggttc	2280
tctagcggtc accctgaaag tccttagatgt	
gactggcaac cccctgcact gcgcctgtgg	2340
ggcggcccttc gtggacttct tgctggaggt	
gcaggctgca gtgcccggcc tgccaggcca	2400
cgtcaagtgt ggcagtcag gtcagctcca	
ggccgcagc atctttgcgc aggatctgcg	2460
cctctgcctg gatgaggccc tctctggja	
ctgttttggc	

<210> 29
 <211> 1032
 <212> PRT
 <213> Mus musculus

<400> 29

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu

225	230	235	240
Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg			
245		250	255
Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser			
260		265	270
Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly			
275		280	285
Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe			
290		295	300
Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu			
305		310	315
Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu			
325		330	335
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala			
340		345	350
Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu			
355		360	365
Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu			
370		375	380
Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met			
385		390	395
Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala			
405		410	415
Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr			
420		425	430
Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu			
435		440	445
Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser			
450		455	460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser
565 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
645 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr
660 665 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn
675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
740 745 750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
805 810 815

Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val
820 825 830

Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
835 840 845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser
850 855 860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
900 905 910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
980 985 990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln
995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
1025 1030

<210> 30
<211> 821
<212> PRT
<213> Mus musculus

<400> 30

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala

340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser
565 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
645 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr
660 665 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn
675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu
690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala
705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn
725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
740 745 750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
805 810 815

Trp Asp Cys Phe Gly
820

<210>	31					
<211>	3200					
<212>	DNA					
<213>	Mus musculus					
 <400>	31					
tgtcagaggg	agcctcgaaa	gaatcccca	tctcccaaca	tggttctccg	tcgaaggact	60
ctgcacccct	tgtccctcct	ggtacaggct	gcagtgtctgg	ctgagactct	ggccctgggt	120
accctgcctg	cttccctacc	ctgtgagctg	aagcctcatg	gcctggtgaa	ctgcaattgg	180
ctgtccctga	agtctgtacc	ccgtttctct	gcggcagcat	cctgctccaa	catcacccgc	240
ctctccctga	tctccaaaccg	tatccaccac	ctgcacaact	ccgacttcgt	ccacccgtcc	300
aacctgcggc	agctgaacct	caagtggAAC	tgtccaccca	ctggcccttag	ccccctgcac	360
ttctcttgcc	acatgaccat	tgagcccaga	acccctctgg	ctatgcgtac	actggaggag	420
ctgaacctga	gctataatgg	tatcaccact	gtgccccgac	tgcccagctc	cctgggtgaat	480
ctgagcctga	gccacaccaa	catcctgggt	ctagatgcta	acagcctcgc	cggccataac	540
agcctgcgcg	ttctcttcat	ggacggaaac	tgctactaca	agaacccctg	cacaggagcg	600
gtgaaggtga	ccccaggcgc	cctcctgggc	ctgagcaatc	tcacccatct	gtctctgaag	660
tataacaacc	tcacaaaagg	gccccccaa	ctgcccccca	gcctggagta	cctcctggtg	720
tcctataacc	tcattgtcaa	gctggggcct	gaagacctgg	ccaatctgac	ctcccttcga	780
gtacttgatg	tgggtggaa	ttgccgtcgc	tgcgaccatg	cccccaatcc	ctgtatagaa	840
tgtggccaaa	agtccctcca	cctgcacccct	gagaccttcc	atcacctgag	ccatctggaa	900
ggcctggtgc	tgaaggacag	ctctctccat	acactgaact	cttcctgggt	ccaaaggctcg	960
gtcaacctct	cggtgctgga	cctaagcgag	aactttctct	atgaaagcat	caaccacacc	1020
aatgcctttc	agaacctaac	ccgcctgcgc	aagctcaacc	tgtcctcaa	ttaccgcaag	1080
aaggtagtcct	ttgccccgcct	ccacctggca	agttccttca	agaacctgggt	gtcactgcag	1140
gagctgaaca	tgaacggcat	tttctccgc	tcgctcaaca	agtacacgct	cagatggctg	1200
gccgatctgc	ccaaactcca	cactctgcatt	cttcaaata	acttcataaa	ccaggcacag	1260
ctcagcatct	ttggtacctt	ccgagccctt	cgctttgtgg	acttgcaga	caatgcatac	1320
agtgggcctt	caacgctgtc	agaagccacc	cctgaagagg	cagatgatgc	agagcaggag	1380
gagctgttgt	ctgcggatcc	tcaccagct	ccactgagca	ccccctgcttc	taagaacttc	1440

atggacaggt gtaagaactt caagttcacc atggacctgt ctcggaacaa cctggtgact	1500
atcaagccag agatgttgtt caatctctca cgccctccagt gtcttagcct gagccacaac	1560
tccattgcac aggctgtcaa tggctctcag ttccctgccgc tgactaatct gcaggtgctg	1620
gacctgtccc ataacaaact ggacttgtac cactggaaat cgttcagtga gctaccacag	1680
ttgcaggccc tggacctgag ctacaacagc cagcccttta gcatgaaggg tataggccac	1740
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac	1800
attcatacccc gtgtgtcctc acatctcaac agcaactcag tgaggttct tgacttcagc	1860
ggcaacggta tggggccgcat gtgggatgag gggggcctt atctccattt cttccaaggc	1920
ctgagtgccc tgctgaagct ggacctgtct caaaataacc tgcataatcct ccggccccag	1980
aaccttgaca acctccccaa gagcctgaag ctgctgagcc tccgagacaa ctacctatct	2040
ttctttaact ggaccagtct gtccttcctg cccaacctgg aagtccctaga cctggcaggc	2100
aaccagctaa aggccctgac caatggcacc ctgcctaatg gcaccctcct ccagaaactg	2160
gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgcctt ggccgtcgag	2220
ctgaaagagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg	2280
cccattgtga tgaacctgac agttcttagac gtgagaagca accctctgca ctgtgcctgt	2340
ggggcagcct tcgttagactt actgttggag gtgcagacca aggtgcctgg cctggctaatt	2400
ggtgtgaagt gtggcagccc cggccagctg cagggccgta gcatcttcgc acaggacctg	2460
cggctgtgcc tggatgaggt cctctttgg gactgccttg gcctttcaact ctggctgtg	2520
gccgtgggca tgggtgggcc tatactgcac catctctgctg gctggacgt ctggtaactgt	2580
tttcatctgt gctctggcatg gctacccttg ctggcccgca gccgacgcag cgcccaagct	2640
ctccccatg atgccttcgt ggtgttcgat aaggcacaga ggcgcgttgc ggactgggtg	2700
tataacgagc tgcgggtgcg gctggaggag cggcgccggc gccgagccct acgcttgcgt	2760
ctggaggacc gagattggct gcctggccag acgcttctcg agaacctctg ggcttccatc	2820
tatggagcc gcaagactct atttgtgctg gcccacacgg accgcgtcag tggcttcctg	2880
cgcaccagct tcctgctggc tcagcagcgc ctgttggaaag accgcaagga cgtgggtggtg	2940
ttgggtatcc tgcgtccgga tgcccaccgc tcccgctatg tgcgactgcg ccagcgtctc	3000
tgccgccaga gtgtgctttt ctggcccccag cagcccaacg ggcaggggggg cttctgggcc	3060
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg	3120
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcattt catgcctgg	3180
tcccgagttt ctctgcctgc	3200

<210> 32
 <211> 2463
 <212> DNA
 <213> Mus musculus

<400> 32		
atggttctcc gtcgaaggac tctgcacccc ttgtccctcc tggcacaggc	tgcagtgctg	60
gctgagactc tggccctggg tacccctgcct gccttcctac cctgtgagct	gaagcctcat	120
ggcctggtgg actgcaattt gctgtcctg aagtctgtac cccgttctc	tgccggcagca	180
tcctgtcca acatcaccccg cctctccttg atctccaacc gtatccacca	cctgcacaac	240
tccgacttcg tccacctgtc caacctgcgg cagctgaacc tcaagtgaa	ctgtccaccc	300
actggccta gccccctgca cttctcttgc cacatgacca ttgagccag	aaccttcctg	360
gctatgcgta cactggagga gctgaacctg agctataatg gtatcaccac	tgtccccgaa	420
ctgcccagct ccctgggtgaa tctgagcctg agccacacca acatcctggt	tctagatgct	480
aacagcctcg cccgcctata cagcctgcgc gttctttca tggacggaa	ctgctactac	540
aagaacccct gcacaggagc ggtgaagggtg acccccaggcg ccctcctggg	cctgagcaat	600
ctcacccatc tgtctctgaa gtataacaac ctcacaaaagg tgcccccca	actgcccccc	660
agcctggagt acctcctggt gtcctataac ctcattgtca agctggggcc	tgaagacctg	720
gccaatctga ctcacccatc agtacttgat gtgggtggga attgccgtcg	ctgcgaccat	780
gcccccaatc cctgtataga atgtggccaa aagtccctcc acctgcaccc	tgagaccttc	840
catcacctga gccatctgga aggccctggg ctgaaggaca gctctcttca	tacactgaac	900
tcttcctggt tccaagggtct ggtcaacctc tcggtgctgg acctaagcga	gaactttctc	960
tatgaaagca tcaaccacac caatgcctt cagaacctaa cccgcctgcg	caagctcaac	1020
ctgtccttca attaccgcaa gaaggatattcc tttgcccccc tccacctggc	aagttccttc	1080
aagaacctgg tgtcaactgca ggagctgaac atgaacggca tcttcttccg	ctcgctcaac	1140
aagtacacgc ttagatggct ggccgatctg cccaaactcc acactctgca	tcttcaaatg	1200
aacttcatca accaggcaca gtcagcatc tttggtacct tccgagccct	tcgctttgtg	1260
gacttgtcag acaatcgcat cagtgggcct tcaacgctgt cagaagccac	ccctgaagag	1320
gcagatgtg cagagcagga ggagctgttg tctgcggatc ctcacccagc	tccactgagc	1380
acccctgctt otaagaactt catggacagg tgtaagaact tcaagttcac	catggacctg	1440
tctcggaaca acctgggtgac tatcaagcca gagatgtttg tcaatctctc	acgcctccag	1500
tgtcttagcc tgagccacaa ctccattgca caggctgtca atggctctca	gttcctgccc	1560

ctgactaatac	tgcagggtgct	ggacctgtcc	cataacaaac	tggacttgtta	ccactggaaa	1620
tcgttcagtg	agctaccaca	gttgcaggcc	ctggacctga	gctacaacag	ccagcccttt	1680
agcatgaagg	gtataggcca	caatttcagt	tttgtggccc	atctgtccat	gctacacagc	1740
cttagcctgg	cacacaatga	cattcatacc	cgtgtgtcct	cacatctcaa	cagcaactca	1800
gtgaggtttc	ttgacttcag	cggcaacggt	atgggccgca	tgtggatga	ggggggcctt	1860
tatctccatt	tcttccaagg	cctgagtgcc	ctgctgaagc	tggacctgtc	tcaaaataac	1920
ctgcatatatcc	tccggccccca	gaaccttgac	aacctccccca	agagcctgaa	gctgctgagc	1980
ctccgagaca	actacctatac	tttcttaac	tggaccagtc	tgtccttcct	gcccaacctg	2040
gaagtccctag	acctggcagg	caaccagcta	aaggccctga	ccaatggcac	cctgcctaatt	2100
ggcacccctcc	tccagaaact	ggatgtcagc	agcaacagta	tcgtctctgt	ggtcccagcc	2160
ttcttcgctc	tggcggtcga	gctgaaagag	gtcaaccta	gccacaacat	tctcaagacg	2220
gtggatcgct	cctgggtttgg	gcccattgtg	atgaacctga	cagttctaga	cgtgagaagc	2280
aaccctctgc	actgtgcctg	tggggcagcc	ttcgttagact	tactgttgg	ggtgcagacc	2340
aaggtgcctg	gcctggctaa	tggtgtgaag	tgtggcagcc	ccggccagct	gcagggccgt	2400
agcatttcg	cacaggacct	gcggctgtgc	ctggatgagg	tcctctcttg	ggactgcttt	2460
ggc						2463

<210> 33
<211> 1032
<212> PRT
<213> Homo sapiens

<400> 33

Met	Gly	Phe	Cys	Arg	Ser	Ala	Leu	His	Pro	Leu	Ser	Leu	Leu	Val	Gln
1															
														10	15

Ala	Ile	Met	Leu	Ala	Met	Thr	Leu	Ala	Leu	Gly	Thr	Leu	Pro	Ala	Phe	
														20	25	30

Leu	Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Leu	Val	Asn	Cys	Asn	Trp	Leu	
														35	40	45

Phe	Leu	Lys	Ser	Val	Pro	His	Phe	Ser	Met	Ala	Ala	Pro	Arg	Gly	Asn	
														50	55	60

Val	Thr	Ser	Leu	Ser	Leu	Ser	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp		
														65	70	75	80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu

305	310	315	320
Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu			
325		330	335
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala			
340		345	350
His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu			
355		360	365
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu			
370		375	380
Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met			
385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly			
405		410	415
Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu			
420		425	430
Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu			
435		440	445
Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu			
450		455	460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser			
465	470	475	480
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser			
485		490	495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val			
500		505	510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu			
515		520	525
Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu			
530		535	540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545 550 555 560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg
675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg
690 695 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
805 810 815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
835 840 845

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
850 855 860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
885 890 895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
900 905 910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
995 1000 1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
1010 1015 1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu
1025 1030

<210> 34
<211> 820
<212> PRT
<213> Homo sapiens

<400> 34

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asn Arg Ile Ser Gly Ala Ser Glu

420

425

430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
515 520 525

Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545 550 555 560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
 660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg
 675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg
 690 695 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
 705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
 725 730 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
 740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
 755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
 770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
 805 810 815

Asp Cys Phe Ala
 820

<210> 35
 <211> 3352
 <212> DNA
 <213> Homo sapiens

<400> 35		
aggctggat aaaaatctta cttcctctat tctctgagcc gctgctgcc ctgtggaaag	60	
ggacctcgag tgtgaagcat cttccctgt agctgctgtc cagtctgccccc gccagaccct	120	
ctggagaagc ccctgcccc cagcatgggt ttctgccgca gcgcctgca cccgctgtct	180	
ctcctgggtgc aggccatcat gctggccatg accctggccc tgggtacatt gcctgccttc	240	
ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct	300	

gtgccccact tctccatggc agcaccccggt ggcaatgtca ccagctttc cttgtctcc	360
aaccgcacatcc accacacctca tgattctgac tttgcccacc tgcccagcct gcggcatctc	420
aacctcaagt ggaactgccc gccgggtggc ctcagcccca tgcacttccc ctgccacatg	480
accatcgagc ccagcacctt cttggctgtg cccacccctgg aagagctaaa cctgagctac	540
aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc cctcagccat	600
accaacatcc ttagtctaga ctctgcccagc ctcgcccggcc tgcatgcctt gcgttccata	660
ttcatggacg gcaactgtta ttacaagaac ccctgcaggc aggcaactgga ggtggccccc	720
ggtgccctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctact	780
gtgggtcccc gcaacctgccc ttccagcctg gagtatctgc tggatgtcata caaccgcata	840
gtcaaaactgg cgccctgagga cctggccaat ctgaccgccc tgcgtgtgct cgatgtggc	900
ggaaattgcc gccgctgcga ccacgcctcc aacccctgca tggagtgccc tcgtcacttc	960
ccccagctac atcccgatac ctgcagccac ctgagccgtc ttgaaggcct ggtgttgaag	1020
gacagttctc tctcctggct gaatgccagt tggatccgtg ggctggaaa cctccgagtg	1080
ctggacactga gtgagaactt cctctacaaa tgcataacta aaaccaaggc ctggcaggc	1140
ctaacacagc tgcgcagact taacctgtcc ttcaattacc aaaagaggggt gtcctttgcc	1200
cacctgtctc tggcccttcc ctgcgggagc ctggatgc tgaaggagct ggacatgcac	1260
ggcatcttct tccgctcact cgatgagacc acgctccggc cactggcccg cctgcccatt	1320
ctccagactc tgcgtctgca gatgaacttc atcaaccagg cccagctcgg catcttcagg	1380
gccttccctg gcctgcgcta cgtggacctg tcggacaacc gcatcagcgg agcttcggag	1440
ctgacagcca ccatggggga ggcagatgga ggggagaagg tctggatgc gcctggggac	1500
cttgcgtccgg ccccaagtggc cactcccagc tctgaagact tcaggccaa ctgcagcacc	1560
ctcaacttca cttggatct gtcacggaac aacctggtga ccgtgcagcc ggagatgttt	1620
gcccagctct cgcacctgca gtgcctgcgc ctgagccaca actgcatttc gcaggcagtc	1680
aatggctccc agttcctgcc gctgaccgggt ctgcaggtgc tagacctgtc ccgcaataag	1740
ctggacactt accacgagca ctcattcagc gagctaccgc gactggaggc cctggacctc	1800
agctacaaca gccagccctt tggcatgcag ggcgtggcc acaacttcag cttcgtggct	1860
cacctgcgca ccctgcgcca cctcagcctg gcccacaaca acatccacag ccaagtgtcc	1920
cagcagctct gcagttacgtc gctgcgggcc ctggacttca gcggcaatgc actggccat	1980
atgtggcccg agggagacact ctatctgcac ttcttccaag gcctgagcgg tttgatctgg	2040

ctggacttgt	cccagaaccc	cctgcacacc	ctcctgcccc	aaaccctgcg	caacctcccc	2100
aagagcctac	aggtgctgcg	tctccgtgac	aattacctgg	ccttcttaa	gtggtgaggc	2160
ctccacttcc	tgccccaaact	ggaagtccctc	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcacccgg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttcg	tggccccccgg	cttctttcc	aaggccaagg	agctgcgaga	gctcaacctt	2340
agcgccaacg	ccctcaagac	agtggaccac	tcctggtttg	ggccctggc	gagtgccctg	2400
caaatactag	atgtaagcgc	caaccctctg	cactgcgcct	gtggggcggc	ctttatggac	2460
ttcctgctgg	aggtgcagggc	tgcctgtccc	ggtctgccc	gccgggtgaa	gtgtggcagt	2520
ccggggccagc	tccagggcct	cagcatctt	gcacaggacc	tgcgcctctg	cctggatgag	2580
ccctctcct	gggactgttt	cgccctctcg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctggac	ctctggtaact	gcttccacct	gtgcctggcc	2700
tggctccct	ggcgaaaaacg	gcaaaagtggg	cgagatgagg	atgcctgccc	ctacgatgcc	2760
ttcgtggct	tcgacaaaac	gcagagcgca	gtggcagact	gggtgtacaa	cgagcttcgg	2820
ggcagctgg	aggagtgcgc	tggcgctgg	gcactccgccc	tgtgcctgg	ggaacgcgac	2880
tggctgcctg	gaaaaacccct	ctttgagaac	ctgtggccct	cggcttatgg	cagccgcaag	2940
acgctgtttg	tgctggccca	cacggaccgg	gtcagtggtc	tctgcgcgc	cagcttcctg	3000
ctggcccagc	agegcctgct	ggaggaccgc	aaggacgtcg	tggtgcgtgt	gatcctgagc	3060
cctgacggcc	gcccgtcccg	ctacgtgcgg	ctgcgcctc	gcctctggc	ccagagtgtc	3120
cctctctggc	cccaccagcc	cagtggtcag	cgcagcttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cgaaacttct	gccagggacc	cacggccgaa	3240
tagccgtgag	ccggaatcct	gcacggtgcc	acctccacac	tcacctcacc	tctgcctgcc	3300
tggtctgacc	ctccctgtct	cgccctccctc	accccacacc	tgacacagag	ca	3352

<210> 36
<211> 2460
<212> DNA
<213> Homo sapiens

<400> 36						
atgggtttct	gcccgtcccg	cctgcaccccg	ctgtctctcc	tggtgcagggc	catcatgctg	60
gccatgaccc	tggccctggg	taccttgccc	gccttcctac	cctgtgagct	ccagccccac	120
ggcctggta	actgcaactg	gctgttcctg	aagtctgtgc	cccacttctc	catggcagca	180
ccccgtggca	atgtcaccag	ccttccttg	tcctccaacc	gcatccacca	cctccatgat	240

tctgactttg cccacctgcc cagcctgcgg catctcaacc tcaagtggaa ctgcccggcg	300
gttggcctca gccccatgca cttccccctgc cacatgacca tcgagcccag cacccttcttg	360
gctgtgccc ccctggaaaga gctaaacctg agctacaaca acatcatgac tgtgcctgcg	420
ctgccccaaat ccctcatatc cctgtccctc agccatacca acatcctgat gctagactct	480
gccagcctcg cggcctgca tgccctgcgc ttccatttca tggacggcaa ctgttattac	540
aagaacccct gcaggcaggc actggaggtg gccccgggtg ccctccttgg cctgggcaac	600
ctcacccacc tgtcactcaa gtacaacaac ctcactgtgg tgccccgcaa cctgccttcc	660
agcctggagt atctgctgtt gtcctacaac cgcatcgta aactggcgcc tgaggacctg	720
gccaatctga cggccctgctg tggctcgat gttggcgaa attggcccg ctgcgaccac	780
gctcccaacc cctgcatgga gtgcctcgat cacttcccc agctacatcc cgataccctc	840
agccacctga gccgttggta aggccctggtg ttgaaggaca gttctctctc ctggctgaat	900
gccagtttgtt tccgtgggtt gggaaacctc cgagtgctgg acctgagtga gaacttcctc	960
tacaaatgca tcaactaaaac caaggccttc cagggcctaa cacagctgcg caagcttaac	1020
ctgtccttca attacaaaaa gagggtgtcc tttgcccacc tggctctggc cccttccttc	1080
gggagcctgg tggccctgaa ggagctggac atgcacggca tcttcttcgg ctcaactcgat	1140
gagaccacgc tccggccact ggccgcctg cccatgtcc agactctgcg tctgcagatg	1200
aacttcatca accaggccca gtcggcatac ttcaaggcct tccctggcct gctacgtg	1260
gacctgtcgg acaaccgcata cagcggagct tcggagctga cagccaccat gggggaggca	1320
gatggagggg agaaggcttg gctgcagcct ggggaccttg ctccggccccc agtggacact	1380
cccgactctg aagacttcag gccaaactgc agcaccctca acttcacctt ggatctgtca	1440
cggaaacaacc tggtgaccgt gcagccggag atgtttgccc agctctcgca cctgcagtgc	1500
ctgcgcctga gccacaactg catctcgacg gcagtcaatg gctcccagtt cctgcgcgtg	1560
accggctctgc aggtgctaga cctgtcccgca aataagctgg acctctacca cgagcactca	1620
ttcacggagc taccgcgact ggaggccctg gacctcagct acaacagcca gccctttggc	1680
atgcagggcg tgggccacaa cttcagcttc gtggctcacc tgccacccct gcccaccc	1740
agcctggccc acaacaacat ccacagccaa gtgtcccagc agctctgcag tacgtcgctg	1800
cgggcccctgg acttcagcgg caatgcactg ggccatatgt gggccgaggg agacctctat	1860
ctgcacttct tccaaggcct gagcggtttg atctggctgg acttgcacca gaaccgcctg	1920
cacaccctcc tgccccaaac cctgcgcaac ctccccaaaga gcctacaggt gctgcgtctc	1980
cgtgacaatt acctggcctt ctttaagtgg tggagcctcc acttcctgccc caaactggaa	2040

gtcctcgacc tggcagaaaa ccggctgaag gccctgacca atggcagcct gcctgctggc 2100
 acccggtcc ggaggctgga tgtcagctgc aacagcatca gcttcgtggc ccccggttc 2160
 ttttccaagg ccaaggagct gcgagagctc aaccttagcg ccaacgcctt caagacagt 2220
 gaccactcct ggtttggcc cctggcgagt gccctgaaa tactagatgt aagcgccaac 2280
 cctctgcact ggcgcctgtgg ggcggccccc atggacttcc tgctggaggt gcaggctgcc 2340
 gtgccccgtc tgcccagccg ggtgaagtgt ggcagtcggg gccagctcca gggcctcagc 2400
 atcttgcac aggacctgcg cctctgcctg gatgaggccc tctcctgggatctttcgcc 2460

<210> 37
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 37
accttgccctg cttccttacc ctgtga 26

<210> 38
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 38
gtccgtgtgg gccagcacaa a 21

<210> 39
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 39
tccatgacgt ttttcatgtt 20

<210> 40
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 40
tccataacgt ttttgatgtt 20

<210> 41
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 41
tccatcacgt ttttgatgtt 20

<210> 42
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 42
tccattacgt ttttgatgtt 20

<210> 43
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 43
tccatggcgt ttttgatgtt 20

<210> 44
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 44
tccatgccgt ttttgatgtt 20

<210> 45
<211> 20
<212> DNA
<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 45

tccatgtcgt ttttgatgtt

20

<210> 46

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 46

tccatgatgt ttttgatgtt

20

<210> 47

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 47

tccatgaagt ttttgatgtt

20

<210> 48

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 48

tccatgaggt ttttgatgtt

20

<210> 49

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 49

tccatgacat ttttgatgtt

20

<210> 50

<211> 20

<212> DNA

<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 50
tccatgacct ttttgatgtt

20

<210> 51
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 51
tccatgactt ttttgatgtt

20

<210> 52
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 52
tccatgacgc ttttgatgtt

20

<210> 53
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 53
tccatgacga ttttgatgtt

20

<210> 54
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 54
tccatgacgg ttttgatgtt

20

<210> 55
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 55
tccatgacgt ctttgatgtt

20

<210> 56
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide
<400> 56
tccatgacgt atttgatgtt

20

<210> 57
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide
<400> 57
tccatgacgt gtttgatgtt

20

<210> 58
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide
<400> 58
tcgtcgaaaa gtcgttttgtt cgtt

24

<210> 59
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide
<400> 59
tgctcgaaaa gtgcgttttgtt gctt

24

<210> 60
<211> 20
<212> DNA

<213> Artificial sequence
<220>
<223> Synthetic oligonucleotide

<400> 60
tccatgacgt tcctgatgct

20

<210> 61
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 61
tccatgagct tcctgatgct

20

<210> 62
<211> 16
<212> PRT
<213> Artificial sequence

<220>
<223> Consensus oligopeptide

<220>
<221> MISC_FEATURE
<222> (4)...(5)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (7)...(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)...(15)
<223> Any amino acid

<400> 62

Gly Asn Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
1 5 10 15

<210> 63
<211> 16
<212> PRT
<213> Homo sapiens

<400> 63

Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys
1 5 10 15

<210> 64
<211> 16
<212> PRT
<213> Mus musculus

<400> 64

Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Ile Cys
1 5 10 15

<210> 65
<211> 31
<212> PRT
<213> Artificial sequence

<220>
<223> Consensus oligopeptide

<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid

<400> 65

Arg Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Xaa Xaa Xaa Xaa Xaa Xaa Tyr
20 25 30

<210> 66
<211> 31
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid

<400> 66

Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Arg Leu Xaa Xaa Xaa Xaa Xaa Xaa Tyr
20 25 30

<210> 67
<211> 31
<212> PRT
<213> Mus musculus

<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid

11

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid

<400> 67

Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Gln Leu Xaa Xaa Xaa Xaa Xaa Tyr
20 25 30

<210> 68
<211> 31
<212> PRT
<213> Homo sapiens

<400> 68

Gln Val Leu Asp Leu Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His
1 5 10 15

Ser Phe Thr Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr
20 25 30

<210> 69
<211> 31
<212> PRT
<213> Mus musculus

<400> 69

Gln Val Leu Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys

1

5

10

15

Ser Phe Ser Glu Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr
20 25 30

<210> 70
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 70
tccaggactt ctctcaggtt 20